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A series of ferrocenyl chalcones, dihydroferrocenyl chalcones and bis-substituted 
ferrocenyl chalcones were synthesized and their antiplasmodial activities were evaluated 
by measuring the inhibition of [3H] hypoxanthine uptake into a chloroquine- resistant 
isolate of Plasmodium falciparum (K1). The selective toxicities of the compounds were 
evaluated by determining their cytotoxicities against mammalian cell lines (MDCK and 
KB3-1). The following physicochemical properties of the ferrocenyl chalcones were 
determined by experimental or in silico methods: lipophilicity, molecular surface area 
and volume, oxidation and reduction potential of ferrocene ring, reduction potential of 
carbonyl linkage, 13C chemical shift of carbonyl carbon and charge difference of carbonyl 
oxygen and carbon. After the physicochemical parameters of the compounds were 
collected, a structure-activity relationship study was carried out with multivariate tools, 
principal component analysis (PCA) and partial least squares projection to latent 
structures (PLS).  The mode of antiplasmodial action of ferrocenyl chalcones was 
investigated by determining their binding affinity to heme, inhibition of β-hematin 
formation, inhibition of GSH mediated heme degradation, effect on the parasite-induced 
new permeation pathways on the erythrocyte, scavenging of ABTS radical cation and 
free radical generation.  
About 1/3rd of the ferrocenyl chalcones showed antiplasmodial activity with IC50 
values less than 20 µM. In general, better activity was observed for compounds with 
ferrocene as ring A. The most active compounds were 1-(3’-pyridinyl)-3-ferrocenyl-2-
propen-1-one (6) and 1-ferrocenyl-3-(4’-nitrophenyl)-2-propen-1-one (28), with IC50 
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values of 4.5 µM and 5.1 µM respectively. These two compounds had selectivity indices 
(against KB3-1 cells) of 8.63 and 36.7 respectively .  
In the QSAR study, the location of ferrocene ring was found to influence 
physiochemical characteristics of the compounds. Series A compounds were generally 
less lipophilic, had ferrocene rings that were more resistant to oxidation and more 
polarized carbonyl linkages.  In the best QSAR model, oxidizability of ferrocene and the 
polarity of the carbonyl linkage were identified as important parameters for 
antiplasmodial activity. 
In the mode of action studies, ferrocenyl chalcones demonstrated little effect on 
binding affinity to heme, inhibition of β-hematin formation, inhibition of GSH mediated 
heme degradation and the parasite-induced new permeation pathways on the erythrocyte. 
On another hand, investigations on the scavenging of ABTS radical cation and free 
radical generation showed that ferrocenyl chalcones could generate free radicals rapidly. 
However, a robust correlation could not be established between the capacity of 
compounds to generate free radicals and antiplasmodial activity. Thus, free radical 
generation may be an important, but not the only factor accounting for the antiplasmodial 
activity of ferrocenyl chalcones. The other physicochemical properties of the ferrocenyl 
chalcones should be considered together with their oxidant potential. 
In conclusion, the study has shown that ferrocenyl chalcones demonstrated 
antimalarial activity in vitro. Ferrocene was found to markedly affect the 
physicochemical properties of ferrocenyl chalcones and to influence antiplasmodial 
activity of these compounds.  
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Malaria is probably one of the oldest diseases to afflict mankind.  Fossils of 
the Anopheles mosquito, the insect vector of malaria, dating back to 30 million years, 
have been uncovered, attesting to the ancient origins of the disease.  Without a doubt, 
malaria had a profound impact on the course of human history.PP1PP Yet, about fifty years 
ago, the world faced the exciting prospect of eradicating malaria.  The insecticide 
1,1,1-trichloro-2,2-bis-(p-chlorophenyl) ethane (DDT) had succeeded in curbing the 
proliferation of the Anopheles mosquito, the vector of Plasmodium, which is the 
causative organism of malaria.  Impressive therapeutic successes had been scored 
with chloroquine – a cheap and highly efficacious antimalarial agent.  Indeed, the 
global dream of eradicating malaria appeared attainable when transmission of 
endemic malaria in several European countries was achieved in the 1960s. 
Unfortunately, the optimism was short-lived as both the Anopheles mosquito and 
Plasmodium showed greater than anticipated staying power.  The spread of drug 
resistance and the environmental hazards associated with DDT meant that fewer 
effective resources were available to combat malaria.  It also highlighted the need to 
address malaria as a global problem that goes beyond the boundaries of individual 
nations. 
In 1998, the Roll Back Malaria (RBM) Global Partnership was launched by 
the World Health Organization (WHO), United Nations Children's Fund (UNICEF), 
United Nations Development Programme (UNDP) and World Bank to provide a 
coordinated international approach to confront malaria, with the goal of halving the 
burden of malaria by 2010.PP2 PP Five years later in 2005, it looked, on the face of things, 
 3
as though not a lot of progress had been made.  About 500 million cases of malaria 
are reported around the world every year, the vast majority in Africa.  There is no 
evidence that this had changed since 2000. In fact, some sources suggested that some 
parts of the African continent had actually seen a resurgence of malaria.PP3  PPThis dismal 
state of affairs has evoked strong criticism.  An editorial in the Lancet, a leading 
medical journal, charged that by not issuing strong technical advice to individual 
countries, the RBM had indirectly contributed to the spread of drug resistance and the 
steady deterioration of eradication efforts.PP4 PP It concluded that the RBM may have 
done “more harm than good.”  The Economist newspaper concurred that while it was 
true that the RBM had proven ineffective because of its unwieldy organizational 
structure, the limited progress had more to do with the lack of effective ways to 
address the disease, the absence of drugs to combat the spread of resistance and the 
lack of monetary support.PP3 PPThese obstacles, however, are being tackled. The 
deployment of bed nets impregnated with insecticides, the extraordinary effectiveness 
of artemisinin, the supply of which is rising to match the demand, and major cash 
injections from philanthropic organizations like the Gates Foundation, would make 
the future brighter than critics might have predicted.  Whether malaria would indeed 
be rolled back over the next five years will depend on how effectively these resources 
are deployed. 
 
1.2 Transition Metal Complexes with Therapeutic Activity: Focus on Ferrocene-
Based Drugs 
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Interest in the therapeutic properties of metal complexes can be attributed to 
several factors. Certainly, the serendipitous discovery of cisplatin, widely 
acknowledged as a leading metal-based drug for the treatment of cancer, has 
highlighted the potential usefulness of metal complexes in medicine. Metal based 
drugs can form additional drug-receptors, thereby enhancing affinity, as the positively 
charged metal center will be attracted to negatively charged biomolecules such as 
nucleic acids and proteins, which are important components of endogenous receptors. 
Not withstanding the benefits of metal-based drugs, their development as drugs has 
not been easy.PP5 
Abrams and Murrer PP 6PP noted that the field of medicinal inorganic chemistry as 
one having “many important applications, but few principles tying the field together.”  
Today, with more applications emerging, the need for core principles governing the 
design of metal-based drugs is even more pressing. Thompson and Orvig PP7 PP proposed 
the following as key therapeutic principles, namely (i) the significance of the dose, (ii) 
the realization that it is the entire chemical entity, and not just the metal ion that 
determines the therapeutic effect, and (iii) the bioavailability of the metal-based 
compound which will determine its relative biochemical impact. 
“The right dose differentiates a poison and a remedy” highlights a particularly 
relevant principle when dealing with metal based drugs.  The toxicity of these 
compounds due to the accumulation of metal ions in the body is of particular concern.  
Thus, the pharmacokinetic profile of the metal complex must be investigated in great 
detail, and favorable pharmacological outcomes must be convincingly demonstrated 
in vivo with animal models before proceeding further.  A mechanistic understanding 
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of how the metal complexes achieve their activities would be desirable as it will 
provide a rational basis for the development of future candidates. 
More so than other metals, metallic iron has long been associated with human 
health.  Natural springs rich in iron deposits (“chalybeate” waters) were widely 
sought for their healing properties, thus establishing the reputations of Bath in 
England, Spa in Belgium and  Llandrindod Wells in Wales.  Today, numerous 
inorganic iron salts are used for the treatment of iron deficiency.PP 8 PP  In contrast, 
organoiron chemistry has been dominated by a single compound – ferrocene. 
 
1.2.1 Ferrocene 
Ferrocene or di(ηPP5 PP-cyclopentadienyl) iron(II) was accidentally discovered by 
Peter L. Pauson and his graduate student Tom Kealy in 1951 when they attempted the 
reductive coupling of the Grignard reagent cyclopentadienyl magnesium bromide in 
the presence of ferric chloride.PP125 PP  As recounted by Pauson in 2001, “ a few drops of 
the yellow solution …. evaporated, leaving yellow crystals. Could we have made a 
yellow hydrocarbon, perhaps even the desired fulvalene? It seemed too good to be 
true.” PP125 PP It turned out that Paulson and Kealy did not synthesize fulvalene, whose 
aromatic character was hotly debated at that time.  Instead they had obtained an even 
more novel addition to the class of non-benzenoid aromatics, a substance that was 
subsequently named ferrocene, with an  “–ene” ending to emphasize its aromatic 
character. 
Ferrocene comprises a ferrous ion (FePP2+ PP) coordinated to two cyclopentadienyl 
(Cp) rings.  The d orbitals on FePP2+ PP are coordinated into the π orbitals on the two 
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cyclopentadienyl radicals to form a unique sandwich structure first predicted by 
infrared and nuclear magnetic resonance spectroscopies and later confirmed by X-ray 
crystallography in 1954.PP125PP  The prevailing belief was that bonds between transition 
metals and hydrocarbon groups were unstable, since all recorded attempts to form 
such linkages had failed.  Ferrocene proved to be a notable exception.  Not only was 
the compound isolable, but it was stable to high temperatures and unaffected by water, 
strong acids and alkalis.  The first Fe-Cp dissociation energy in the gas phase was 
found to be 380 kJ/mol in the gas phase.PP10 PP The unique stability of ferrocene is 
attributed to the distribution of 18 π electrons in the e BB2gBB and a BB1g BB non bonding 
molecular orbitals.  Not withstanding its unique stability, ferrocene behaves like an 
aromatic compound.  It is susceptible to direct electrophilic substitution reactions, 
giving rise to a variety of substituted ferrocenes. 
Compared to other metallocenes, ferrocene is more widely employed in drug 
design.  This is prompted by several factors, foremost of which is the reputation of 
ferrocene as a “safe” metallocene.  Acute and chronic tests of ferrocene and several of 
its derivatives attested to the relative safety of these compounds in many mammalian 
species (dogs, rats, mice, monkeys).PP11, 12, 13 PP  Despite this reassuring data, the extent to 
which iron is released from ferrocene-containing compounds during metabolism is 
still not known.  Ferrous iron can catalyze free radical reactions, leading to lipid 
peroxidation of cellular membranes and the formation of reactive oxygen species 
(ROS) via the Fenton reaction.PP14  PPSome investigations suggested that the metal ion 
(FePP2+PP) in ferrocene was not readily removed,PP15, 16PP or if it was, the ion was quickly 
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incorporated into the iron-protein storage complex ferritin and processed by the body 
in the same way as dietary iron, thus minimizing its harmful potential.PP16, 17, 18 
Medicinal chemists are also open to the inclusion of ferrocene into their drug 
design strategies because of the novelty introduced by its presence.  Ferrocene is 
widely regarded as a substitute for the aromatic benzene ring.  Ferrocene is aromatic 
but more electron donating than benzene (σBBpara ferrocene BB= - 0.18, σBBpara benzeneBB=0.01).PP19 PP  In 
terms of shape, ferrocene is as “wide” as benzene but substantially “thicker”.  It is 
also more lipophilic than benzene (πBBferroceneBB=2.46, πBBbenzene BB=1.96)PP 19 PP and its inclusion 
into a molecule can be expected to influence membrane permeability and drug-like 
character to good advantage.  Since inappropriate pharmacokinetics is one of the 
main reasons why lead compounds fail to transform into effective drugs,PP20 PP the 
potential usefulness of ferrocene in this regard has been recognized by medicinal 
chemists. 
There are many examples in the literature citing the use of ferrocene in drug 
design strategies.  In one study on some non-steroidal anti-inflammatory agents, the 
replacement of the aromatic ring by ferrocene did not improve anti-arthritic or platelet 
aggregatory activities in the resulting compounds.PP21 PP The authors concluded that 
ferrocene was not an appropriate bioisostere of the phenyl or pyrrole ring. 
Investigations with ferrocene-containing penicillins, cephalosporins and rifamycins 
showed that the inclusion of ferrocene did not confer any special advantage.PP22, 23PP On 
the other hand, significant changes in activity profiles had been recorded when 
ferrocene was introduced into established drugs like tamoxifen and chloroquine.  
These are discussed in the following paragraphs. 
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1.2.2 Ferrocifens 
Tamoxifen is an example of a selective estrogen receptor modulator (SERM), 
which are compounds with tissue-selective estrogenic activities. The pharmacological 
goal of these drugs is to produce estrogenic actions in those tissues where such effects 
are beneficial (such as bone, brain, liver during postmenopausal hormone replacement) 
and to have either no activity or an antagonistic effect in tissues such as breast and 
endometrium, where estrogenic actions might be undesirable.PP24 PP Tamoxifen is widely 
used for the treatment of breast cancer but has limited efficacy for several reasons.  
For one, its activity is restricted to estrogen receptor positive (ER+) tumours which 
occur in approximately 60% of breast cancer cases.  Treatment efficacy with 
tamoxifen decreases with time due to the acquisition of drug resistance by the 
tumours.  Ferrocifens - compounds derived from the replacement of one of the phenyl 
rings of tamoxifen with ferrocene, was one of the approaches made to improve the 






Tamoxifen                                1 
In a ferrocifen, of which compound 1 is a typical example, the presence of the 
triphenylethylene-like framework of tamoxifen ensured that recognition for the 
estradiol receptor is retained. The addition of ferrocene introduced an oxidizing / 
reducing genotoxic aspect that was absent in tamoxifen. It was hypothesized that 
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ferrocene could induce damage to DNA because the ferrous ion was oxidized to a 
ferricenium-type radical ion that could either cleave DNA directly by associating with 
it, or induced the formation of reactive oxygen species that were responsible for 
genotoxicity. Several investigations lend support to this hypothesis, which will be 
discussed in a latter section. 
In a related approach, the grafting of ferrocene to organic diphenol structures 
related to resveratrol and diethylstilbesterol which were compounds known to 
recognize the estrogen receptor, provided further confirmation of the important 
modulatory influence of ferrocene.PP25 PP In this investigation, the ferrocenyl diphenol 2 
inhibited the growth of both hormone dependent (ER+) and hormone independent 
(ER-) breast cancer cell lines.  Replacing ferrocene with phenyl to give the diphenol 3 
resulted in a loss of the antiproliferative effect against both cell lines. Interestingly, 
compound 4 which was isomeric with 2 had only a modest antiproliferative activity 
against ER- cells and a weak proliferative effect on ER+ cells.  These results showed 
that the presence of ferrocene was a necessary but not sufficient prerequisite for 
antiproliferative activity.  The contrasting properties of compounds 2 and 4 suggested 











2                                 3                                   4 
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1.2.3 Ferroquine 
Ferroquine, also known as “ferrochloroquine” or “ferrocenyl chloroquine”, 
was synthesized and evaluated for antiplasmodial activity by Biot and co-workers in 
1997.PP8 PP  Ferrocene was inserted in place of two methylene groups in the butyl side 
chain of chloroquine and the terminal amino group was varied to include several 
basic functionalities.  The most promising compound was the dimethyl analogue 
(ferrochloroquine) which was 22 times more active than chloroquine against a 

























5                                                        6 
Subsequent structure-activity studies showed that ferrocene itself had no 
antimalarial activity and that the ferrocene-chloroquine combination was effective 
only when ferrocene was covalently bonded to chloroquine.PP26 PP The enantiomers of 
ferrochloroquine  showed equivalent antiplasmodial activity in vitro but were less 
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active than the racemate in vivo.PP27 PP The attachment of ferrocene to other positions of 
chloroquine (compounds 5 and 6) proved to be detrimental.PP28 PP These findings 
suggested that ferrocene was optimally located in ferrochloroquine. 
It was anticipated that N-dealkylation of the terminal amino function of 
ferrochloroquine would be an important metabolic pathway of the drug.PP26 PP The 
resulting dealkylated metabolites might be more active than ferrochloroquine, if the 
analogy to chloroquine held true.  This led to the syntheses of the desmethyl and 
didesmethyl analogues of ferrochloroquine, but unlike the metabolites of chloroquine, 























8                                                                               9 
In ferrochloroquine, the quinoline ring and the terminal basic side chain were 
attached to the same cyclopentadienyl ring of ferrocene, i.e. the substitution pattern 
was 1,2.  Beagley and co-workers investigated the effect of attaching the substituents 
to different cyclopentadienyl rings, namely, to explore the effect of a 1,1’-substitution 
pattern as shown in 7.  Compound 7 PP29PP was equipotent with ferrochloroquine against 
chloroquine sensitive organisms but showed greater potency against resistant strains.  
However, in another pair of 1,2 and 1,1’ ferrocenyl analogues (compounds 8 and 9), a 
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different profile was noted.  Without more examples, it was difficult to comment 
further on the relative importance of the 1,2 versus 1,1’ substitution pattern on 
ferrocene.  However, some differences would be expected.  In 1,2-substitution, one of 
the cyclopentadienyl rings of ferrocene was unsubstituted and X-ray crystallography 
showed that the orientation of this ring made it almost parallel to quinoline.  This 
might enhance binding to potential receptors like heme, if the latter was an important 














10: n=3    14: n=3 
11: n=4    15: n=4 
12: n=5    16: n=5 
13: n=6    17: n=6 
In another study, the methylene chain connecting N2 and N3 in 8 was varied 
from n = 2 to n = 3, 4, 5 or 6 (10, 11, 12, 13).  N3 was also modified to a urea moiety 
to give another series of compounds (14, 15, 16, 17).PP30 PP Some interesting observations 
were made for the two series.  Better activity was found for the urea analogues 
against sensitive strains of plasmodia (P. falciparum D10), but not against resistant 
strains where comparable activities were observed for the two series.  Extending the 
methylene side chain caused a fall in antiplasmodial activity of the ureas but not for 
the non-ureas 10-13.  Both series showed a progressive decrease in the half-wave 
potential of the ferrocene analogues as the methylene chain was extended from n = 2 
 13
to n = 4.  The half wave potential measures the ease with which FePP2+ PP in ferrocene 
loses an electron, that is, undergoes oxidation to FePP3+ PP.  The results indicated that the 
urea analogue with the shorter methylene chain had a higher half-wave potential and 
also greater antiplasmodial activity.  The significance of this observation remains to 
be fully explored but it may signal a role for the oxidizability of FePP2+ PP in ferrocene for 
antiplasmodial activity.  In contrast, Beagley and co-workersPP 29 PP found equivalent 
activity for ferrochloroquine and its phenyl analogue 18 and concluded that the 






The original hypothesis that led to the design of ferrochloroquine was that 
since the Plasmodium had a strong affinity for free iron, an effective way of reducing 
chloroquine resistance of the parasites would be to introduce iron to a chloroquine 
molecule.PP9 PP Fe PP2+ PP in ferrocene would in effect act as a “bait” to promote uptake and 
accumulation of the drug within the food vacuole of the parasite. While 
ferrochloroquine was indeed found to be more effective than chloroquine against 
resistant organisms, the contribution of ferrocene to activity remained an open 
question.  Biot and co-workers provided one of the few detailed investigations into 
the mechanism of action of ferrochloroquine.PP31 
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According to their proposal, the quinoline ring of ferrochloroquine 
participated in a π-π stacking interaction with heme, thus preventing its aggregation 
to form hemozoin.  They showed that ferrochloroquine formed complexes with heme 
in solution, and inhibited β-hematin formation.  Therefore, both chloroquine and 
ferrochloroquine may share the same drug target (heme) in plasmodia.  What then 
was the role of the ferrocenyl side chain in ferrochloroquine?  The authors proposed 
that the side chain caused a reduction in affinity of the molecule for the postulated 
transporter linked to chloroquine resistance, P. falciparum chloroquine resistance 
transporter (PfCRT) which served to efflux chloroquine from the food vacuole.  
Several physicochemical characteristics of ferrochloroquine accounted for this unique 
property.  Firstly, the inclusion of ferrocene increased lipophilicity. The greater 
lipophilicity of ferrochloroquine allowed it to block the PfCRT pore, much like a 
resistance-reversing agent (for example, verapamil).  Secondly, the pKa values of 
ferrochloroquine (pKaBB1BB = 8.19, pKaBB2 BB = 6.99) were lower than that of chloroquine 
(pKaBB1BB = 10.03, pKaBB2 BB= 7.94).PP32PP The crystal structure of neutral ferrochloroquine 
showed a strong intramolecular hydrogen bond between the anilino nitrogen and the 
tertiary dimethylamino function.  This served to lower the pKa of the side chain 
nitrogen atom as well as to reduce the N-N distance of the side chain. These 
characteristics (greater lipophilicity, shorter N-N distance, lower basicity) of 
ferrochloroquine may endow it with a poorer affinity for the chloroquine transporter 
PfCRT. Thus, more ferrochloroquine was retained within the food vacuole, where it 
could presumably interact with its target, resulting in greater activity against resistant 
plasmodia. 
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1.2.4 Other ferrocenyl antiplasmodial agents 
The success of ferrochloroquine prompted other investigators to incorporate 
ferrocene into compounds with known antimalarial activity, with the hope of 
uncovering compounds with better activity against resistant organisms.   Delhaes and 
coworkers synthesized four ferrocenyl artemisinin analogues, of which 19 (ICBB50BB 14 
nM) was found to be as active as artemisinin (ICBB50 BB 13 nM) against chloroquine-
resistant P. falciparum (Dd2).PP33 PP The hypothesis was that the incorporation of 
ferrocene would modify the endoperoxide bridge which was widely held to be critical 
for the inhibition of PfATP6, the potential target of artemisinins, based on the 
artemisinin template.PP129 PP However, ferrocene did not appear to confer any significant 












Ferrocene was also incorporated into mefloquine and quinine, namely by 
replacing the piperidinyl group of mefloquine or the quinuclidinyl group of quinine 
with ferrocene (20, 21). Unfortunately, both compounds had lower antimalarial 
activity than their parent compounds, possibly due to the poor stability of the 
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Besides the earlier cited examples, several novel ferrocene analogues were 
also evaluated for antiplasmodial activity. Itoh and coworkers reported the 
antiplasmodial activity of ferrocenyl ellagitannins which contained biphenic acid and 
ferrocene rings on the glucose core (22).PP35 PP Notably, the omission of ferrocene 
resulted in less active compounds.  Haworth and Halon designed a series of 
benzimidazolium salts with N-ferrocenylmethyl substituents, of which 23 is an 
example, and found submicromolar inhibitory activities among several members.PP36PP 
Among some ferrocene triazacyclononane quinoline conjugates synthesized by Biot 
et al,PP37PP the bis-quinoline analogue with one ferrocene ring 24 was slightly more active 
than chloroquine against resistant plasmodia, but less effective against a sensitive 
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strain. Interestingly, 25 with one quinoline ring and two ferrocene rings was 
significantly less active than chloroquine against both sensitive and resistant strains. 
The authors proposed that the presence of two bulky ferrocene groups would 
introduce undesirable steric factors that could deter binding of the quinoline ring to 
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1.2.5 Cytotoxic ferrocenyl compounds 
The cytotoxicity of ferrocenyl compounds cannot be discussed in isolation, 
without considering the ferricenium (also called ferrocenium) compounds.  Ferrocene 
and the ferricenium cation form a redox couple.  Ferrocene readily loses an electron 
to form the ferricenium cation [ (ηPP5 PP-CBB5 BBHBB5 BB) BB2BB Fe PP+ PPXPP-PP.], which is a relatively stable free 
radical species.  Electron transfer between ferrocene and ferrocenium occurs rapidly 
and reversibly.PP38PP  Since the electrochemical potential for this reaction falls within the 
range of other biological redox couples, electron transfer could occur between 
ferrocene/ferrocenium and other biological electron donor/acceptor pairs.PP39 PP For 
example, peroxidases catalyzed the oxidation of ferrocene by hydrogen peroxide to 
give the ferricenium cation.PP40 PP The reverse reaction (ferricenium Æ ferrocene) was 
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mediated by NADH and metalloproteins.PP41 PP Ferricenium cation also combined with 
free radicals to give ferrocene after an initial proton elimination,PP42PP and was reduced 
by the superoxide anion radical.PP43 PP  Another biologically significant reaction was the 
oxidation of ferrocenylcarboxylate anion by the highly reactive hydroxyl radical to 
give ferricenium carboxylate.PP44 
The biologically relevant equilibrium between ferrocene and the ferricenium 
radical cation raises an important question that is pertinent to the cytotoxicity of this 
class of compounds, namely the identity of the active species responsible for the 
cytotoxic effect.  An early study by Köpf-Maier and co-workers PP124PP showed that 
ferrocene had no anti-tumour activity in Ehrlich ascites tumour -bearing mice.  On the 
other hand, activity was noted for several water-soluble ionic ferricenium salts with 
non-hydrophobic counter ions such as picrate, trichloroacetate, but not for those that 
were less water soluble (ferricenium molybdate). These observations suggested that 
activity was related to achieving an optimal balance of lipophilicity and 
hydrophilicity in the target compound, most likely to ensure adequate uptake into 
cells.  Thus, several attempts were made to increase the solubility of ferrocenyl 
derivatives, either by derivatization with polar substituents or by pharmaceutical 
means. Caldwell and co-workers demonstrated antiproliferative activity in several 
water soluble polyaspartamide ferrocene conjugates.PP45PP Neuse and Kanzawa reported 
the activity of water soluble ferrocenyl acetic acid and ferrocylthiomalic acid against 
carcinoma cells of the lung.PP46  PPOn the other hand, a water soluble cyclodextrin 
inclusion complex of ferrocene had no activity against Ehrlich ascite tumour (EAT) 
cells in vivo.PP47PP  Neither was activity detected for ferrocenecarboxylic acid or 
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ferroceneacetic acid against EAT cells.  These conflicting results suggested that water 
solubility of ferrocene derivatives may not be the only limiting factor in determining 
cytotoxic activity. 
Unlike the ambiguity surrounding the cytotoxic properties of ferrocenyl 
compounds, there was consensus on the in vivo anti-tumour activity of ferricenium 
salts, and agreement on the need for iron to exist in its +3 oxidation state.  The 
ferricenium radical cation was sufficiently reactive and interacted with DNA directly 
- by charge transfer, electrostatic attraction or even intercalation with the nucleotide 
bases - to bring about its cytotoxic activity.PP47 PP An alternative viewpoint proposed that 
the ferricenium cation generated reactive hydroxyl radicals that were indirectly 
responsible for its activity.PP47PP In support of their hypothesis, Osella and coworkers PP47 
PPused electron spin resonance (ESR) to demonstrate the formation of a radical adduct 
when ferricenium carboxylic acid hexafluorophosphate was incubated with a spin trap 
(DEPMPO).PP47 PP  Addition of Ehrlich ascites tumour cells attenuated the ESR signals, 
indicating that the cells had reacted with the free radicals generated from the 
reduction of the ferricenium specie. Non-specific DNA strand breakage was observed 
in cells treated with the ferricenium salt, which led the authors to conclude that the 
DNA damage might be due to the oxidative action of these free radicals. 
The redox equilibrium between ferrocene and ferricenium raises the 
possibility that the ferricenium radical cation and /or the free radicals associated with 
its generation are the final mediators of the cytotoxic response.  Therefore, the form 
in which the drug was administered (ferrocene or ferricenium salt) may not be a 
critical issue.PP45 PP  The critical requirements for activity would then be the solubility of 
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the compound (to ensure adequate access into cells) and the redox potential of the 
couple.PP45PP  Electron transfer between ferrocene and ferricenium should fall within a 
range that permited exchange with other biological counterparts, so that the 
equilibrium between the ferrocenyl and ferricenium species could be set up in a 
specific body compartment.  In other study, it was proposed that the formal reduction 
potential which drove the position of the equilibrium between the ferrocenyl and 
ferrocenium species should be 220 mV or less.PP38  PPThis hypothesis had gained wide 
support among several investigators.  Ong and co-workersPP 48PP attributed the cytotoxic 
activity of a ferrocenyl acridine (26) to the formation of the ferricenium ion in the 







The acridine ring positioned the ferrocene moiety in the vicinity of DNA and 
the ferricenium ion once generated, reacted with nucleophilic groups in DNA. Top 





Fe PP2+     PP +     O BB2 BB    →     Fe PP3+     PP+     O BB2 PBPB● –PP     (1) 
  FePP2+      PP+      OBB2 PBPB● –     PP +     2HPP+    PP→     FePP3+     PP+     H BB2 BBOBB2 BB     (2) 
   FePP2+      PP+      HBB2 BBO BB2BB    →    Fe PP3+ PP    +    OHPP–      PP+    OH PP● PP     (3) 
 
Notwithstanding these findings, ferrocene-containing compounds may have 
other mechanisms of action. In one study on acetyl and carboxaldoxime ferrocenes, it 
was found that these compounds inhibited topoisomerase II (Topo II), possibly by 
interfering with the formation of the DNA-Topo II complex.PP50 PP Yet another 
investigation showed that ferrocene had an anti-tumour effect when administered at 
very low doses (2000 times less that LDBB50BB of ferrocene) to mice with B-16 
melanoma.PP51 PP  The authors postulated that p21 PPras PP was a molecular target of ferrocene. 
The activation of T lymphocytes depended on p21 PPrasPP, which was itself activated by 
cellular redox stress. The authors found that immune cells from ferrocene-treated 
tumour-bearing mice were capable of eliciting an anti-tumour reaction in control mice. 
































 A review of the literature on ferrocene-containing compounds had shown the 
widespread application of this metallocene in drug design strategies for several 
therapeutic areas.  In many instances, the inclusion of the metallocene improved 
activity or introduced a new dimension that was hitherto absent in the non-ferrocenyl 
derivative.  The examples of ferrochloroquine and ferrocifens are good illustrations 
that come to mind.  In keeping with the utilization of ferrocene in drug design, there 
is a growing interest in understanding how the ferrocene ring contributed to biological 
activity.  On one hand, several investigations pointed to an “active” role for the 
ferrocene ring, namely as a source of ferricenium radical cations and /or reactive 
oxygen species that had a direct influence on activity.PP45, 46, 47PP  On the other hand, 
ferrocene may intervene in a more discreet fashion to modulate activity.  There was 
evidence to support a structural role for ferrocene, possibly as a hydrophobic space in 
place of a phenyl ring.PP30PP Aside from imposing a physical presence, the 
physicochemical characteristics introduced by ferrocene should not be trivialized, as 
seen from the investigations on ferrochloroquine.PP8, 26, 27, 28 PP  It was also plausible that a 
grey zone existed where there was an interplay between these two proposed 
contributions of the metallocene.  The extent of each contribution may depend on the 
biological activity being considered. 
 The aim of this thesis is to investigate the contribution of ferrocene to 
antiplasmodial activity, using chalcones as target molecules.  The choice of the 
chalcone template was prompted by the fact that chalcones had been widely 
investigated for their antiplasmodial activity PP52PP and chalcone analogs with different 
substituents were readily obtained by chemical syntheses.  With a library of diverse 
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chalcones bearing substituents of different electronic and lipophilic characteristics on 
hand, structure-activity relationship (SAR) studies would be greatly facilitated.   
We hypothesized that the introduction of ferrocene into the chalcone template 
would have an important impact on antiplasmodial activity, possibly by affecting the 
physicochemical characteristics of the target compounds, which would in turn 
influence the manner by which these compounds exerted their antiplasmodial effects.  
The hypothesis of this project would be investigated through the following 
approaches: 
1. To design isomeric ferrocenyl chalcones in which the location of ferrocene in the 
chalcone template has been “switched” while maintaining consistency in other parts 
of the molecule.  The purpose is to assess the structural role of ferrrocene with respect 
to its location.  If ferrocene functions as an “inert” spacer, then its positioning in the 
template should not influence physicochemical characteristics of the isomers. 
2. To synthesize, characterize, purify a series of substituted isomeric ferrocenyl 
chalcones, selected reduced derivatives and bis-substituted ferrocenyl analogues to 
establish a structure-activity profile with respect to the importance of the location of 
ferrocene, substitution pattern, the α,β-unsaturated linkage and the impact of 
introducing more than one chalcone side chain on antiplasmodial activity. 
3. To evaluate the selective antiplasmodial activity of the synthesized compounds on 
a chloroquine-resistant isolate, P. falciparum K1 (in vitro), a murine strain of 
chloroquine sensitive P. berghei ANKA (in vivo, for selected members) and 
cytotoxicity against mammalian cell lines to establish the selectivity profile of the 
synthesized compounds.  
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 4.  To assess the relationship between physicochemical properties of ferrocenyl 
chalcones and antiplasmodial activity through a quantitative structure-activity 
relationship (QSAR) study.  Size, electronic, lipophilic and electrochemical 
parameters of the synthesized compounds will be determined from experiment or in 
silico, and their correlation to antiplasmodial activity assessed by multivariate 
analytical methods, principal component analysis (PCA) and partial least squares 
project to latent structures (PLS).  
5. To investigate the effect of selected ferrocenyl chalcones on probable mechanisms 
of antiplasmodial activity, namely binding to heme, β-hematin formation, inhibition 
of glutathione-dependent heme degradation, inhibition of sorbitol-induced lyses of 
infected erythrocytes and the generation of free radicals.  



































The term chalcone is given to the 1,3-diphenylprop-2-en-1-one framework.  
Chalcones occur in nature as precursors of flavonoids.  They are also readily 
synthesized in the laboratory and structural modifications of the chalcone template 
are readily achieved.  The biological activities of chalcones are equally wide-
ranging.PP53, 54PP  Not many structural templates can claim association with such diverse 
pharmacological activities, of which cytotoxicity, anti-tumour, anti-inflammatory, 
antiplasmodial, antileishmanial, antioxidant, immunosuppression are some examples.  
In this regard, chalcones can be regarded as a privileged structure, a term used to 
describe selected structural motifs capable of binding to multiple, unrelated classes of 
receptors or enzymes with high affinity.PP55 PP  This chapter describes the rationale of 
design and synthesis of the present series of ferrocenyl chalcones.  The numbering of 
the chalcone template that is used in this chapter is shown in the following diagram: 















3.2 Rationale of Drug Design 
3.2.1 Ferrocenyl chalcones 
 In order to investigate our hypothesis that ferrocene has an important impact 
on the antiplasmodial activities of chalcones, we have designed two series of 
ferrocenyl chalcones.  Series A ferrocenyl chalcones have ferrocene as ring A.  Series 
B refer to chalcones that have ferrocene as ring B.  Regioisomeric pairs are generated 








                  Compound 14                                                           Compound 2 
                   (Series A)                                                                    (Series B) 
 Fifteen such pairs were synthesized in this investigation.  Attention was paid 
to the choice of substituents on the phenyl ring.  As far as possible, the selection was 
guided by the principles underlying the Craig Plot, namely to choose substituents that 
have a reasonable coverage of hydrophobicity and electronic characteristics.  The 
substituent groups used in this investigation are circled in Figure 3.1. 
 
Figure 3.1: Spread of substituents over the four quadrants of the Craig Plot PPaPP 
 
 a:  σ and π values of substituents were obtained from Reference 56.   
The Hammett constant σ measures the electron-donating (mesomeric and 
inductive) character of the substituent group.  A positive value (+ σ) indicates that the 
 29
group has an electron withdrawing effect, the strength of which is related to the 
magnitude of the σ value.  A negative value (- σ) signifies an overall electron 
donating effect.  The Hansch hydrophobic substituent constant (π) gives an indication 
of the hydrophobic (lipophilic) character of the group.  Large positive values (+ π) are 
associated with hydrophobic groups while negative values (- π) imply that the group 
is hydrophilic.  As shown in Figure 3.1, groups from each quadrant of the Craig Plot 
had been selected.  Those indicated with an asterisk (*), however, were only found in 
series A and did not have a series B counterpart.  
Another modification that was employed in this investigation was the use of 
other aromatic residues, namely heteroaromatic and bicyclic ring structures, in place 
of the substituted phenyl ring.  The rings used were quinoline and pyridine, which are 
π-deficient heteroaromatic systems and naphthalene.  Ferrocenyl chalcones with 
quinoline and pyridine rings are weakly basic.  Comparison of quinoline and 
naphthalene analogs would cast light on the importance of the basic nitrogen atom for 










Table 3.1 Structures of series A and B ferrocenyl chalcones 
                                  Ring A Ring B
O
 
Series A Series B 
No.PP PP Ring A Ring B No. Ring A Ring B
13 Phenyl 1 Phenyl 
14 4-methoxyphenyl  2 1-methoxyphenyl 
15 2,4-dimethoxyphenyl 3 2,4-dimethoxyphenyl 
16 2-naphthalenyl 4 2-naphthalenyl 
17 1-naphthalenyl 5 1-naphthalenyl 
19 4- hydroxyphenyl 7 4-hydroxyphenyl 
21 4-chlorophenyl 43 4-chlorophenyl 
25 4-fluorophenyl 44 4-fluorophenyl 
38 2-pyridinyl 32 2-pyridinyl 
18 3-pyridinyl 6 3-pyridinyl 
39 4-pyridinyl 33 4-pyridinyl 
40 2-nitrophenyl 34 2-nitrophenyl 
41 3-nitrophenyl 35 3-nitrophenyl 
28 4-nitrophenyl 36 4-nitrophenyl 
42 2,4-dimethylaminophenyl 37 2,4-dimethylaminophenyl 
20 4-methylphenyl 8 2,4-dihydroxyphenyl 
22 3-chlorophenyl 9 2-hydroxyphenyl 
23 2-chlorophenyl 10 2,3,4-trimethoxyphenyl 
24 2,4-dichlorophenyl 11 4-ethoxyphenyl 
26 2,4-difluorophenyl 12 4-butoxyphenyl 
Fc 
 
27 4-trifluoromethylphenyl   
29 4-cyanophenyl   
30 3-quinolinyl   
31 




4-quinolinyl   
 
 PPa PP Fc =  Ferrocene 
 
An investigation on organometallic diphenolic compounds had shown that the 
positioning of ferrocene influenced antiproliferative activity, which led the authors to 
conclude that it was not the presence of ferrocene per se, but its influence on the 
“organic portion of the molecule” that determined the balance between proliferative 
and antiproliferative activities in these molecules.PP25PP The influence of ferrocene may 
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be exerted through changes in the physicochemical properties of the compound, of 
which steric, hydrophobic and electronic characteristics are the most typical.  These 
aspects would be investigated in the regioisomeric pairs of ferrocenyl chalcones. 
Theoretically, the regioisomers would have quite similar whole molecule parameters, 
like volume and surface area that assess the bulk of the compound.  On the other hand, 
they would differ in their steric parameters since these properties model the shape of 
the compounds. Hydrophobicity and steric parameters are often correlated and if this 
was the case for the ferrocenyl chalcones, significant differences would not be 
anticipated in the hydrophobicity of the regioisomers.  
In the case of electronic properties, differences would be expected because 
locating ferrocene adjacent to a carbonyl group (as in series A) would not be the same 
as attaching ferrocene to the α,β-unsaturated linkage (series B).  Ferrocene is electron 
donating (σ BBpara FerroceneBB -0.18 compared to σ BBpara phenyBB 0.01) and when it is present as 
ring B, electron donation to the α,β-unsaturated enone moiety can occur (Figure 3.2).  
When it is present as ring A, electron donation may be less effective unless ferrocene 
and the linkage are sufficiently planar to allow delocalization of the π electrons.  It 
had been noted in one study that the phenyl rings A and B of chalcone exhibited 
different degrees of rotational flexibility (ring A > ring B), which in turn influenced 
the overall planarity of the template and the degree of delocalization between the 
rings and the α,β-unsaturated enone.PP57 PP  Since it was not known how the presence of 




Figure 3.2 Proposed involvement of ferrocene in electron delocalization in series A 

















from ferrocene (ring B)
 
 
3.2.2 Dihydroferrocenyl chalcones 
 The reduction of the α,β-unsaturated linkage in chalcones gives rise to 
dihydrochalcones.  Like chalcones, dihydrochalcones have a wide range of biological 
properties.PP58PP The loss of the double bond results in a loss of the rigidity and overall 
planarity of the template. Rings A and B will not be cross-conjugated with each other 
and there will be no electron delocalization from ring B to the carbonyl linkage.  
Chalcones are typical Michael reaction acceptors because electron delocalization in 
the α,β-unsaturated carbonyl entity creates an electrophilic centre that will attract 
nucleophilic groups.  The electrophilic centre is considered “soft” and attracts soft 
nucleophiles like thiols, rather than hard nucleophiles like amino and hydroxyl 
groups.PP59 PP Dihydrochalcones will not behave in this manner. 
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The importance of the α,β-unsaturated linkage for the biological properties of 
chalcones has not been widely investigated.  In one report, modifications of the α,β-
double bond in chalcones were found to marginally affect antiprotozoal properties.PP60 PP  
A study on the chemoprotective and toxic potentials of chalcones and 
dihydrochalcones showed greater cytotoxicities (rat liver epithelial cells) for the 
chalcones.PP61 PP  But they had similar inhibitory activities against CYP1A-dependent 7-
ethoxyresorufin-O-deethylase (EROD), lipid peroxidation and gap junctional 
intercellular communication.  
Three pairs of regioisomers bearing contrasting hydrophobic and electronic 
properties (+ σ, + π versus -σ, -π) were synthesized in this investigation (Table 3.2).  
 
Table 3.2: Structures of Series A and B dihydroferrocenyl chalcones 
                                 Ring A Ring B
O
 
Series A Series B 
No. Ring A Ring B No. Ring A Ring B 
R13 Phenyl R1 Phenyl 
R14 4-methoxyphenyl R2 4-methoxyphenyl 
R21 
Fc 
4-chlorophenyl R43 4-chlorophenyl 
Fc 
 
3.2.3 Bis-substituted ferrocenyl chalcones 
 In this series, the ferrocene ring is attached to two chalcone-like entities in a 
symmetrical manner.  In series A bis-substituted ferrocenyl chalcones (Bis13, Bis14, 
Bis25), ferrocene was retained as ring A and the side chains were attached to different 
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cyclopentadienyl rings (1,1’ substitution).  In series B bis-substituted ferrocenyl 
chalcones (Bis1, Bis2), ferrocene was ring B.  Only two isomeric pairs were 
synthesized, namely Bis1, Bis13, and Bis2, Bis14. (Table 3.3) 
 
Table 3.3 Structures of bis-substituted ferrocenyl chalcones 





Series A Series B 


























3.3 Chemical Considerations 
3.3.1 Synthesis of ferrocenyl chalcones 
 The syntheses of the two series of ferrocenyl chalcones proceeded by base-
catalyzed Claisen-Schmidt condensation, with some modifications.PP62PP For series A,  
acetylferrocene was reacted with the appropriate aldehyde in the presence of 
potassium hydroxide as the base catalyst.  In the case of series B, ferrocene aldehyde 
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was reacted with the appropriate aromatic ketone under similar conditions to give the 
desired compound. Scheme 3.1 shows the outline of syntheses for series A and B.  
 

















(a) KOH, EtOH, rt. 
 
The mechanism of the reaction is shown in Scheme 3.2.  The methyl group of 
acetyl ferrocene or the non-ferrocenyl aromatic ketone was deprotonated by the base 
catalyst (KOH).  The resulting enolate attacked the carbonyl group of the aldehyde 
via a nucleophilic addition reaction. The ferrocenyl chalcone was formed after 
dehydration.  
































When the condensation involved aldehydes or ketones that have hydroxyl 
groups, it was necessary to protect the hydroxyl group to prevent reaction with the 
aldehydic carbonyl group.  Protection was carried out using 2H-3,4-dihydropyran, in 
the presence of pyridinium p-toluenesulphonate.  After condensation, the protecting 
group was removed by acid hydrolysis to generate the product with the free hydroxyl 
group. (Scheme 3.3) The protection–deprotection step was necessary for all hydroxyl 
groups except those attached to the ortho position. For these compounds, the 
reactivity of the hydroxyl group was reduced, perhaps by steric factors, and no 
protection was necessary.   
 




































(a) Pyridinium p-toluenesulphonate in CH BB2 BBClBB2 BB(b) KOH, EtOH, rt. (c) 4M HCl, rt. 
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The mechanism of protection and deprotection of the hydroxyl group is given 
in Scheme 3.4.  2H-3,4-Dihydropyran was attacked by a proton from the pyridinium 
cation (pKa ∼ 5.2) to give a species that was positively charged at the α-carbon.  The 
nucleophilic phenolic hydroxyl group attacked the positive charge with loss of proton 
(possibly to pyridine from the pyridinium cation) and formed an acetal.  After 
Claisen-Schmidt condensation, the protected hydroxyl group was removed by acid 
hydrolysis.  Mechanistically, the deprotection reaction was the reverse of the reaction 
introducing the pyran moiety.  
 














































3.3.2 Synthesis of dihydroferrocenylchalcones 
 The reduction of the α,β-unsaturated double bond in the ferrocenyl chalcone 
was carried out using catalytic hydrogenation, with palladium (supported on carbon) 
as catalyst (Scheme 3.5). Palladium is probably the best catalyst for the 
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hydrogenation of alkenes (and alkynes) as the reaction can be achieved at low 
pressures, and palladium is generally known to be resistant to catalyst poisons.PP63 PP  The 
dihydroferrocenyl chalcones were obtained in reasonable yields (approximate 85%).  












(a) Pd/C 10%, EtOAc, HBB2BB, 30psi, rt. 
 
3.3.3 Synthesis of bis-substituted ferrocenyl chalcones 
Mashburn and coworkers reported that 1,1’-diacetylferrocene and 
benzaldehyde underwent an alkali-catalyzed condensation to form mono- and 
dibenzaldehyde derivatives and a yellow product.PP64 PP The structure of the yellow 
product was subsequently found to be 3-phenyl-[5]-ferrocenophane-1,5-dione.PP65 PP The 



















3-phenyl-[5]-ferrocenophane-1,5-dionemono-benzal derivative dibenzal derivative
Red Yellow  
 In the present investigation, the formation of the monobenzaldehyde was 
avoided by using a two-fold excess of the reacting benzaldehyde.  To minimize the 
occurrence of the self-condensation yellow product, the reaction was monitored with 
thin-layer chromatography to establish the optimum time for the reaction.  The same 
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procedure was followed for the reaction between the acetophenone and 1,1’-
ferrocenedicarboxyaldehyde. (Scheme 3.6)  
 























(a) KOH, EtOH, rt. 
 
3.3.4 Characterization by proton NMR spectroscopy 
  The α,β-unsaturated linkage in the ferrocenyl chalcone gave rise to two 
doublets (δ 6 – 8 ppm) due to the vicinal protons on the double bond.  The trans (E) 
configuration of the bond was indicated by the coupling constant of these protons. 
Vicinal protons on a trans isomer have a greater coupling constant (J BBHα-Hβ BB = 11-18 
Hz) than the cis isomer (J BBHα-Hβ BB = 5-10 Hz) because of the larger dihedral angle 
between the protons. The coupling constants of the vicinal protons indicated that the 
ferrocenyl chalcones were obtained in the E configuration.  When the double bond 
was reduced to give dihydroferrocenyl chalcones, the chemical shift of the α,β-
protons moved predictably upfield (∼ δ 3 ppm) because the carbon atoms were no 
longer spPP2PP hybridized.  
 40
 The presence of the ferrocene ring was indicated by three distinct chemical 
shifts at δ 4.2, 4.5 and 4.9 ppm.  These protons were upfield compared to the phenyl 
protons because the cyclopentadienyl (Cp) rings in ferrocene is electron rich.  The 
five protons on the unsubstituted Cp ring shared the same chemical environment and 
were observed as a single peak at 4.2 ppm, integrating for 5 protons. The peaks at 4.5 
ppm and 4.9 ppm belonged to the four protons on the other Cp ring. These protons 
were shifted downfield because the ring was attached to either the electron 
withdrawing carbonyl bond (series A) or the double bond (series B).   
 
3.4 Experimental methods 
3.4.1 General experimental methods 
Melting points were uncorrected.   PP1 PPH NMR chemical shifts were determined 
on a Bruker (DPX 300 MHz) spectrometer and reported in δ (ppm) relative to TMS 
as internal standard.  Mass spectra (nominal and accurate) were collected on a VG 
Micromass 7035 E mass spectrometer by electron spray ionization.  Elemental 
analyses for carbon, hydrogen and iron were determined by Chemical and Molecular 
Analysis Center (CMAC), National University of Singapore and indicated by their 
symbols if they were within ± 0.4% of the theoretical values. The purity of selected 
compounds was also determined by reverse-phase HPLC (Zorbax Eclipse XDB-C18 
column, 4.6 x 150 mm, 5 µm, on a Shimazu LC-2010 system with UV detector set at 
300nm) using two different solvent systems (methanol-water and acetonitrile-water).  
Reagents and solvents were of synthetic grade or better.   
 
 41
3.4.2 Syntheses of ferrocenyl chalcones 
 The general procedure for preparing ferrocenyl chalcones that did not require 
protection of the hydroxyl groups is described in the following paragraph.    
The substituted ketone (3mmol) and KOH (0.2 g) were dissolved in ethanol 
(5ml) in a round bottom flask and stirred at room temperature for 10 min. An 
ethanolic solution of the substituted aldehyde (3 mmol, 5 ml) was added dropwise and 
the mixture was stirred at room temperature for 2 to 24 hours. The reaction was 
monitored by TLC on silica gel sheets (with fluorescent indicator) using 
tetrahydrofuran (THF) -hexane (1:4) as eluting solvent. At the end of the reaction, the 
solution was neutralized with 2 M HCl. When a precipitate was obtained after 
neutralization, it was removed by filtration, washed with water and a small amount of 
cold ethanol. The crude product was recrystallized with ethanol. If no precipitate was 
obtained on neutralization, the solution was extracted with ethyl acetate (20 ml, 3 
times). The organic layer was dried with anhydrous NaBB2BBSO BB4 BB and removed by 
evaporation under reduced pressure to give a liquid residue. The latter was passed 
through a column of silica gel (230-400 mesh ASTM) and eluted with THF-hexane 
(1:4). The yields of the synthesized compounds, their melting points, spectroscopic 
and elemental analyses data are presented in Table 1, Appendix. 
The general procedure for preparing ferrocenyl chalcones that required 
protection of the hydroxyl groups is described in the following paragraph.  
4-Hydroxyacetophenone, 2,4-dihydroxyacetophenone or 4-hydroxy-
benzaldehyde (3 mmol), pyridinium p-toluenesulphonate (0.2 mmol) and 2H-3, 4-
dihydropyran (8 mmol) were dissolved in methylene chloride (10 ml) and stirred for 4 
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hours at room temperature. The reaction mixture was then washed with 1M NaBB2BBCOBB3 BB 
(20 ml, 3 times), the organic layer was separated, dried over anhydrous NaBB2BBSO BB4 BB and 
concentrated in vacuo to give the crude tetrahydropyranyl ether as a yellow colored 
product (solid or liquid).  PP1 PPH-NMR spectrum of the product was taken to confirm the 
formation of the product.  It was then used without purification for the subsequent 
condensation with aldehyde or ketone.  A methanolic solution of the aldehyde or 
ketone, protected as the tetrahydropyranyl ether (3 mmol) was added to a stirred 
solution of the ferrocenyl ketone/ aldehyde (3 mmol) in methanol (5 ml). A 
methanolic solution of sodium hydoxide (3% w/v, 5 ml) was added to the reaction 
solution drop wise, stirring was continued for 24 hours. Removal of the 
tetrahydropyranyl groups was achieved by acid hydrolysis, using 4 M HCl (2 ml) 
which was added to a stirred solution of the crude product in ethanol (10 ml), stirred 
(4 hours, room temperature) and then diluted with water (40 ml). The mixture was 
extracted with ethyl acetate (50 ml, 3 times) and the combined organic phases were 
concentrated in vacuo to give the crude hydroxylated ferrocenyl chalcone. The crude 
product was purified by column chromatography using silica gel (230-400 mesh 
ASTM) and THF-hexane (1:4) as mobile phase. All compounds were characterized 
by PP1 PPH-NMR spectroscopy, accurate mass spectrometry and elemental analysis (Table 
1, Appendix). 
 
3.4.3 Synthesis of dihydroferrocenyl chalcones 
The ferrocenyl chalcone (3 mmol) was dissolved in ethyl acetate (20 ml), 0.1 
g of 10% Pd on carbon was added and the mixture was hydrogenated at 30 psi, 4 
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hours on a shaking Parr Hydrogenator.  At the end of the reaction, the catalyst was 
filtered off, the solvent was evaporated under pressure and the residue was dried in 
vacuo. The crude product was purified by column chromatography using silica gel 
(230-400 mesh ASTM) and ethyl acetate-hexane (1:4) as mobile phase. Yields, 
melting points and spectroscopic data of the compounds are given in Table 1, 
Appendix.  
 
3.4.4 Synthesis of bis-substituted ferrocenylchalcones 
To a stirred solution of 1,1’-diacetylferrocene or 1,1’-
ferrocenedicarboxaldehyde (2 mmol) with KOH (0.2 g) in 10 ml ethanol was added 
dropwise an ethanolic solution (10 ml)  of the aldehyde or ketone (10 mmol). The 
reaction was monitored with TLC using THF-hexane (1:4) as eluting solvent. After 
about 6 hours stir at room temperature, the solution was filtered to remove the solid 
residue which was recrystallized in ethanol. All compounds were characterized by 
PP
1
PPH-NMR and accurate mass (Table 1, Appendix). 
 
3.5 Summary 
The syntheses of 56 ferrocenyl chalcones, selected dihydro analogues and bis-
substituted ferrocenyl chalcones were successfully achieved using standard synthetic 
procedures.  The compounds were characterized by proton NMR and mass 
spectrometry (accurate mass).  Their purities were determined by elemental analyses 
and for selected compounds, by reverse phase HPLC as well.  Compounds that gave a 
single peak on the HPLC chromatogram (using two different mobile phases), with 
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peak area of > 95%, were deemed to be sufficiently pure for biological evaluation.  A 
limitation, however, is that since detection utilized a UV detector, impurities that do 
not absorb UV will not be detected. Among the synthesized compounds were 15 pairs 
of regioisomers, in which rings A and B had been switched.  The physicochemical 
characterization and biological evaluation of these compounds would give valuable 
information on how the position of ferrocene in the chalcone template affected these 
properties.  The importance of the double bond and the inclusion of more than one 
chalcone side chain were assessed from the dihydro and bis-substituted ferrocenyl 
chalcones.   The information would be used to establish structure-activity 




















INVESTIGATIONS OF THE ANTI-PLASMODIAL 


















 The ferrocenyl chalcones were evaluated for in vitro antiplasmodial activity 
on a chloroquine-resistant isolate of P. falciparum (K1).  The compounds were tested 
for their ability to inhibit the uptake of radiolabelled hypoxanthine into Plasmodium.  
The malarial parasites are unable to carry out de novo synthesis of purines from non-
nucleotide precursors and are dependent on salvage pathways for their supply of 
preformed purine bases. PP66PP  Hypoxanthine is the major source of purines for the 
growth of Plasmodium.  The uptake of hypoxanthine serves as an important 
parameter of parasite growth and the extent to which a compound inhibits 
hypoxanthine uptake by Plasmodium is a useful measure of its potency as an 
antiplasmodial agent.   
 The ferrocenyl chalcones were also tested against a murine strain of 
Plasmodium .  Such models are a convenient means of evaluating the in vivo effects 
of potentially useful antimalarial agents.  The main criticisms are that the human 
immune system is different from that of mice, and drugs have different 
pharmacokinetic profiles in man and mice.  On the other hand, all mammalian 
Plasmodium species have similar life cycles and established antimalarial agents are 
equally effective in mice and man.PP67PP 
 The selectivity of the antiplasmodial activity of the test compounds is also 
reported in this Chapter.  It is important to establish that a substance that kills 
plasmodial cells is not toxic to mammalian cells at the same concentration.  Thus, the 
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in vitro selectivity index of the test compound (ICBB50 mamallian cellBB / IC BB50 plasmodia BB) was 
determined, where IC BB50 BBis the concentration that inhibited cell growth (plasmodia or 
mammalian cell line) by 50%.  The choice of the mammalian cell line should be made 
carefully.  Cell lines that are very sensitive or too robust may give deceptive 
selectivity indices.  In this investigation, a human epidermoid cancer cell line (KB3-1) 
and a normal mammalian cell line (Madin Darby Canine Kidney cells) were used.  
The KB cells had been used to determine selectivity indices for antiplasmodial 
agents.PP68PP  It was noted that this cell line exhibited a favorable intermediate sensitivity 
to a large number of cytotoxic agents when compared to other cell lines.PP69 PP  Since 
cancer cell lines might exhibit loss of checkpoint controls in their cell cycle, 
selectivity tests were also carried out on normal mammalian cells. The MDCK cell 
line was selected for this purpose.  The cytotoxicity of the test compounds on these 
two cell lines was determined using the microculture tetrazolium assay.PP70, 71PP  Cells 
with functional mitochondria have succinate dehydrogenase which is capable of 
reducing the yellow tetrazolium dye [MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide ] to an insoluble purple product, formazan.  The 
amount of formazan formed was quantified by spectrophotometry (λ max = 590 nm) 
and correlated to the viability of the cells. 
 
4.2 Experimental methods 
4.2.1 Materials   
Dulbecco’s Minimum Essential Medium (DMEM) and phosphate -buffered 
saline (PBS) were purchased from NUMI, (Singapore). Fetal Bovine Serum (FBS) 
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was from Gibco BRL Life Technology (NY, USA).  Nalgene Cryo 1˚C freezing 
container and 96-well plates were purchased from Nalge Nunc International, 
Rochester, (NY, USA). Tissue culture flasks were from Cellstar, Greiner Bio-One 
GmbH, North Carolina, USA. A Tecan Spectra Fluor PP®PP multi-well plate reader was 
used. The liquid scintillation counter employed was Beckman LS-1801PP®PP.  The 
following chemicals were purchased from Sigma Chem. Co. (MO, USA): glutamine, 
penicillin/ streptomycin, non-essential amino acids, sodium pyruvate, trypsin-EDTA, 
chloroquine diphosphate. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) was purchased from BDH (Poole, England).  Other reagents were of 
analytical grade.  MDCK cells were a gift from Dr Theresa Tan, Department of 
Biochemistry, National University of Singapore.  KB3-1 cells were a gift from Dr 
Caroline Lee, Department of Biochemistry, National University of Singapore. 
 
4.2.2 In vitro evaluation of antiplasmodial activity using P. falciparum (K1) 
a) Preparation of culture medium 
i) Stock medium 
RPMI 1640 medium solution (10.4 g dissolved in 800ml of double-distilled 
water) was mixed with 5.94 g HEPES to give a final concentration of 25mM HEPES. 
The pH of the medium was adjusted to 6.75, and the volume was adjusted to 960 ml 
with double-distilled water. Gentamicin sulfate was added to the medium solution at a 
final concentration of 40 μg/ml to prevent bacterial contamination. The stock medium 
was sterilized by filtration through a 0.45 μm millipore filter and stored at 4˚C for use 
within 4 weeks. 
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ii) Incomplete medium 
4.2 ml of 5% (w/v) sodium bicarbonate was added to 100 ml stock medium to 
yield a medium with final concentration of 0.2% sodium bicarbonate. The incomplete 
medium was kept at 4˚C for use within 2 days. 
iii) Complete medium 
4.2 ml of 5% (w/v) sodium bicarbonate and 11.5 ml of human serum were 
added to 100 ml stock medium to give a final concentration of 10% (v/v) serum and 
kept at 4˚C for use within 3 days. 
 
b) Preparation of uninfected red blood cells 
Human blood was centrifuged at 2000 rpm at 4˚C for 10 min. After removal 
of plasma and buffy coat, packed red cells were washed twice with excess amount of 
incomplete medium. The cells were resuspended  with complete medium to 50% 
(v/v). The red blood cells were kept at 4˚C for use within a week. 
 
c) Preparation of parasitized red blood cells 
From continuing established culture, the parasitized red blood cells were 
centrifuged for 10 min. After supernatant was discarded, the red blood cells were 
resuspended with an equal volume of complete medium. Thin film was made and the 
level of parasitemia was calculated by counting not less than 1000 erythrocytes on the 
slide. The parasitemia was adjusted to 0.5% with freshly washed erythrocytes, and the 
cells were suspended with complete medium to give a final cell suspension of 3%. 
The cell suspension was dispensed into 60 x 15 mm petri dish, which was then placed 
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in the candle jar. The candle was lit and the candle jar was sealed after the candle 
flame went out to produce an atmosphere of low O BB2BB and high COBB2 BB (17% OBB2 BB, 3% COBB2 BB, 
80% NBB2 BB). The candle jar was placed in 37˚C incubator.  The culture medium was 
changed every day by gently draw out the old medium without removing the cells. 10 
ml fresh medium was added and the solution was gently resuspended. The thin smear 
was made to check the parasitemia and the condition of the cells. 
 
d) Synchronization of parasites 
In order to obtain ring stage parasites for the testing, the cells were 
synchronized before use. The cells in the petri dish were suspended and centrifuged at 
2000 rpm for 10 min. The supernatant was removed and the cells were resuspended 
with 5 times the equivalent volume of 5% sorbitol. The solution wqas allowed to 
stand at room temperature for 10 min before centrifuging again at 2000 rpm for 10 
min. The supernatant was discarded and the cells were washed with incomplete 
medium. A thin smear was made to confirm the cells were synchronized (more than 
90% parasites at ring stage). The cells were cultured for another cycle before they 
were used for testing. 
 
e) Determination of parasitemia  
The thin blood film was made and fixed with methanol before staining with 
Gemsa’s stain. The level of parasitemia was determined by counting the number of 
viable parasites in 1000 erythrocytes. 
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f) Antiplasmodial activity test 
The drug stock solutions were freshly prepared in DMSO immediately before 
the test. The stock solutions were further diluted to at least 5 different concentrations 
with complete medium before testing.  The synchronized parasite infected red blood 
cells were diluted with complete medium, and 50% (v/v) uninfected erythrocytes 
were added to give a final concentration of 1.5% hematocrit with 1% parasitemia.  
200μl of the cell suspension was added to each of the inner 72 wells of the 96-well 
plate. The peripheral wells were filled with incomplete medium to prevent 
evaporation. 25 μl of diluted drug solutions were added to the wells. In all cases, 
concentration of DMSO in diluted solution was less than 0.5% (v/v). The effect of 
DMSO was also monitored as control in each plate.  After 24 hours incubation at 
37˚C, 25 μl of 0.5 μCi [PP3 PPH]-hypoxanthine was added to each well. After 18 hours 
incubation, the parasites were harvested onto glass fiber filters (Whatman grade 934 
AH), and lysed with distilled water. The filters were dried in 60˚C oven and then 
transferred into 1.5 ml Eppendorf tubes. 0.6 ml liquid scintillation cocktail (0.35% 
(w/v) 2,4-diphenyloxazole and 0.005% (w/v) 1,4-bis[2-(5-phenyloxazolyl)] benzene 
in toluene) was added to each tube. The amount of radioactivity in each tube was 
determined on a liquid scintillation counter.  Each compound was tested at least twice, 
at different 5 concentrations, to obtain a concentration-response curve.  The ICBB50BB of 
the compound (concentration required to inhibit hypoxanthine uptake by 50% 





4.2.3 in vivo evaluation of antimalarial activity against mice infected with P. berghei 
(ANKA) 
The in vivo test was carried out using a chloroquine sensitive strain of P. 
berghei (ANKA). Parasitized erythrocytes (50%) were taken from –80°C freezer and 
thawed in a 37°C water bath within 1min. Because Plasmodium had been kept 
dormant at low temperatures, it was necessary to subject them to at least 3 passages in 
uninfected mice before they were used for in vivo tests.  Thus, an aliquot (250 μl) of 
the thawed infected blood was inoculated intraperitoneally into Swiss albino mice 
(male, 25 g).  Blood from the infected mice was collected when the parasitemia 
reached 50% (about 9 days), and an aliquot (80 μl) of the freshly collected blood was 
inoculated into uninfected mice. This was repeated on two more occasions.  The in 
vivo evaluation was started on Day 0 when the mice were infected. Three continuous 
doses of the test compound (100 mg/kg in 0.06 ml DMSO) were administered by 
intraperitoneal injection on Day 1, 2 and 3 respectively. Each compound was tested 
against three mice. Chloroquine was used as a positive control and it was given as an 
aqueous solution of 52 mg/kg in a single dose on Day 1.  DMSO was the negative 
control and 0.06 ml was administered to the mice daily from Day 1 to Day 3. 
 Thin layer blood smears were made from the tail blood of each mouse daily 
with the tail blood. The blood smears were fixed with methanol and stained with 5% 
Giemsa for 10 min. The slides were rinsed with tap water, dried and examined under 
the  microscope. The level of parasitemia was assessed by counting 300-500 
erythrocytes per slide.  
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The survival times and parasitemia of the treated infected mice were 
monitored daily.  The mice treated with DMSO (negative control) had high levels of 
parasitized erythrocytes (∼ 80%) and succumbed to the infection between Day 5 to 
Day 7. Mice treated with chloroquine had low levels of parasitemia (less than 10%) 
and perished after 14 days.  
Compounds 1,6 and 28 were also inoculated into uninfected mice at a dose of 
100 mg/kg (in 0.06 ml DMSO) for three consecutive days. Each compound was 
tested against three mice. The appearance and behavior of the mice were monitored 
daily.   
 
4.2.4 Evaluation of cytotoxic activity against MDCK and KB-3-1 cells 
a) MDCK (Madin-Darby Canine Kidney) cells 
The growth medium (500 ml) was prepared by mixing 450 ml Dulbecco’s 
Minimum Essential Medium (DMEM) with 50 ml FBS, 5 ml glutamine, 5 ml 
penicillin/ streptomycin, 5 ml Non-Essential Amino Acid and 5 ml sodium pyruvate. 
The cells were cultured in a 75 cmPP3 PP tissue culture flask, and the culture 
medium was changed every 2 days until reaching confluency. Sub-culturing was then 
carried out at a split ratio of 1 to 5. A 75 cmPP3 PP tissue culture flask of cells were 
trypsinized with 5 ml 0.5% trypsin-EDTA till cell detachment was noticed. 4 ml of 
the trypsin solution was then drawn out and the culture flask was kept at 37°C for 5 
minutes. When 90% of the cells were split from each other, 10ml culture medium was 
added into the flask and the cells were rinsed down by a pipette.  For consistency, 
only cells with passage number of 20 to 25 were used for experiments. The cells were 
 54
cryo-preserved until they were required for experiments. Cryovials were filled with 
aliquots of about 10PP6 PP cells suspended in 1ml of medium containing 10% DMSO as 
cryoprotectant. The vials were cooled gradually from room temperature to -80˚C by 
keeping them overnight in a Nalgene Cryo 1˚C freezing container placed in a -80˚C 
freezer. The vials were removed the next day and stored in a liquid nitrogen Dewar 
until they were required for use. 
 
b) KB-3-1 cells 
The culture medium for KB-3-1 cells (500 ml) was prepared by mixing 450 ml 
Dulbecco’s Minimum Essential Medium (DMEM) with 50 ml FBS.  The cells were 
cultured in the same way as MDCK cells, except the cells were cryopreserved in FBS 
with 10% DMSO instead of the culture medium. 
 
c) Microculture tetrazolium assay 
The assay was carried out following reported methods.PP70, 71 PP MDCK or KB-3-1 cells 
were trypsinized upon reaching confluency and the concentration of the cells was 
determined by counting the cells on a slide. The cells were diluted to 1×10PP5PP cells/ml 
with medium (90% DMEM with 10% serum). An aliquot cell suspension (100 μl) 
was added to each well in a 96-well plate. 8 wells were left empty and act as controls 
for each plate.  
The cells were incubated for 24 hours for attachment and recovery after trypsinization. 
The drugs were prepared in DMSO and diluted to a series of concentrations with 
medium. The drug solutions were gently introduced into the wells without disturbing 
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the cells. Positive control (SDS) and negative control (dextran) were made in each 
plate as well.  After the cells were incubated with drugs at 37˚C, 5% CO BB2 BB for 24 hours, 
the supernatant in the wells was discarded and replaced with 100 μl of 0.5 mg/ml 
MTT (dissolved in pH 7.4 HBSS-HEPES buffer). The plates were incubated for 
another 3 hours before the supernatant was removed, after which the wells were 
washed with PBS (100 μl).  DMSO (150 μl) was added to each well to dissolve the 
purple formazan crystal. After 10 minutes, when the crystal had dissolved, the plates 
were read on a multi-well plate reader at a wavelength of 590 nm. 
 
4.3 Results and discussion 
4.3.1 In vitro antiplasmodial activities of ferrocenyl chalcones 
Table 4.1 gives the ICBB50 BB values for in vitro antiplasmodial activity of the test 
compounds and their selectivity indices against KB31 and MDCK cell lines. Some 







Table 4.1 In vitro antiplasmodial activity of ferrocenyl chalcones 
Series A Series B 
Ferrocenyl Chalcones and Phenyl Chalcones 
Ring A Ring B
O
 
Selectivity Index PPePP Selectivity Index 
No. Ring APP aPP Ring B 
 ICBB50 BB 
(µM)PP bPP (MDCK)PP c PP (KB) PP d PP 
No. Ring A Ring B  ICBB50 BB (µM) 
(MDCK)PP PP (KB) PP PP 
13 Phenyl 19.0 2.94 3.10 1 phenyl 175 0.23 0.44 
14 4-methoxyphenyl  17.0 1.82 1.15 2 4-methoxyphenyl 410 0.15 0.25 
15 2,4-dimethoxyphenyl 18.0 3.85 1.84 3 2,4-dimethoxyphenyl 24.5 1.54 2.77 
16 2-naphthalenyl 73.5 0.68 0.53 4 2-naphthalenyl 21.0 2.86 2.51 
17 1-naphthalenyl 72.5 0.53 1.19 5 1-naphthalenyl 47.4 2.63 2.68 
19 4- hydroxyphenyl 20.6 5.00 1.40 7 4-hydroxyphenyl 36.0 1.72 1.93 
21 4-chlorophenyl 14.5 3.57 2.06 43 4-chlorophenyl 78.5 ND ND 
25 4-fluorophenyl 12.1 5.26 17.6 44 4-fluorophenyl 32.7 ND ND 
38 2-pyridinyl 58.3 ND PPf PP 0.57 32 2-pyridinyl 53.6 ND 12.2 
18 3-pyridinyl 17.0 2.86 1.22 6 3-pyridinyl 4.6 5.26 8.63 
39 4-pyridinyl 14.0 ND 4.08 33 4-pyridinyl 31.6 ND 4.02 
40 2-nitrophenyl 53.8 ND 2.53 34 2-nitrophenyl 39.4 ND 3.40 
41 3-nitrophenyl 41.7 ND 0.96 35 3-nitrophenyl 36.5 ND 0.59 
28 4-nitrophenyl 5.1 14.29 36.7 36 4-nitrophenyl 61.7 ND ND 
42 2,4-
dimethylaminophenyl 
58.7 ND 2.86 37 2,4-dimethylaminophenyl 131 ND 0.57 
20 4-methylphenyl 147 0.49 0.60 8 2,4-dihydroxyphenyl 31.5 2.94 3.17 
22 3-chlorophenyl 36.2 1.49 1.32 9 2-hydroxyphenyl 73.5 0.74 1.51 
23 2-chlorophenyl 42.4 1.64 1.50 10 2,3,4-trimethoxyphenyl 22.5 2.27 3.40 
24 2,4-dichlorophenyl 29.4 2.27 1.66 11 4-ethoxyphenyl 200 0.23 0.51 
26 
Fc 
2,4-difluorophenyl 23.2 2.94 6.68 12 4-butoxyphenyl 
Fc 






Series A Series B 
Selectivity Index  Selectivity Index 
No. Ring APP 
PP 




(MDCK) PP PP (KB) PP PP 










58.4 0.47 1.18 45 Fc Fc 26.9 ND ND 
29 4-cyanophenyl 26.5 3.33 11.2 C45 phenyl phenyl 47.4 ND ND 
30 3-quinolinyl 18.2 3.70 0.87 C6 3-pyridinyl phenyl 24.9 ND ND 
31 
Fc 
4-quinolinyl 14.0 14.29 7.50 C28 phenyl 4-
nitrophenyl 
18.5 ND ND 
Dihydroferrocenyl Chalcones 
Ring A Ring B
O
 
Selectivity Index Selectivity Index 
No. Ring A Ring B ICBB50 BB (µM) 
(MDCK) PP PP (KB) PP PP 








R13 Phenyl 132 ND 0.92 R1 phenyl 27.2 ND ND 




67.2 ND ND 
R21 
Fc 
4-chlorophenyl 191 ND 2.02 R43 4-chlorophenyl 
Fc 
35.6 ND ND 








Series A Series B 
Selectivity Index Selectivity Index 
No. R ICBB50 BB (µM) 
(MDCK) (KB) 





21.3 ND ND Bis1 
O
 





















PPSeries A compounds have ferrocene (Fc) as ring A. Series B compounds have ferrocene (Fc) as ring B.  Ph = phenyl 
PP
b  




PPSelectivity index = ICBB50BB for cytotoxicity against MDCK cells / ICBB50BB P. falciparum. 
PP
d  
PPSelectivity index = ICBB50BB for cytotoxicity against KB3-1 cells / IC BB50BB P. falciparum. 
      PPePP The IC BB50 BB values for cytotoxicity against MDCK and KB3-1 cells are shown in Table 4, Appendix. 
      PPf PP Not determined. 
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Regioisomeric ferrocenyl chalcones 
 Among the ferrocenyl chalcones were 15 pairs of compounds (regioisomers) 
in which rings A and B had been switched.  When the antiplasmodial activities of the 
regioisomers were compared, the member with ferrocene as ring A (series A) was 
generally found to be more active than its isomer with ferrocene as ring B (series B).  
This trend was observed in nine pairs of regioisomers and with one exception (33, 39), 
all the compounds had phenyl as ring A or B.   
When naphthalene was present, the reverse was observed and the series B 
isomer was more active. When pyridine was present, the results were mixed.  The 2-
pyridinyl regioisomers (32,38) had similar activities, the series B isomer (6) was more 
active in the 3-pyridinyl regioisomers and the 4-pyridinyl isomers (33, 39) followed 
the general trend (series A > series B).  Mixed outcomes were also noted for nitro 
substituted ferrocenyl chalcones.  Among the 2-nitro (40, 34) and 3-nitro (41, 35) 
regioisomers, the series B isomer was more active but the 4-nitro (28, 36) 
regioisomers followed the general trend (series A > series B).  
 The reasons for the contrasting trends could only be speculated upon. Perhaps 
the general trend (series A > series B) applied primarily to ferrocenyl chalcones with 
phenyl rings, and not those with heterocyclic (pyridine) or polycyclic (naphthalene) 
rings.   It was noted that pyridine and nitrophenyl are both electron withdrawing 
groups and coincidentally, the “normal” behavior was observed for the 4-nitro and the 
4-pyridinyl isomers, and not the 2 and 3 isomers. The mesomeric electron-
withdrawing effects (-M) of the azomethine nitrogen and the nitro group are strongest 
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at the 4-position.  It is not known how or why this should affect activity but the 
similarity is noteworthy. 
 
Series A ferrocenyl chalcones 
 In view of the better activity associated with series A, additional analogues in 
this series were synthesized to obtain a better understanding of how substitution on 
ring B affected activity.  The unsubstituted ring B (13) had moderate activity (ICBB50 BB 19 
μM).  The introduction of an electron-withdrawing halogen functionality (4-chloro 21 
or 4-fluoro 25) caused a modest increase in activity (ICBB50 BB 12-14 μM).  But positional 
isomerism was noted for the chloro substituent because the 2-chloro and 3-chloro 
analogues had markedly reduced activities (36-42 μM), in contrast to the 4-chloro 
analogue (21, 14.5 μM).  Disubstitution of ring B with two chloro (24) or two fluoro 
(26) groups did not improve activity (23-29 μM).  Neither was the introduction of 4-
trifluoromethyl (27), a more hydrophobic and electron-withdrawing substituent than 
the halogens, found to be beneficial.   
Interestingly, the 4-nitro analogue (28) had exceptionally good activity (ICBB50BB 5 
μM).  In fact, 28 was found to be the most active series A compounds. The nitro 
group is strongly electron withdrawing (σ BBpara BB 0.78) but is less hydrophobic (π for 
aromatic nitro = -0.28) PP 56 PP than the halogens and CFBB3 BB.  But this may not be the only 
reason for its good activity. The cyano functionality (29) has almost the same σ (0.66) 
and π (-0.57) values as the nitro, but was not associated with good activity (ICBB50BB 26 
μM).  On the other hand, the cyano group is linear and electron delocalization is not 
as extensive as the bulkier nitro group. Secondly, the position of the nitro group 
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affected activity markedly, as can be seen from the lower activities of the 2-nitro (40) 
and 3-nitro (41) analogues.  The positioning and bulk of the nitro functionality may 
be important in this regard. 
When a lipophilic electron donating group like methyl (+π, -σ) was 
introduced into ring B, a significant drop in activity was observed (20, ICBB50BB 147 μM). 
A smaller decrease was observed with the dimethylamino analogue (42), which is 
also a (+π, -σ) group.  Evidently, groups with these characteristics adversely affected 
activity.  
 The methoxy and hydroxyl groups are characterized by (-π, -σ) values, in 
contrast to the halogens (+π, +σ).PP56 PP  It was observed that the introduction of 4-
methoxy into ring B did not affect activity significantly (14, ICBB50 BB 17 μM).  Neither did 
the presence of additional methoxy (15) or hydroxyl groups improve activity. 
 Therefore, for the series A compounds, the SAR indicated an overall 
preference for electron withdrawing groups that were not excessively hydrophobic (-1 
< π < 1).  Additional requirements may be the location of the group (preferably at the 
4 position) and possibly, the ability to participate in hydrogen bonding as hydrogen 
bond acceptors (a characteristic of the nitro group). 
 
Series B ferrocenyl chalcones 
  The SAR for the series B ferrocenyl chalcones showed several differences 
compared to the series A compounds.  The unsubstituted ring A analog (1) had very 
poor activity (IC BB50 BB 175 μM) and a general improvement was observed when groups of 
varying π and σ properties were introduced.  Thus, the 4-hydroxy and 4-fluoro 
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analogues had almost equivalent activities (ICBB50 BB 32-36 μM), despite their contrasting 
σ and π characteristics.  The 4-nitro group which was optimal for series A was not 
outstanding in series B.  The contribution of the 4-methoxy group deserved some 
comment. The 4-methoxy analogue (2) was even less active than the unsubstituted 
compound (1), but introducing additional methoxy groups (dimethoxy 3, trimethoxy 
10) improved activity.  It may be that a bulky or highly substituted ring B is essential 
for good activity.  In support of this hypothesis, it was noted that replacing phenyl 
with the larger naphthalene ring (3,4) improved activity to a marked extent.  
 Therefore, different SAR was deduced for series B and series A compounds.  
There was no clear preference for electron donating or withdrawing groups or a 
particular range of hydrophobicity among the series B compounds, but there was an 
indication that the size of ring B was important. 
 
Ferrocenyl chalcones with naphthalene, pyridine and quinoline rings 
 It had been mentioned that series B compounds with naphthalene and 3-
pyridinyl rings were more active than their series A analogues, in contrast to the 
general trend.  It may be that a larger or bulkier ring B is required for activity.  This 
would explain the good activity of the series B naphthalenyl compounds (4, 5).  On 
the other hand, it cannot be said that a bulky ring A was detrimental to activity.  
Napthalene and quinoline rings share similar steric characteristics but only the 
naphthalenyl analogues (16, 17) had poor activity.  The quinolinyl analogues (30, 31) 
were almost as active as the phenyl (13) and pyridinyl counterparts (18, 39). One 
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possibility was that size could be tolerated at ring A, if it had electron withdrawing 
properties.   
 Mention must be made of the 3-pyridinyl analogue 6 because it had the 
greatest activity among the series B compounds.  Effect of positional isomerism was 
again evident as neither the 2-pyridinyl nor 4-pyridinyl analogues were as active as 
the 3-pyridinyl compound.  
 
Substitution of ferrocene with phenyl in series A and B   
 The importance of the ferrocene ring would be clearly indicated by comparing 
the activities of compounds in which ferrocene had been substituted with phenyl.  A 
few examples are available for comparison (Table 4.2) 
 
Table 4.2 Antiplasmodial activity of ferrocenyl chalcones compared with phenyl 
chalcones 
No. Ring A Ring B ICBB50 BB(μM) 
13 Fc Ph 19 
1 Ph Fc 175 
45 Fc Fc 27 
C45 Ph Ph 47 
2 4-ethoxyphenyl Fc 200 
C2 4-ethoxyphenyl Ph 43 PPaPP 
3 2,4-dimethoxyphenyl Fc 25 
C3 2,4-dimethoxyphenyl Ph 56 PPaPP 
10 2,3,4-trimethoxyphenyl Fc 23 
C10 2,3,4-trimethoxyphenyl Ph 16 PPaPP 
7 4-hydroxyphenyl Fc 36 
C7 4-hydroxyphenyl Ph 30 PPaPP 
28 Fc 4-nitrophenyl 5 
C28 Ph 4-nitrophenyl 19 
6 3-pyridinyl Fc 5 




PP IC BB50 BB values for inhibition of [3H] hypoxanthine uptake into P. falciparum (K1). PP72 
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Comparing the activities of compounds 1, 13, 45 and C45, one would 
conclude that introducing ferrocene into the chalcone template improved activity (45 
and C45), but this effect was dependent on which phenyl ring was replaced by 
ferrocene.  Clearly, replacing a phenyl ring A with ferrocene was more beneficial (13 
versus 1).   
The activities of compounds 2, 3, 7, 10 and their phenyl analogues 
demonstrated the effect of substituting a ring B ferrocene with phenyl.  Since a ring B 
ferrocene was not optimal to start with, replacing it with phenyl resulted in improved 
activity for C2, C7 and C10.  For compounds 3 and C3, the ferrocene analogue (3) 
was more active, showing that if the other ring carried appropriate substituents, the 
poor activity associated with a ring B ferrocene could be overcome. 
Compounds 6 and 28 were the most active ferrocenyl chalcones in their 
respective series.  Replacing ferrocene with phenyl in these compounds resulted in a 
marked decrease in activity, indicating that the exceptional antiplasmodial activities 
of compounds 6 and 28 were associated with the presence of ferrocene. 
 
Effect of reducing the α,β-unsaturated linkage: dihydroferrocenyl chalcones 
 A comparison of the ICBB50BB values of the few dihydroferrocenyl chalcones with 
their unsaturated analogues showed that the loss of the double bond affected 
compounds with ferrocene as ring A more than those with ferrocene as ring B (Table 
4.3).  Thus, the three dihydroferrocenyl chalcones (R13, R14, R21) were 6-10 times 
less active than their corresponding members in Series A.  The reverse was observed 
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for R1, R2 and R43, where the reduced compounds were 2-6 times more active than 
the corresponding members in series B.   
 Therefore, the loss of the double bond affected activity differently and based 
on the limited examples available, was influenced by the position of the ferrocene 
ring in the chalcone template. 
 
Table 4.3 Antiplasmodial activity of dihydroferrocenyl chalcones compared with 
ferrocenyl chalcones 
Ring A Ring B
O
 
Series A Series B 
No. Ring A Ring B 
IC BB50BB 
(µM) No. Ring A Ring B 
IC BB50 BB 
(µM) 
R13 phenyl 132 (19.0) R1 phenyl 
27.2 
(175) 











PPValues in brackets are ICBB50BB for ferrocenyl chalcone counterparts. 
 
Activity of the bis-substituted ferrocenyl chalcones  
  The antiplasmodial activites of the limited number of bis-substituted 
ferrocenyl chalcones showed that the same trend of greater activity residing in series 
A compounds was observed for these members.  However, the introduction of an 
addition chalcone like side chain to the ring A ferrocene caused a slight decrease in 
activity (Table 4.4).  In contrast, activity showed a marked improvement when a 
second chalcone side chain was introduced into the ring B ferrocene. 
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Table 4.4 Antiplasmodial activity of bis-substituted ferrocenyl chalcones compared 
with ferrocenyl chalcones 
No. Ring A Ring B 
IC BB50 BB 
(µM) No. Ring A Ring B 
IC BB50BB 
(µM) 
Bis13 phenyl 21.3 (19.0) Bis1 phenyl 
55.6 
(175) 






4-fluorophenyl 23.5 (12.1)  
PP
a  
PPValues in brackets are ICBB50BB for monomers. 
 
4.3.2 Selectivity of antiplasmodial activity of ferrocenyl chalcones 
 The selectivity indices given in Table 4.1 showed that the majority of 
ferrocenyl chalcones did not demonstrate impressive selectivities against Plasmodium.  
Fortunately, the least selective compounds were also those with poor antiplasmodial 
activities  (for example, compounds 16, 17, 2, 20, 1).  Compounds 6 and 28 which 
were the most active compounds in their respective series had reasonable selectivity 
indices against KB3-1 cells.  Compounds 25, 26 and 31 also exhibited reasonable 
selectivities in their antiplasmodial activities. Selectivity indices obtained with the 
MDCK cells were generally of the same order as those obtained with KB3-1 cells.   
 
4.3.3 In vivo antimalarial activities of ferrocenyl chalcones 
 None of the ferrocenyl chalcones reduced the parasitemia in P.berghei 
infected mice at the tested dose of 100 mg/kg (x 3 days).  These animals eventually 
perished due to the high parasitemia.  Healthy mice on the same dose regiment of 
compounds 1, 6 and 28 remained healthy and did not perish until Day 14. The 
absence of in vivo activity in spite of evidence of in vitro activity might be an 
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indication that the compounds failed to reach their site of action because of solubility 
problems, interaction with plasma proteins, or other pharmacokinetic factors.   
 
4.4 Conclusion 
 Of the 56 ferrocenyl chalcones, dihydro- and bis- analogues evaluated for 
antiplasmodial activity against P. falciparum K1 trophozoites, 11 compounds had 
moderately good activity, with ICBB50BB values of less than 20 μM.  The most active 
compounds were (1-(3-pyridinyl)-3-ferrocenyl-2-propen-1-one) (6) and (1-
ferrocenyl-3-(4-nitrophenyl)-2-propen-1-one) (28), both of which had ICBB50 BB values of 5 
μM.  The phenyl analogues of 6 and 28 showed diminished antiplasmodial activities, 
underscoring the important role of ferrocene for antiplasmodial activities. The 
selectivity indices of 6 (8.6) and 28 (37) suggested that they preferentially acted 
against Plasmodium compared to KB3-1 cells.  These compounds did not cause 
healthy mice to perish when administered consecutively at 100 mg/kg by 
intraperitoneal injection but the same regiment failed to clear parasitemia in infected 
mice. 
 SAR revealed the importance of maintaining ferrocene as ring A in the 
chalcone template.  When ferrocene was ring A, the substituents of choice on ring B 
appeared to be those that were electron withdrawing. The hydrophobicity of the 
substituent was less important.  The importance of maintaining the α,β-unsaturated 
linkage was underscored by the loss of activity in the dihydroferrocenyl chalcones 
that had ferrocene as ring A. However, introducing an additional chalcone side chain 
to the same ferrocene ring did not adversely affect activity. 
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 A different SAR was observed for series B ferrocenyl chalcones.  For these 
compounds, the hydrophobic and electronic properties of the substituents on ring A 
did not appear to be critical.  However, the size and bulkiness of ring A may be 
important.  In addition, reducing the double bond and introducing an additional 
chalcone side chain appeared to improve activity. 
 Thus, the location of ferrocene in the chalcone template had a decisive effect 








































 In the previous chapter, the location of the ferrocene ring in the chalcone 
template was shown to exert an important influence on antiplasmodial activity. This 
observation raises the question as why the position of ferrocene should have such an 
effect.  We hypothesized that the position of ferrocene influenced with changes in the 
physicochemical characteristics of the series A and B ferrocenyl chalcones, which in 
turn, translated to differences in antiplasmodial activity. In order to investigate this 
hypothesis, we have determined and analyzed selected steric, hydrophobic and 
electronic characteristics of the ferrocenyl chalcones. The correlation of these 
properties to antiplasmodial activity was examined by multivariate analytical tools, 
principal component analysis (PCA) and partial least squares projection to latent 
structures (PLS), to establish quantitative structure activity relationships. 
 The hydrophobicity of the ferrocenyl chalcones was experimentally 
determined from HPLC-derived capacity factors (log kw).  The crystal structures of 
representative chalcones from series A (28) and B (1, 12) were determined by X-ray 
crystallography and analyzed to obtain a better understanding of shape differences in 
the two series.  Energy minimized structures were constructed in silico using these 
crystallographic parameters to determine Connolly volume and surface areas of the 
compounds.   
In the case of electronic properties, attention was paid to the carbonyl linkage 
and the ferrocene ring.  The polarity of the carbonyl linkage is influenced by both 
rings A and B.  The carbonyl linkage is adjacent to ring A and its polar character 
would reflect in part the electron donating or withdrawing character of the ring.  The 
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carbonyl linkage is also conjugated to ring B, via the α,β-unsaturated linkage and is 
also affected by the donating/withdrawing nature of ring B. The polarity of the 
carbonyl bond was deduced from the charge differences on the oxygen and carbon 
atoms, determined by the Gasteiger-Huckel method from energy minimized structures.  
It was also assessed from the PP13 PPC chemical shift of the carbonyl carbon.  The chemical 
shift of the carbon is determined in part by the electronic nature of its neighbouring 
groups and gives insight on the polarity of the linkage.   
The carbonyl linkage in chalcones undergoes irreversible electrochemical 
reduction.  The reduction potential associated with this process was reported to be 
correlated to the substituent constant σ BBnBB of substituents on rings A and B.PP73 PP 
Moreover, it was reported that these groups had the same effect on the reduction 
potential irrespective of the ring on which they were located.PP73PP  Thus the reduction 
potential of the carbonyl linkage would give useful information of the electronic 
environment in the chalcone.  
Ferrocene is oxidized to ferricenium radical cation by a reversible one-
electron reaction and the redox potentials associated with this reversible process are 
influenced by the electronic environment of the metallocene.  Thus electrochemical 
potentials for oxidation / reduction of ferrocene and the carbonyl linkage were 
determined by cyclic voltammetry and used to assess the electronic characteristics of 
the ferrocenyl chalcones.  
 
5.2 Experimental Methods 
5.2.1 Materials 
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TBAP (Tetra-n-butylammonium perchlorate) was purchased from TCI Chemicals 
(Tokyo, Japan).  Zorbax Eclipse XDB-C18 column (4.6 x 150 mm, 5 μm) was 
purchased from Agilent Technologies (US). HPLC system used in the study was 
Shimazu LC-2010.  NMR spectroscopy data was collected with Bruker ACF 300 
instrument.  Stripping voltammeter (EG & G Princeton Applied Research, Model 
264A) and (Graptec XY, Model WX 2400) were used in the cyclic voltammetry study.  
Crystallographic data was collected with Bruker AXS SMART CCD diffractometer, 
reduced with SMART & SAINT,PP PPVer 5.6 (Bruker AXS, Inc., Madison, WI) and 
manipulated with teXsan (Structure analysis Package, Molecular Structure 
Corporation, Houston, TX).   
 
5.2.2 Determination of lipophilicity by reverse phase HPLC  
The lipophilicity parameter log kBBw BB was determined by measuring the capacity 
factor (k’) with a reversed phase HPLC method using a Zorbax Eclipse XDB-C18 
column (4.6 x 150 mm, 5μm) as stationary phase and methanol-HBB2BBO as mobile phase   
Four to 5 mobile phases with different methanol-HBB2 BBO composition ranging from 60-
85% w/w were used in the test for each compound. Determinations were carried out 
at room temperature (23°C) with flow rate of 1.0 ml/min and UV detector set at 300 
nm. The stock solutions (10PP-5 PPμM) were prepared in methanol. An aliquot of 100 μl 
stock solution with 10 μl acetone were diluted to 1ml with methanol. A volume (20 μl) 
of the prepared solution was injected for the determination of retention time with each 
mobile phase composition. Triplicate determinations were done for the test 
compounds at each mobile phase composition. The capacity factor (k’) was calculated 
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from log k’ = log [(Vs-Vo) / Vo], where Vs and Vo were the retention times of test 
compound and acetone respectively. A linear regression of log k’ values of each 
compound against mobile phase composition with extrapolation to 100% aqueous 
phase gave log kw (at pH 7.0) for the compound.  
 
5.2.3 Determination of the chemical shift of the carbonyl carbon 
The chemical shift of the carbonyl carbon of the test compound was 
determined by PP13 PPC NMR spectroscopy, with deuterated chloroform as solvent and 
tetramethylsilane as reference. Determinations were made on a Bruker ACF 300 
instrument. 
 
5.2.4 Determination of oxidation and reduction potentials by cyclic voltammetry 
The electrochemical measurements were carried out at room temperature 
(23PPoPPC) on a stripping voltammeter equipped with recorder.   The cell was filled with a 
solution of the test compound (1 mM) in anhydrous acetonitrile containing 0.1 M 
TBAP and degassed with NBB2 BB, 10 min to eliminate oxygen and water. A glassy carbon 
electrode served as the working electrode and Ag/ AgNOBB3 BB (10 mM in anhydrous 
acetonitrile containing 0.1 M TBAP) was used as reference electrode.  The working 
electrode was polished before measurements were made at a scan rate of 50 mVs PP-1 PP.  
Cathodic peak potentials were measured relative to the Ag/AgNO BB3 BB reference 
electrode. The oxidation and reduction potentials of ferrocene were found to be 0.049 
V and 0.111 V respectively, which were in keeping with literature values.PP74PP 
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5.2.5 X- ray crystallography 
Crystallographic data of compounds 1, 12 and 28 were collected on a Bruker 
AXS SMART CCD diffractometer using Mo-Kα radiation at 223 K so that θBBmax BB was 
30.1º (30.0º for 12). Data were reduced.PP75PP The structures were solved by heavy-atom 
methods (PATTY in DIRDIF) PP76 PP and refined (anisotropic displacement parameters, H 
atoms in calculated positions, and a weighting scheme of the form w = 1/[σPP2PP(FBBo PBPB2 PP) + 
aPPP2 PP + bP] where P = (FBBo PBPB2 PP + 2FBBc PBPB2 PP)/3) on FPP2 PP (SHELXL-97).PP77PP Structures are drawn with 
ORTEP at 50% displacement ellipsoids.  Data manipulation was with teXsan  and 
data have been deposited at the CCDC with deposition numbers 257045 (1), 257044 
(12) and 257043 (28).  
Crystal data for compounds 1, 12 and 28 are given in Table 3 of Appendix. 
 
5.2.6 Molecular modeling methods 
The series A and B ferrocenyl chalcones were constructed in silico using the 
crystallographic parameters of 28 and 1 respectively. The bond between ferrocene 
and the adjacent carbon was constrained and the charge on the iron was assigned  +2 
by the Gasteiger-Huckel method.  Other charges (carbonyl carbon and oxygen) were 
similarly assigned. Minimization was carried out using the molecular mechanics force 
field MMFF 94 (Sybyl 6.6, Tripos Associates, St Louis, Mo) with calculations 
continued until the root mean square gradient was less than 0.001 kcalmolPP-1 PP. The 
method was verified by comparing the dimensions of the minimized structure of 12 
and that of its crystal structure. Bond angles and lengths were found to be comparable.  
Connolly volume and surface areas were calculated from MOLCAD in Sybyl 6.6.  
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5.2.7 Statistical Methods 
Multivariate data analyses were carried out using SIMCA-P, version 8.0 (Umetrics, 
AB, Umea, Sweden) with default settings.  Statistical analyses were carried out on 
SPSS 13.0 (SPSS Inc., Chicago, IL). 
 
5.3 Results and Discussion 
The physicochemical characteristics of the ferrocenyl chalcones are listed in Table 1, 
Table 2 and Table 3 of Appendix.  Each property (steric, hydrophobic, electronic) 
will be discussed in the following paragraphs, followed by an analysis of the results 
by PCA and PLS to establish a quantitative structure-activity relationship. 
 
5.3.1 Lipophilicity 
Lipophilicity was evaluated by determining the retention times of the test 
compound as it eluted out from a hydrophobic stationary phase using a mobile phase 
comprising of methanol –water in varying proportions.  The retention time reflects 
the partitioning of the compound between the non-polar stationary phase and the 
polar mobile phase.  A lipophilic compound is preferentially adsorbed onto the 
nonpolar column and will have a longer retention time.  The proportion of methanol 
and water in the mobile phase also affects retention time.  Methanol is less polar 
compared to water.  A mobile phase with a higher proportion of methanol will elute a 
lipophilic sample from the column in a shorter time than a mobile phase with a lower 
proportion of methanol.  The retention time obtained at each mobile phase is 
converted to a “capacity factor” (log k’) and a plot of log k’ values against the % 
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composition of mobile phase gives, upon extrapolation, the capacity factor at 100% 
aqueous phase.  This value (log kw) is a measure of the lipophilicity of the compound 
at the pH of the aqueous phase (pH 7.0). The magnitude of log kw increases with the 
lipophilicity of the compound. 
The log kw of the 15 pairs of regioisomeric compounds in series A and B 
were compared using paired samples statistics.  The mean log kw of the series A 
compounds was 3.63 ± 0.57, as compared to 3.87 ± 0.57 for series B.  The difference 
was significant at p = 0.003 (2-tailed). Thus, the series A compounds were less 
lipophilic than their series B counterparts.   
El Tayar and co-workers PP78PP showed that partition coefficient (log P), a 
common measure of lipophilicity, can be factorized into a volume term (V) and a 
polarity term (Λ).  Both terms encoded solute-solvent interactions in the aqueous and 
organic phases.  The volume term captured hydrophobic interactions while the 
polarity term described dipole-dipole interactions and hydrogen bonds.  It will be 
shown later that the compounds in series A and B shared very similar Connolly 
surface areas and volumes.  If it is assumed that the volume contributions to 
partitioning were similar, then the differences in the log kw values might be attributed 
to the polarity term.  Thus, the location of ferrocene as ring A or ring B will affect 
this term to different degrees. 
 
5.3.2 X-ray crystal structures of compounds 1, 12 and 28 
The crystal structures of compounds 1 and 12 (series B) and compound 28 
(series A) were determined by X-ray crystallography. Table 5.1 lists selected 
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geometrical parameters (bond angles, bond distances and torsion angles) of these 
compounds.  The numbering shown in Table 5.1 is that given in the ORTEP 
structures of the compounds (Figure 5.1). 
 
Table 5.1 TTSelected bond distances (Å), bond angles (TTTTºTT) and torsion angles ( TTTTºTT) 
of compounds 1, 12, and 28TTTT 
Bond distances (Å) 1 12 28 
C1-O1 1.216(4) 1.227(3) 1.219(3) 
C1-C2 1.485(4) 1.476(3) 1.480(3) 
C2-C3 1.324(4) 1.325(3) 1.318(3) 
C1-C11 1.496(4) 1.491(3) 1.464(3) 
C3-C31 1.456(4) 1.448(3) 1.462(3) 
Fe-Cg1PPaPP 1.645(2) 1.640(1) 1.648(1) 
Fe-Cg2PPaPP 1.652(2) 1.649(1) 1.654(1) 
 
Bond angles (º) 1 12 28 
O1-C1-C2 120.9(3) 121.3(2) 121.6(2) 
O1-C1-C11 119.9(3) 120.0(2) 121.3(2) 
C2-C1-C11 119.2(3) 118.8(2) 117.1(2) 
C1-C2-C3 119.8(3) 121.3(2) 121.3(2) 
C2-C3-C31 126.2(3) 126.1(2) 127.6(2) 
 
Torsion angles (º) 1 12 28 
C11-C1-C2-C3 -176.9(3) 175.4(2) 177.6(2) 
C12-C11-C1-C2 170.6(3) -163.0(2) -3.4(3) 
C1-C2-C3-C31 179.6(3) -178.1(2) -174.8(2) 
C2-C3-C31-C32 15.7(5) -12.2(4) -175.0(2) 
Cg1…Fe…Cg2 PPa PP 179.5(1) 179.5(1) 178.7(1) 
PP
a  


















 The torsion angles (C11-C1-C2-C3, C1-C2-C3-C31) were close to 180PPo PP, 
indicating that the α,β-unsaturated carbonyl moiety was planar in both series of 
ferrocenyl chalcones.  The bond lengths of the carbonyl linkage (C1-O1) and the α,β-
unsaturated bond (C2-C3) were typical of a formal carbonyl bond and a carbon-
carbon double bond, which indicated that there was limited delocalization of the π 
electrons over the α,β-unsaturated carbonyl moiety, despite the planarity of this 
moiety.   
 The bond angles subtended by the carbon atoms (C1, C2, C3) of the α,β-
unsaturated carbonyl linkage were also examined. Angles subtended at C1 (O1-C1-
C2, O1-C1-C11) and C2 (C1-C2-C3) atoms deviated only marginally from the ideal 
angle of 120PPo PP.  By contrast, the angle at C3 (C2-C3-C31) had a larger deviation (6-7PPo PP) 
from the expected angle of 120PPoPP.  Atom C31 belonged to ring B and was phenyl 
(compound 28) or ferrocene (compounds 1 and 12).  Thus, the deviation was related 
more to the presence of an aromatic ring at the end of the α,β-unsaturated linkage, 
and not to the nature of ring B.  But it was interesting to note that the presence of an 
aromatic ring (ring A) at the beginning of the α,β-unsaturated linkage was not 
associated with the same degree of deviation (C2-C1-C11 deviated from the ideal 
angle of 120PPo PP by 1-3 PPo PP). 
 The torsion angle C12-C11-C1-C2 measured the orientation of ring A with 
respect to the α,β-unsaturated linkage.  When ring A was phenyl (as in 1 and 12), the 
torsion angles ranged from 163PPo PP -171PPo PP.  When ring A was ferrocene (as in 28), the 
torsion angle was 3PPo PP.  These data indicated that phenyl and ferrocene were twisted to 
different degrees.  There was greater planarity between a ferrocenyl ring A and the 
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α,β-unsaturated linkage, as compared to a phenyl ring A and the α,β-unsaturated 
linkage.  
 An examination of the torsion angle C2-C3-C31-C32 indicated the 
orientation of ring B with respect to the α,β-unsaturated linkage.  There was again 
evidence from the data that the phenyl and ferrocene rings B were twisted to different 
extents.  When ring B was phenyl (as in 28), there was a 5 PPo PP deviation from planarity.  
When ring B was ferrocene (as in 1 and 12), a larger deviation (12-15PPoPP) was evident.  
Based on these two torsion angles, compound 28 appeared to be more planar than 
compounds 1 and 12 with respect to the orientation of rings A, B and the α,β-
unsaturated linkage.  Thus, the presence of ferrocene per se did not ensure a planar 
orientation.  Rather, having ferrocene as ring A might be the more important factor.  
Crystallographic data of another series A compound (besides 28) would have 
provided further confirmation.  
 
Figure 5.2 Torsion angles of rings A and B in diphenylchalcone PP79 
 






An earlier investigation found that the phenyl ring A in chalcone had a lower 
energy barrier to rotation than the phenyl ring B.PP79PP  Ring A had greater rotational 
flexibility and a larger torsion angle (33.5PPo PP) compared to ring B (18.7PPo PP) (Figure 5.2).  
The phenyl ring A in compounds 1 and 12 also had large torsion angles (10-17PPoPP) but it 
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was interesting to note that when ferrocene was present as ring A, the torsion angle 
was significantly smaller.  More examples are needed to provide further confirmation, 
but tentatively, it would appear that the presence of a ferrocene ring A was associated 
with greater planarity in the chalcone template. 
With regard to the ferrocene ring, crystallographic data showed that the rings 
were symmetrically disposed about the iron atom.  Viewed down the Cg1..Fe..Cg2 
axes, where Cg1 and Cg2 were the centroids of the cyclopentadienyl rings, the two 
rings were eclipsed in all three compounds. 
 
5.3.3 Volume and surface areas 
 Using the crystallographic data of 28, the other ferrocenyl chalcones of series 
A were constructed in silico.  Compound 1 was used in a similar capacity for 
compounds in series B.  Once the structures were constructed and minimized using 
the Sybyl software, their Connolly surface areas and volumes were determined. The 
Connolly parameters measured the solvent accessible molecular surfaces of the 
compounds.  As seen from Table 2 (Appendix), there was a strong correlation 
between surface area and volume parameters.  Regioisomers from series A and B also 
had similar volumes and surface areas, as would be expected. 
 
5.3.4 Electronic character of the carbonyl linkage in series A and B ferrocenyl 
chalcones 
 The charges on the oxygen and carbon atoms of the carbonyl bond were 
determined by the Gasteiger-Huckel method from energy minimized structures and 
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reported as the difference in charge between the two atoms.  A large charge 
difference indicated that the carbonyl bond was highly polarized.  A comparison of 
the charge difference between the regioisomers of series A and B showed that the 
mean charge difference was 0.231 (±0.01, n = 15) in series A and 0.153 (±0.01, n = 
15) in series B.  Thus, the carbonyl bond was polarized to a greater extent in series A 
than in series B (paired t-test, p < 0.001). 
 The PP13PPC chemical shift of the carbonyl carbon was also determined.  In the 
polarized carbonyl bond, the carbonyl carbon is electron deficient.  Literature values 
showed that acetone absorbs at 203.8 ppm and acetaldehyde at 199.3 ppm.PP80 PP  
Replacing the methyl of acetone or acetaldehyde by a phenyl group or an α,β-
unsaturated bond resulted in an upfield shift of the carbonyl absorption (benzaldehyde 
190.7 ppm, acetophenone 195.7 ppm), PP80 PP presumably due to electron donation from 
these electron rich groups.  Therefore, when the carbonyl carbon becomes less 
electron deficient, it has a smaller chemical shift.  By extension, electron donating 
groups on rings A or B can be expected to reduce the electron deficient character of 
the carbonyl carbon and cause an upfield shift to smaller δ values, while electron 
withdrawing groups on rings A or B will shift the carbonyl carbon to larger δ values 
(downfield shift). Besides electronic factors, the chemical shift of the carbonyl carbon 
is also influenced by the orientation of ring A.  If ring A is constrained out-of-plane, a 
shielding effect is induced on the carbonyl bond and an upfield shift will be 
observed.PP81 
 The chemical shift of the carbonyl carbon in series A was 192.64 (± 0.42, n = 
20) as compared to 189.34 (± 2.23, n = 20) for the series B compounds. The 
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difference was statistically significant at p < 0.001.  Thus, the carbonyl carbon was 
more electron deficient in series A, and accordingly, more polarized.  A similar 
conclusion was reached based on charge difference of the carbon and oxygen atoms 
as described earlier. 
 The deshielding of the carbonyl carbon in series A may be explained by steric 
and electronic factors. 
Steric Factors 
 The X ray structure of 28, a representative series A compound, showed that 
ferrocene (ring A) and the carbonyl bond were closely aligned on the same plane 
(torsion angle C12-C11-C1-C2: -3.4PPo PP).  In this orientation, the carbonyl carbon would 
fall within the paramagnetic field current of the ring and was deshielded.  On the 
other hand, the phenyl ring A of 1 and 12 (representative series B compounds) were 
constrained out-of-plane as seen from their torsion angles C12-C11-C1-C2 (170.6PPo PP, 
163.0PPo PP). Their carbonyl carbon atoms would be held above or below the plane of the 
ring and experienced a shielding effect. 
Electronic Factors 
 To have a better understanding of the electronic effects of ferrocene, the 
chemical shifts of the carbonyl carbon of selected dihydroferrocenyl chalcones were 
determined (Table 5.2).  Hydrogenation of the α,β-unsaturated double bond has two 
important effects on the carbonyl bond. First, the mesomeric electron shift from the 
double bond to the carbonyl linkage cannot occur and the latter would have less 
single bond character. (Figure 5.3) 
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Figure 5.3 Mesomeric electron delocalization in ferrocenyl and dihydroferrocenyl 
chalcones 















Second, ring B is no longer conjugated to the carbonyl linkage in 
dihydroferrocenyl chalcones. Ring B may exert a weak inductive effect but it would 
have less effect on the carbonyl linkage, which will be influenced primarily by ring A. 
Table 5.2 shows a downfield shift of the carbonyl carbon upon reduction of 
the double bond. Without electron donation from the double bond, the carbonyl 
carbon is more polarized and deshielded.  In compounds that had both ferrocene and 
phenyl rings, the carbonyl carbon was more deshielded when adjacent to ferrocene.  
The chemical shifts of compounds R1 and R13, and compounds 1 and 13 were 
illustrative of this trend and might imply that ferrocene is not as electron donating as 
phenyl when directly attached to a withdrawing carbonyl function.  This is contrary to 







Table 5.2 PP13PPPPC-NMR chemical shifts of carbonyl carbon in ferrocenyl and non-
ferrocenyl chalcones, and their reduced analogs. 
Compound Chemical shift δ ppm PPa PP Compound 
Chemical shift δ 
ppm PPaPP 


































192.33   
PP
a 
PPDetermined in deuterated chloroform as solvent and TMS as internal standard on 300 
MHz Bruker ACF 300 spectrometer. 
 
 The reduction potential of the carbonyl bond in the ferrocenyl chalcones were 
determined by cyclic voltammetry.  A large reduction potential indicated that the 
carbonyl bond was more resistant to reduction.  Alston and Fry PP73PP reported that the 
reduction potential of the carbonyl bonds in chalcones were correlated to a special 
substituent constant σPPn PP which encoded the inductive and field effects of the groups.  
The customary Hammett constants which incorporated both inductive and mesomeric 
effects, gave a poorer correlation. Dimmock and co-workers found that the 
reducibility of the double bond influenced the cytotoxicity of Mannich-base 
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chalcones and conformationally restricted chalcones.PP53PP  However, in this investigation, 
the reduction potentials of the series A and series B ferrocenyl chalcones were not 
statistically different when evaluated by paired sample statistics (p = 0.695).  Thus, 
the location of ferrocene did not affect the reducibility of the carbonyl bond. 
 In summary, the character of the carbonyl bond was markedly influenced by 
the location of the ferrocene ring in the chalcone template. When adjacent to 
ferrocene, the carbonyl bond was more polarized. This was supported from 
measurements of the charge difference of the carbon and oxygen atoms of the bond, 
and the chemical shift of the carbonyl carbon.  The electron donating character of 
ferrocene appeared to be diminished somewhat when it was adjacent to the carbonyl 
bond. It is not entirely clear why this was the case. On the other hand, the reducibility 
of the carbonyl bond was not affected by the position of ferrocene in the chalcone 
template. 
 
5.3.5 Oxidizability of the ferrocene ring 
 Ferrocene is oxidized to ferricenium via a reversible one-electron reaction.  
The reaction involves the oxidation of ferrous (Fe PP2+ PP) in ferrocene to ferric (FePP3+PP) by 
electron loss.  We determined the electrochemical potentials for the forward reaction 
(Ep PPFc (Oxi)PP , oxidation of ferrocene, Fe PP2+ PP Æ FePP3+ PP) and the reverse reaction (EpPPFc (Red) PP, 
Fe PP3+ PPÆ FePP2+PP).  A large positive EpPPFc (Oxi)PP indicated that the oxidation reaction did not 
occur readily.  A large positive EpPPFc (Red) PPindicated that the reduction reaction was 
readily brought about.  The oxidation and reduction potentials were incorporated in a 
single term, the formal potential Eo’, which was the mean of Ep PPFc (Red)PP and EpPPFc (Oxi)PP.  
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A large formal potential signified resistance of the ferrocene ring to undergo 
oxidation.  Another parameter derived from the oxidation and reduction potentials 
was ΔEp, the difference between EpPPFc (Oxi)PP and EpPPFc (Red)PP.  This parameter reflected the 
reversibility of the one-electron transfer reaction in ferrocene, and theoretically, 
should have a value of 0.060 V.  Experimentally, a mean value of 0.062 V (standard 
deviation ± 0.007, n = 44) was obtained, an indication that the reaction was reversible. 
 Figure 5.4 illustrates the cyclic voltammetric curves for compounds 1, 13 and 
ferrocene.  Compound 1 (series B) had lower EpPPFc (Oxi)PP and Ep PPFc (Red)PP values than its 
regioisomer (13) in series A. In fact, a comparison of the formal potentials of the 15 
regioisomeric ferrocenyl chalcones in series A and B showed that the series B 
compounds had significantly lower values (0.186 ± 0.024 V) than their series A 
analogues (0.314 ± 0.039 V) when evaluated by paired samples statistics (p < 0.001).  
In other words, ferrocene was more resistant to oxidation when it was ring A.  
 
Figure 5.4 Cyclic voltammetric curves for compounds 1, 13 and ferrocene 
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 The formal potential of ferrocene is influenced by the electron donating 
/withdrawing groups in its vicinity.  When an electron withdrawing group is present, 
the oxidation potential of ferrocene increases.  Numerous examples attested to this 
trend.PP82PP For example, the oxidation potential of ethynyl ferrocene was reported to be 
0.150 V, a more positive value than that obtained for ethyl ferrocene (-0.06 V) under 
similar conditions.PP82PP The triple bond in ethynyl is electron withdrawing and reduced 
the electron density at Fe PP2+ PP, thus making electron loss from iron more difficult.   This 
may also be true for the ring A ferrocene in series A, since it is adjacent to the 
carbonyl function.  But this may not be a satisfactory explanation for several reasons. 
First, if the carbonyl group had withdrawn electrons from ferrocene, then it should 
not be so highly polarized, as found from investigations on its chemical shift and the 
charge difference on the carbonyl bond. Secondly, when ferrocene is ring B, it is 
adjacent to the α,β-unsaturated linkage, which is also electron withdrawing by an 
inductive effect. But the ferrocene ring B was more readily oxidized than the 
ferrocene ring A.  Thus, it is difficult to explain the difference in the formal potentials 
of ferrocene in the series A and B compounds.  
 
5.3.6 Correlation of the physicochemical properties and antiplasmodial activities of 
ferrocenyl chalcones 
 Various physicochemical properties have been described for the series A and 
B ferrocenyl chalcones in the preceding paragraphs.  Differences in several properties 
were detected for the two series of compounds.  These were lipophilicity (series A 
less lipophilic than series B), the polarity of the carbonyl linkage (more polar in series 
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A than series B), and the ease of oxidizability of the ferrocene ring (ferrocene is 
harder to oxidize when present as ring A).  In Chapter 4, it was concluded that the 
location of ferrocene in the chalcone template influenced antiplasmodial activity. 
SAR was described in qualitative terms, without reference to the physicochemical 
properties of the compounds.  In order to arrive at a more quantitative assessment of 
structure-activity relationships, principal component analysis (PCA) and partial least 
squares projection to latent structures (PLS) were applied. 
 PCA is a pattern recognition technique that aims at summarizing information 
residing in the original data into a form that can reveal relationships between the 
compounds and the parameters used in their characterization.PP83PP  PCA would be able to 
show if the series A and B compounds do indeed differ significantly in their 
physicochemical properties, and if so, which properties contributed to the observed 
differences.  PLS is a regression extension to PCA.  The usefulness of PLS is that it 
will reveal how differences in physicochemical properties (if detected by PCA) 
influenced antiplasmodial activity. PCA and PLS are projection methods and are 
preferred tools for QSAR in situations where some of the independent variables may 
be correlated, as in this particular situation. 
 
a) Principal component analysis (PCA) of series A and B ferrocenyl chalcones 
 The physicochemical parameters used for PCA are listed in Table 2 of the 
Appendix. ΔEp was excluded because this parameter was the same for both series. 
Only series A and B ferrocenyl chalcones were analyzed (Table 3.1).  
Dihydroferrocenyl chalcones and bis-substituted ferrocenyl chalcones were excluded.  
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 Using 9 physicochemical parameters and 44 compounds, PCA yielded a 
significant two-component model (rPP2 PP= 0.75, qPP2 PP= 0.55).  This meant that the 
properties captures by these components could account for 75% of the observed 
variation, with a predictability level of 55%.  The 1PPst PP component makes a greater 
contribution to the model than the 2PPndPP component.  The loadings plot shows the 
correlation between the original parameters and the principal component.  The 
loadings are actually coefficients for the variables that contribute to each principal 
component.  The loading plot of this model identified the redox properties (EpPPFc (Oxi) PP, 
EpPPFc (red)PP, Eo’) of ferrocene, the charge difference in the carbonyl bond and the 
chemical shift of the carbonyl carbon (in order of decreasing contribution) as 
important contributors to the 1PPst PP component.  The 2 PPnd PP component received inputs from 
size parameters and lipophilicity.  The reduction potential of the carbonyl bond did 
not contribute to either component.  This is shown in Figure 5.5. 
 




 Another useful plot derived from PCA is the score plot which shows the 
distribution of the compounds according to their principal components. Compounds 
that are clustered together in the score plot have similar physicochemical properties 
while compounds that are dispersed have dissimilar profiles.  The Hotelling eclipse in 
the score plot is also depicted in the score plot.  Compounds lying outside the eclipse 
are outliers. 
 Figure 5.6 shows the score plot for the model.  A notable feature of the score 
plot was the clustering of the series A compounds (▲) on the left hand quadrant, with 
the exception of two members (the nitro analogues 40 and 42).  The series B 
compounds (■) were spread out on the right hand quadrant of the plot. Compound 12 
was identified as an outlier. This pattern of distribution reflected the different 
physicochemical properties in the two series of compounds.  These properties were 
those that contributed to the 1PPst PP principal component, namely the redox properties of 
ferrocene and the charge distribution of the carbonyl bond. 
  
Figure 5.6 Score plot of principal components tBB1 BB versus tBB2 BB for ferrocenyl chalcones 
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b) Partial least squares projection to latent structures (PLS)  
The next question that required consideration was how the differences in 
physicochemical properties revealed by PCA influenced antiplasmodial activity.  PLS 
was used to investigate this problem. Before embarking on PLS, the score plot 
(Figure 5.6) was considered again.  The separation of series A and B compounds in 
the score plot implied that the two series should not be combined together for 
structure-activity analysis.  However, when each series was analyzed separately, no 
meaningful PLS model was derived.  On the other hand, when compounds with 
naphthalene (4, 5, 16, 17), pyridine (6, 18, 32, 33, 38, 39) and quinoline rings (30, 31) 
were omitted, a significant one-component model was obtained (rPP2 PP = 0.31, qPP2 PP= 0.25).  
But the model statistics indicated it was a weak model, which could account for only 
one-third of the observed variation and at a low level of predictability. Further 
investigations showed that the quinolines 30, 31 and pyridines 18, 38, 39 (pyridine is 
ring B in these compounds) could be included with little change in model statistics (rPP2PP 
= 0.34, qPP2 PP= 0.26).  However, a shortcoming of this approach was the omission of 
compound 6 (one of the two most active compounds) from the model.  Thus, it was 
appropriate to explore the effect of including this compound in the course of model 
refinement.  The basic steps involved in refining the model were omission of outliers 
(compounds with large differences in predicted and observed biological activities) 
and removal of variables that did not significantly contribute to the model.  The 
model was validated by selecting a test set of compounds and using it to predict the 
activity of the remaining compounds.  Finally, two satisfactory models (10 and 35) 
were identified and their characteristics are given in Table 5.3.   The main difference 
 93
between models 35 and 10 was the inclusion of compound 6 in model 35 and its 
exclusion in model 10.    
 
Table 5.3 Statistics of PLS models 10 and 35 
 
 Model 35 (without 6) Model 10 (with 6) 
Compounds All except napthalenes (4, 5, 
16, 17), Ring A pyridines (6, 
32, 33), outliers (2, 7, 20).  
N PPaPP = 34 
All except napthalenes (4, 5, 
16, 17), Ring A pyridines (32, 
33), outliers (2, 7, 20).  
N  PPa PP = 35 
X variables X PPb PP= 5 
Log kw, Eo’, PP13PPC chemical 
shift, Ep PPFc Red PP, charge 
difference (C=O) 
X PPb PP= 5 
Log kw, Eo’, PP13PPC chemical 
shift, Ep PPFc Red PP, surface area. 
Model statistics r PP2PP = 0.43, qPP2 PP = 0.39 
 
r PP2PP = 0.33 qPP2 PP = 0.28 
Test Set Compounds 14, 23, 34, 37, 
39 and 43.  
X variables as above. 
Significant 2 component 
model, q PP2 PP = 0.81.  
Compounds 19, 24, 34, 36, 40 
and 43.  
X variables as above. 
Significant 2 component 
model, qPP2 PP = 0.71. 




PPNumber of compounds in model 
PP
b  
PPNumber of X variables 
PP
c  
PPRoot mean square error of prediction. This is the level of predictability obtained 
when the test set was used to predict the activity of the remaining (unselected) 
compounds in the model.  
 
 
A more robust model (35) was obtained when compound 6 was excluded (rPP2 PP = 
0.43, q PP2 PP =0.39).  This model was derived using 5 variables: log kw, Eo’, chemical 
shift of carbonyl carbon, Ep PPFc Red PP, and charge difference on the carbonyl bond.  The 
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relative importance of each variable can be assessed from its VIP (variable 
importance in the projection) value.  Variables with a value greater than 1 are 
generally considered to make a significant contribution to activity.  The VIP plot for 
the variables used in model 35 is presented in Figure 5.7. Of these 5 parameters, the 
redox properties of the ferrocene ring made the greatest contribution to activity.  The 
correlation between these parameters and antiplasmodial activity was given in the 
Coefficients Plot (Fig 5.8).  Parameters with positive values (Eo’, PP13 PPC chemical shift, 
EpPPFc (red)PP, charge difference on carbonyl) affected activity directly while those with 
negative values (log kw) had an inverse relationship with activity. Six compounds 
were randomly selected from the 34 compounds and designated as the test set.  It was 
used to predict the activity of the remaining 28 compounds.  The level of prediction 
(root mean square error of prediction) was fair (RMSEP = 0.30). 
 








When compound 6 was included, a weaker model (10) resulted (rPP2 PP = 0.33, qPP2 PP = 
0.28).  The parameters used to construct the model were similar to those used in 
model 35, except for the inclusion of surface area in place of charge difference of the 
carbonyl bond. The VIP and coefficient plots of this model are given in Figure 5.9 
and Figure 5.10.  Again, the importance of the redox properties of ferrocene was 
evident from these plots.  Six compounds were randomly selected to form a test set 
and the resulting model was used to predict the activity of the remaining 29 
compounds.  Quite surprisingly, a better level of prediction was obtained with the 





Figure 5.9 VIP plot for PLS model (10) 
 




In summary, PCA had shown that series A and B ferrocenyl chalcones 
possessed different physicochemical characteristics.  These differences related to the 
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oxidizability of ferrocene, the charge distribution on the carbonyl function and  
lipophilicity.  Moreover, these parameters were also found to contribute to  
antiplasmodial activity.  The final models (10 and 35) showed that better activity was 
associated with members with ferrocene rings that were not readily oxidizable (large 
Eo’ and Ep PPFc (red)PP), have carbonyl bonds that were polarized (carbon atoms have large 
chemical shifts, large charge difference between carbon and oxygen atoms), were not 
excessively lipophilic and had smaller surface areas.  These were essentially the 
features of the series A compounds. 
 
5.4 Conclusion 
 In this chapter, physicochemical characteristics of the ferrocenyl chalcones 
related to size, lipophilicity and electronic character were determined and analyzed.  
It was observed that many of these properties differed for the series A and B 
compounds.  These differences pertained to the oxidizability of ferrocene, the charge 
distribution on the carbonyl bond and lipophilicity.  Series A compounds were 
generally less lipophilic, had ferrocene rings that were more resistant to oxidation and 
had more polarized carbonyl linkages.  These differences were further confirmed by 
PCA, which showed a clear segregation of the two series of compounds based on 
these properties.  PLS showed that these same differences contributed to the general 
trend of greater antiplasmodial activity associated with series A compounds. Thus, 
the location of ferrocene in the chalcone template affected selected physicochemical 
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 The hypothesis proposed in this thesis was that the introduction of ferrocene 
into the chalcone template would have an important impact on antiplasmodial activity, 
namely by affecting the physicochemical characteristics of the target compounds.  It 
was further proposed that these changes in physicochemical characteristics would 
influence the mechanism(s) of antiplasmodial activity in some way.  In the previous 
chapters, evidence was presented to show that the location of ferrocene in the 
chalcone template affected selected physicochemical properties and that the 
differences in these properties, in particular the redox characteristics of ferrocene, 
were broadly related to the variation in the antiplasmodial activities observed for the 
ferrocenyl chalcones. The question that must now be addressed was how these 
differences and their observed correlation to antiplasmodial activity were related to 
ferrocene.  Does ferrocene exert its effects through the ferrocene/ferrocenium 
equilibrium, as proposed for cytotoxic ferrocenyl compounds, or does it intervene in a 
less direct manner, like for example, affecting access to a target site arising from 
changes in physicochemical characteristics?  To have a satisfactory answer to these 
questions, it is necessary to have a good understanding of how antiplasmodial 
chalcones exert their activity against the parasite.  Unfortunately, this remains an 
open question.  
 The antiplasmodial activity of chalcones was investigated as early as 1949 but 
they were not pursued as lead compounds as only modest activities were noted.PP84PP  It 
was not until the 1990s when interest in chalcones was rekindled. Two reasons 
accounted for this change – the antiplasmodial activity of licochalcone A, a chalcone 
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derivative isolated from the roots of the Chinese liquorice PP85, 86PP and the outcome of a 
database search for compounds that could fit the active site of malarial cysteine 
proteases.PP87PP The latter revealed that several chalcones had an excellent fit and this 
connection was pursued by other investigators, but with unconvincing outcomes.PP88 PP   
The mode of action of licochalcone A against Plasmodium had been actively 
investigated but did not give definitive results.   
 Not withstanding the gaps in knowledge pertaining to the mode of action of 
antiplasmodial chalcones, the ferrocenyl chalcones were investigated for their effects 
on (i) detoxification of heme, (ii) parasite-induced permeation pathways on 
Plasmodium-infected erythrocytes and (iii) oxidant /antioxidant properties.  The 
rationale for focusing on these areas for investigation is discussed in the following 
paragraphs. 
 
6.2 Investigations of The Heme Binding Properties of Ferrocenyl Chalcones 
Upon entry into the erythrocytes, the trophozoites of Plasmodium degrade 
hemoglobin in their food vacuoles. Degradation is mediated by two aspartic 
proteinases and one cysteine protease to give amino acids that serve as nutrients for 
the parasite’s growth.PP89, 90 PP The by-product of this digestive process is 
ferroprotoporphyrin IX, Fe (II) PPIX, which has a transient existence and is rapidly 
oxidized by molecular oxygen to ferriprotoporphyrin IX (Fe(III)PPIX), commonly 
known as hematin.  Low concentrations of hematin induced redox damage to host 
proteins and membranes, inhibited parasite enzymes and lysed erythrocytes.PP91 PP  
Therefore, the parasite must have effective approaches to sequester hematin in order 
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to ensure their continued survival.  Among the known approaches are crystallization 
of hematin to a non-toxic insoluble hemozoin dimer, glutathione-dependent 
degradation of hematin and peroxidative degradation of hematin. 
 Hemozoin was originally regarded as a polymer resulting from the 
coordination of the central iron atom of one heme molecule to the carboxylic acid 
function of an adjacent heme molecule.PP92 PP  The prevailing view was that  hemozoin 
consisted of an array of dimers of heme linked via iron-carboxylate bonds as 
represented in Figure 6.1.PP93PP However, formation of non-toxic hemozoin could not 
adequately deal with the accumulation of toxic hematin within parasitized 
erythrocytes, since about 90% of hematin was converted to hemozoin.PP126, 127 PP Other 
alternative pathways had been proposed to deal with the disposal of toxic heme.  
Non-polymerized heme might move out from the food vacuole into the cytosol of the 
parasite where it was degraded by glutathione (GSH).PP95, 96PP   



















Another possibility was that hematin might react with hydrogen peroxide 
produced within the food vacuole to bring about its own breakdown.  This is 
illustrated in Scheme 6.1.  In the presence of molecular oxygen, the ferrous ion in 
Fe(II)PPIX was oxidized to Fe(III)PP IX with the formation of a superoxide radical 
that spontaneously dismutated to hydrogen peroxide.  The latter could in turn react 
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with Fe(III)PP IX, triggering its decomposition.  Loria and coworkers found that 
chloroquine inhibited the peroxidative degradation of heme by hydrogen peroxide.PP97 PP  
They postulated that chloroquine formed a tight complex with Fe(III)PP IX and 
prevented its breakdown by hydrogen peroxide. It is generally accepted that 
chloroquine interfered with heme disposal by many routes, of which the inhibition of 
heme crystalization,PP98, 99PP GSH-dependent degradationPP 94, 100PP and peroxidase-mediated 
degradation PP97 PP were notable. 
 
Scheme 6.1 Reaction of heme with hydrogen peroxide 
FP – Fe(II)                           FP – Fe(III) 
                                e PP- 
OBB2 BB                           O BB2 PBPB●
- 
                                         HPP+ PP 
                           ½ HBB2 BBOBB2 BB + ½ OBB2 BB 
 
                                           FP – Fe(III)                       FP – Fe(III)----H BB2 BBOBB2 
                                                
                                                     FP – Fe(IV)* 
  
                                                   FPBBox  BB+ Fe(III)              
                                                                                                                                   
Investigations into the interaction of antiplasmodial chalcones with heme 
degradation had given different results.  One study on antiplasmodial hydroxylated 
and alkoxylated chalcones showed that these compounds did not interfere with heme 
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sequestration.PP101 PP On the other hand, xanthohumol and its derivatives showed 
inhibition of GSH-dependent heme degradation.PP102PP Xanthohumol is a prenylated 
chalcone isolated from the hops plant (Humulus lupulus) and had modest in vitro 
antiplasmodial activity (ICBB50 BB 8-24 µM). However, the authors conceded that 
xanthohumol and related compounds might have other modes of action, besides 
inhibiting the breakdown of heme.     
Investigations had shown that the presence of ferrocene in ferroquine resulted 
in greater lipophilicity, shorter inter-nitrogen distances and lower basicity, which in 
turn gave the compound a poorer affinity for the chloroquine transporter.PP31PP  We had 
also shown that isomeric series of ferrocenyl chalcones had different physicochemical 
properties that appeared to be correlated to antiplasmodial activities.  Thus, it was of 
interest to investigate if these compounds interfered with the degradation of heme, 
and if there were differences in the levels of activity, whether these were related to 
the presence or location of ferrocene in the compound.  Three aspects were 
investigated – binding to heme, β-hematin formation and GSH-mediated degradation 
of heme. 
 
6.2.1 Experimental methods 
6.2.1.1General experimental methods and materials 
UV absorptions were determined on a HP 8453 UV/Vis diode array 
spectrophotometer.  IR spectra were collected on a JASCO FTIR 430.  The following 
chemicals were purchased from Sigma-Aldrich (St. Louis, Mo): porcine hematin 
(ferriprotoporphyrin IX hydroxide), hemin (ferriprotoporphyrin IX chloride), 
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monooleoylglycerol (MOG), glutathione (GSH), chloroquine diphosphate. Other 
reagents were of analytical grade.   
 
6.2.1.2 Binding to heme   
 Appropriate aliquots of hematin (4 mM stock solution in 0.1 M NaOH, freshly 
prepared and kept at 4PPo PPC before use) and test compound (stock solutions of 200 mM 
in DMSO) were added to a cuvette (1 ml) containing 40% (v/v) methanol in sodium 
acetate buffer (10 mM, pH 5.5) to give final concentrations of 15 µM heme and 2 -
128 µM test compound.  The final concentration of DMSO was maintained at less 
than 0.1% (v/v) to minimize the effect of solvent on the results.  The solution was 
agitated by vortexing (15 s) before absorbance of the Soret band at 400 nm was read.  
Correction of background absorbance was made using the same solution without 
hematin.  Chloroquine was used as positive control for these experiments.  The 
decrease in Soret band absorbance was expressed as a % of the control absorbance 
obtained in the absence of test compound. % Decrease in absorbance = [Absorbance 
BBcontrol BB – Absorbance BBtest BB ] / Absorbance BBcontrolBB   Each compound was tested three times. 
 
6.2.1.3 Inhibition of β-hematin formation 
 A solution of MOG (0.4 mM) in 90 mM sodium acetate buffer (pH 5) was 
prepared by sonication (10 min).  Aliquots of freshly prepared hematin solution (50 
µl of stock solution 6 mM in 50 mM NaOH) and test compound (100 µl of a stock 
solution prepared in DMSO) were mixed in an Eppendorf tube (2 ml), after which 
was added 500 µl of the MOG solution, and the volume made up to 1 ml with sodium 
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acetate buffer (90 mM, pH 5).  The final concentration of the test ranged from 1 -
1000 µM. The sample was incubated at 37 PPoPPC for 24 h with gentle shaking.  Following 
incubation, the samples were centrifuged at 27000 g, 15 min, 4PPoPPC.  The pellet was 
washed by resuspension in DMSO (400 µl) until the supernatant was colourless.  This 
step removed unreacted hematin from β-hematin which is insoluble in DMSO.  The 
pellet was then dissolved in 950 μl HEPES buffer (pH 7) containing 2.5% SDS.  50 
μl of NaOH (1 M) was added to dissociate and dissolve β-hematin.  The amount of 
hematin produced was determined by UV-spectroscopy at 400 nm.  A control 
experiment in the absence of test compound was carried out concurrently. Positive 
control chloroquine was prepared in distilled water and its inhibition of β-hematin 
formation was investigated over concentration range of 1-100 µM.   The amount of β-
hematin formed in the presence of test compound was expressed as a % of the amount 
formed under control conditions, based on the absorbances of hematin which was 
produced when the pellets were dissolved in HEPES buffer.  The experiments were 
repeated at different concentrations of selected test compounds to give ICBB50BB for the 
inhibition of β-hematin formation. Each ICBB50 BB determination was repeated at least 
twice for each compound.  
 
6.2.1.4 Inhibition of GSH mediated heme degradation 
The method of Atamna and GinsburgPP 104 PP was followed with some 
modifications. 0.3 mM Heme stock solution was prepared by dissolving hemin in 0.1 
M NaoH. A stock solution of GSH  (200 mM) was prepared in 0.2M HEPES buffer 
(pH = 7.0). The stock solutions were prepared freshly and kept in the fridge (4°C) 
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prior to the experiment.  The test samples were dissolved in DMSO (chloroquine was 
dissolved in water) and diluted to the desired concentration with 0.2 M HEPES buffer 
(pH = 7.0). The final concentration of DMSO was less than 0.1% (v/v).  Heme (10µl 
to give final concentration of 3µM in 1ml cuvette) and sample (final concentrations of 
0.1- 100 µM in 1ml cuvette) were mixed in 0.2 M HEPES buffer (pH = 7.0) in a 
cuvette (1 ml) and pre-warmed at 37°C for 10min. The reaction was started by adding 
an aliquot of GSH  (10 µl to give final concentration of 2 mM) to the contents of 
cuvette.  The absorbance of Soret band of heme was monitored at 396 nm by a UV-
VIS spectrophotometer (HP 8453) at 60 sec time intervals over 30 min at 37°C.  The 
results were plotted as time as X-axis and absorbance as Y-axis. The slope of the 
linear part of the curve was recorded to give the rate of decomposition of heme.  A 
gentle slope (small gradient) was indicative of a slow rate of degradation.  The 
degradation of heme was also monitored under the following conditions (i) absence of 
GSH, (ii) presence of GSH, (iii) presence of test compound only. 
The ICBB50BB for inhibition of GSH-mediated heme degradation was determined 
for selected compounds. In this case, the rates of degradation were obtained for 
various concentrations of the compound (0.1, 1, 3, 6, 10, 20, 50, 100 µM) and 
expressed as a % of the control rate of degradation of heme in the presence of GSH.   
% Inhibition is given by the expression: 
% Inhibition =  [1 – Gradient BBTest compound + Heme + GSH  BB/ Gradient BBHeme + GSH BB] x  100 




Table 6.1 Results of heme binding, β-hematin formation inhibition and GSH dependent heme degradation inhibition 
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ICBB50BB (μM) % ICBB50BB 
(μM) 
13 Ph 8.1  82.9  1 Ph 19.5  45.0 2.74 
14 4-MeOPh 0 549 80.5  2 4-MeOPh 27.7 >1000 30.9 3.08 

















18 3-Pyridinyl 8.6  76.9  6 3-Pyridinyl 23.4 >1000 30.9 3.47 
19 4-OHPh 12.3  84.7  7 4-OHPh 7.6  39.8 2.74 
20 4-MePh 18.0  72.8  8 2,4-diOHPh 43.4 73.4 43.9 3.94 









23 2-ClPh 1.7  78.9  11 4-EtOPh 10.7  41.1 4.51 
24 2,4-diClPh 0  94.4  12 4-ButOPh 20.3 >1000 79.0  
38 2-Pyridinyl 8.0    32 2-Pyridinyl 35.3    
39 4-Pyridinyl 30.4    33 4-Pyridinyl 29.2    
40 2-NO BB2BBPh 19.8    34 2-NO BB2BBPh 24.7    
41 3-NO BB2BBPh 26.6    35 3-NO BB2BBPh 19.6    
28 4-NO BB2BBPh 32.7 >1000 71.9 42.13 36 4-NO BB2BBPh 1.6    
42 4-MeBB2 BBNPh 19.4    37 4-MeBB2 BBNPh 
Fc 
1.6    
25 4-FPh 15.7  79.7        
26 
Fc 
2,4-FPh 16.2  79.7        
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Ring B % Decrease 
in 
Absorbance 




















ICBB50BB (μM) % ICBB50BB 
(μM) 
27 4-CFBB3BBPh 0  84.9        
29 4-CNPh   100        
30 3-Quin 344  59.0        
31 3-Quin 103  91.9        
R13 Ph 4.0    R1 Ph Fc 0.3    
R21 4-ClPh 3.5           
C28 
Fc 
4-NOBB2BBPh 0    C6 3-Pyridinyl Ph 0    




PP% Decrease in absorbance was obtained at 128 μM of samples.   
  % Decrease in absorbance of heme = (1 - Absorbance BBheme + sample (128µM) BB / Absorbance BBheme BB) x 100%   
PP
b  
PP% Rate of GSH dependent degradation is the speed of GSH dependent heme degradation in the presence sample versus that without sample 
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6.2.2 Results and discussion 
Table 6.1 summarizes the results of the investigations on the degradation of 
heme in the presence of ferrocenyl chalcones. 
 
6.2.2.1 Binding to heme 
 Commercially available heme is ferriprotoporphyrin IX (Fe (III) PPIX) and 
could be purchased as hemin chloride or hematin.  In hemin chloride, the ferric ion is 
linked to chloride and in hematin, it is linked to a hydroxide ion.  In both forms, the 
ferric ion is present in the high spin penta-coordinated state.  In this investigation, 
hematin was used and would be referred to as heme in this discussion.  
The binding of ferrocenyl chalcones to heme was investigated at pH 5.5, to 
mimic the acidic pH of the plasmodial food vacuole.  Heme displayed a sharp 
absorbance band (Soret band) at 400nm, with a shoulder at 360nm.  When binding to 
heme occurred, the absorbance of the Soret band decreased.  The positive control, 
chloroquine, showed a concentration – dependent decrease in the Soret band (Figure 









Figure 6.2 Spectral analysis of heme in the presence of 0, 2, 4, 8, 16, 32, 64 
and 128 µM chloroquine at pH 5.5. 
 
The most active antiplasmodial compounds (6 and 28) caused moderate 
decreases in absorbance (23% and 33% respectively) at 128µM.  Negligible decreases 
were noted at 16 µM, a concentration that was close to their antiplasmodial ICBB50 BB 
values (data not presented).  Interestingly, the phenyl analogues of 6 and 28 (C6, C28) 
showed no binding to heme at the highest concentration (128 µM), which were quite 
similar to an earlier finding on the heme binding affinities of alkoxylated and 
hydroxylated chalcones, which showed that affinities were modest and not correlated 
with antiplasmodial activities. PP101 
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Reduction of the α,β-unsaturated bond resulted in diminished heme binding (1 
and R1; 21 and R21) but the inclusion of an additional chalcone side chain to give the 
bis-substituted ferrocenyl chalcones appeared to enhance binding affinity (Table 6.2). 
 
Table 6.2 Heme binding results of bis-substituted ferrocenyl chalcones 























35.0 (25: 15.7) 
PP
a 
PP % Decrease in absorbance was obtained at 128 μM of samples.   
   % Decrease in absorbance of heme = (1 - Absorbance BBheme + sample (128µM) BB / Absorbance BBheme BB) x 
  100%   
PP
b  
PPThe % decrease in absorbance of heme for the mono ferrocenyl chalcone analog 
 
6.2.2.2 Inhibition of β-hematin formation 
β-Hematin is the synthetic equivalent of hemozoin, the characteristic malarial 
pigment that is produced on detoxification of heme.  Compounds that exhibited heme 
binding should concurrently reduce the production of hemozoin.  Fitch et alPP 103 
PPreported that the formation of β-hematin in vitro could be demonstrated using 
synthetic lipids as catalysts.  Several investigatorsPP PPhad used monooleoylglycerol 
(MOG) for this purpose and their methods were adopted in the present 
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investigations.PP106, 107  PPThe formation of β-hematin was confirmed by showing  
characteristic IR peaks at 1662 and 1209 cmPP-1 PP. PP103PP  The positive control, chloroquine, 
inhibited β-hematin formation with an ICBB50BB of 48 µM, compared to the literature 
value of 32 µM.PP106 PP Interestingly, chloroquine with an in vitro antiplasmodial ICBB50 BB in 
the nanomolar range displayed micro-molar inhibition of β-hematin formation.   
The IC BB50BB values for inhibition of β-hematin formation were determined for 
eleven compounds.   Except for 14, the remaining compounds had demonstrated 
strong binding affinities to heme (>20% decrease in Soret band absorbance).   As 
seen from Table 6.1, the most potent inhibitor (8) inhibited the formation of β-
hematin with an ICBB50BB of 74 µM.  It also had a reasonably good binding affinity to 
heme.  However, there was no apparent correlation between heme binding and 
inhibition of β-hematin for the other compounds.  
 
6.2.2.3 Inhibition of GSH mediated heme degradation 
Inhibition of GSH-mediated heme degradation was assessed by monitoring 
changes in the Soret band of heme in the presence of GSH and 6 μM test compound. 
Figure 6.3 shows the time dependent decrease in the absorbance of the Soret band 
when heme was incubated with GSH or GSH and 6 μM chloroquine. Heme was 
stable at room temperature for 30 minutes, in the absence of light. The addition of 
GSH greatly accelerated the degradation as seen from the rates of change in 
absorbance (GSH + heme: 7.54x10PP-5 PPAU/s compared to heme alone 1.04x10 PP-5 PPAU/s).  
The addition of chloroquine slowed the degradation in the presence of GSH.  At 6 μM 
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chloroquine, the rate of decrease in absorbance was 3.71x10 PP-5 PPAU/s.  The finding was 
consistent with other reports.PP94, 100, 106, 108 PP  
Figure 6.3 Absorbance change of heme, heme with GSH and heme, GSH and CQ (6 
µM) 
 
Several ferrocenyl chalcones prevented the decrease in heme absorbance in 
the presence of GSH.  Most of these compounds belonged to series B and several 
were as effective or more so than chloroquine.  In terms of ICBB50 BB values, compounds 7 
and 10 were the most active inhibitors of this process, but in general, the correlation 
to antiplasmodial activity was not evident.   
GSH is a soft nucleophile and can attack the α,β-unsaturated linkage of 
chalcones in a Michael-type reaction. (Figure 6.4) 
Figure 6.4 Reaction of GSH with α,β-unsaturated linkage of chalcone 
O
GSH
O H SGOH H SG
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Thus, it might be that GSH was “consumed” by the test compound and less 
was available for degrading heme.  However, a large excess of GSH (final 
concentration of 2 mM) was used in these experiments, compared to the 
concentration of the test compound (6 μM).  Therefore, assuming 1:1 stoichiometry in 
the reaction, the test chalcone could not have depleted GSH to any significant extent.  
 
6.2.3 Conclusion 
The present findings showed that the antiplasmodial activity of ferrocenyl 
chalcones was not related to interference with the degradation of heme. The presence 
of ferrocene might have enhanced binding to heme to some extent (as seen from the 
heme binding properties of 6 and C6, 28 and C28) but on the whole, these differences 
were not correlated to antiplasmodial activity.  The same conclusions were drawn 
from the effect of the ferrocenyl chalcones on other processes related to heme 
degradation.  
 
6.3 Effect of Ferrocenyl Chalcones on The Parasite-induced New Permeation 
Pathways on The Erythrocyte 
Plasmodium is known to induce new permeation pathways in the host 
erythrocyte membrane.PP109-112PP  These pathways allow the entry of a wide range of 
substances into the erythrocyte, most of which are essential nutrients required for the 
survival of the parasite.  The permeation pathways are only found in infected 
erythrocytes and thus constitute a selective and attractive target against Plasmodium.  
Tubovesicular membrane (TVB) and parasitophorous vacuola membrane (PVM) 
were reported to be potential targets for artemisinis.PP128PP  Several structurally diverse 
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compounds had been found to inhibit these parasite-induced channels as shown in 
experiments that demonstrated their ability to interfere with the transport of small 
solutes like sorbitol, choline via channels into parasitized erythrocytes.  These 
compounds included the flavonoid phlorizin, several sulphonyl ureas, 
arylaminobenzoates and cinnamates,PP113-116PP many of which also had antiplasmodial 
activity.  Alkoxylated and hydroxylated chalcones with antiplasmodial activities were 
also found to inhibit the plasmodial – induced permeation pathways in parasitized 
erythrocytes, where a correlation between antiplasmodial activities and inhibition of 
the pathways were observed for half of the investigated chalcones.PP117PP  Compared to 
other known inhibitors of the parasite-induced channels, the chalcones were notable 
in two respects.  These were their selective toxicity against Plasmodium, and the 
absence of anionic character in the chalcones, which would make them unlikely 
candidates to bind to plasma proteins. In view of this finding, it was of interest to see 
if ferrocenyl chalcones also inhibited the permeation pathways.  Representative 
members covering a range of antiplasmodial activities were tested for their effects on 
sorbitol-induced hemolysis of P. falciparum infected erythrocytes.  
 
6.3.1 Experimental methods 
 The effects of ferrocenyl chalcones (1, 6, 13, 28, 30) on the parasite-induced 
permeation pathways were investigated by a sorbitol hemolysis method described in 
the literature.PP117PP These 5 representative compounds were chosen from Series A and 
Series B ferrocneyl chalcones to cover an antiplasmodial activity ranging over 5 µM 
to 175 µM.  The experiments were carried out by Dr Go Mei Lin.  Compounds 6 and 
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28 were the most active compounds identified (ICBB50 BB 5 µM), compound 13 and 30 had 
ICBB50BB values of 19 and 18 µM respectively, and compound 1 was the least active (ICBB50 BB 
175 µM).  Briefly, sorbitol was taken up into parasitized erythrocytes (P. falciparum 
FAF-6, chloroquine resistant) via the permeation pathways.  The net uptake of 
sorbitol and water caused the erythrocytes to hemolyze with the release of 
hemoglobin. The amount of hemoglobin released was measured 
spectrophotometrically at 540 nm.  The rates of hemolysis gave a semiquantitative 
estimate of the net rate of influx of sorbitol.  Hemolysis was reduced in the presence 
of inhibitors and the rates of hemolysis were a convenient measure of inhibitory 
potencies.  
 
6.3.2 Results and discussion 
 The ferrocenyl chalcones did not inhibit the rate of hemolysis of parasitized 
erythrocytes at 10 µM or 100 µM.  In fact, no hemolysis was detected at these 
concentrations.  The positive control, furosemide inhibited hemolysis by 53% at 10 
µM while chloroquine did not inhibit the process at the same concentration. 
 
6.3.3 Conclusion 
 The antiplasmodial activities of ferrocenyl chalcones were not related to the 
inhibition of the parasite-induced permeation pathways.  Although only a small 
number of ferrocenyl chalcones were tested, the absence of inhibitory activity might 
be due to the presence of ferrocene.  
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6.4 Oxidant Properties of Ferrocenyl Chalcones 
The blood and liver stages of plasmodia encounter considerable oxidative 
stress from reactive oxygen species produced either by themselves, the erythrocytes 
or the host immune cells.PP118 PP Enhancing oxidative stress and/or restraining the 
plasmodial antioxidant defence mechanisms are viable approaches to curtailing 
plasmodial growth. Oxidants (like peroxides) and agents that undergo 
oxidation/reduction cycling (such as methylene blue) had antimalarial activity.PP119PP The 
metal ion in ferrocene undergoes reversible electron transfer and may participate in 
redox cycling with reduction of oxygen to reactive oxygen species at the expense of 
reducing equivalents such as NADPH.  The antiproliferative activity of ferrocenyl 
compounds had been traced to free radicals formed during the course of electron 
transfer between FePP2+ PP/FePP3+ PP and other biological electron donors/acceptors.PP38PP   
As described in Chapter 5, QSAR had shown that the oxidizability of 
ferrocene was an important determinant of antiplasmodial activity in ferrocenyl 
chalcones.  In general, better activity was found for series A compounds in which 
ferrocene was more resistant to oxidation.  These findings suggested a role for 
ferrocene beyond that of a spacer group or a replacement for phenyl.  
An investigation carried out by another student in this laboratory showed that 
selected ferrocenyl chalcones actually accelerated the breakdown of heme in the 
presence of hydrogen peroxide.PP120PP  When heme was incubated with hydrogen 
peroxide, there was a fall in the Soret band absorbance of heme over 15 min, 
indicative of peroxidative degradation.  Chloroquine (30 µM) prevented the fall in 
absorbance, as reported in the literature.PP97 PP  A few ferrocenyl chalcones (1, 6, 8, 13, 15, 
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18, 27) actually accelerated the fall in absorbance to a significant extent (p < 0.05), 
while others (1, 28, 30, 31) had results similar to the control.  For those ferrocenyl 
chalcones that hastened the fall in absorbance, this could be attributed to their ability 
to accelerate peroxidative degradation of heme, which would in turn suggest that 
ferrocenyl chalcones were capable of producing oxidant species.   
Thus, the oxidant properties of the ferrocenyl chalcones were investigated in 
two approaches, namely, in experiments to determine the ability of ferrocenyl 
chalcones to transfer electrons to a stable radical cation (2,2’-azinobis(3-
ethylbenzothiazoline-6-sulfonic acid, ABTSPP•+ PP) and by electron paramagnetic 
resonance (EPR) spectroscopy to detect the formation of free radicals when a spin 
trap was incubated with ferrocenyl chalcones.  
 
6.4.1 Experimental methods 
6.4.1.1 Materials  
The following chemicals were purchased from Sigma-Aldrich (St. Louis, Mo): 
5,5-dimethyl-1-pyrroline-N-oxide (DMPO), N-tert-Butyl-α-phenylnitrone (PBN), 
TEMPO, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox), 2,2’-
Azinobis(3-ethylbenzothiazoline-6-sulfonic acid diammonium salt (ABTS) was 
obtained from Fluka Chem. Co,  Steinheim, Germany).  Tetrabutylammonium 
perchlorate (TBAP) was purchased from TCI, Tokyo, Japan. Other reagents were of 
analytical grade. 
  
6.4.1.2 Scavenging of ABTS radical cation 
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 Stock solutions of ABTS (7 mM) and potassium persulfate (0.245 M) were 
prepared in distilled water. Aliquots of ABTS (1 ml) and potassium persulfate (10 µl) 
were mixed to give a stock solution that was kept in the dark at 23PPoPPC for 16 h to 
optimize the production of the radical cation.  After this time, the solution which 
contained ABTSPP•+ PP was diluted with PBS (pH 7.4) to an absorbance of 0.70 (±0.02) at 
734 nm.  An aliquot of the test sample (10 µl, freshly prepared in 80% ethanol) was 
mixed with this solution (990 µl) in a 1ml cuvette and the absorbance was recorded 
over a period of 5 min.  The final concentration of the test sample and Trolox 
(positive control) ranged from 2.5 – 15 µM. The scavenging ability of the test 
compound was determined from the reduction in the absorbance of ABTSPP•+ PP after 5 
min at a specific concentration of the compound.  At least two determinations were 
made for each concentration of test compound. 
              % Reduction of ABTS PP•+ PP absorbance = 100 – [Abs BBTest + ABTS•+ BB / Abs BBABTS•+ BB] 
TEAC (Trolox equivalent antioxidant capacity) of the test compounds were obtained 
using the method of Re et al PP121 PPwhich involved determining the gradient of the line 
obtained by plotting % scavenging activity (after 5 min) against concentration of test 
compound and dividing it by the gradient of the line obtained for Trolox under similar 
conditions.   
 
6.4.1.3 Spin trapping measurements 
Spin trapping experiments were carried out to identify the radicals produced 
when the ferrocenyl chalcones were dissolved in aqueous media.  DMPO was treated 
before use with activated charcoal to remove paramagnetic impurities.  PBN was used 
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as received.  Stock solutions (1 mM) of the spin traps were prepared in deionized 
water and kept refrigerated and protected from light.  The compounds were prepared 
in DMSO and diluted to the desired concentration with deionized water.  The 
concentration of DMSO in the final solutions was 1% v/v.  Chelating agents DTPA 
(for DMPO) and EDTA (for PBN) were added (10 PP-3 PP M) to the final solutions. The test 
compound and spin trap were incubated for 45 min (22PPo PPC) in an open flask containing 
1.5 ml of reaction mixture in which the final concentration of spin trap and test 
compound were 100 mM and 100 µM respectively.  About 600 µl of the reaction 
mixture was transferred at 5 min intervals to a standard quartz flat cell for 
measurement, after which the solution was returned to the incubation mixture.  
Spectra were recorded on a Burker spectrometer (Bruker BioSpin Gmbh, Rheinstetten 
/ Karlsruhe, Germany, Elexsys Series E500 CW-EPR X-band, 9-10 GHz) with 
SuperX TEBB102 BBmode cavity. Instrument settings were modulation frequency 100 KHz, 
modulation amplitude 1 G, receiver gain 60 dB, time constant 81.9 ms, sweep rate 
149.4 G/min, microwave frequency ≈ 9.75 GHz, microwave power 20 mW.  
Manganese in magnesium oxide marker and spin standard TEMPO at final 
concentrations of 5, 10, 50 and 100 µM, were used to quantify the nitroxide spin 
adducts. 
 
6.4.2 Results and discussion 
6.4.2.1 Scavenging of ABTS radical cation 
 ABTS formed a stable and long lived radical cation (ABTS PP•+ PP) in the presence 
of potassium persulfate, a strong oxidizing agent. The resulting free radical cation is 
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green in colour, with absorption maxima at 634, 734 and 815 nm.  In the presence of 
an antioxidant (a substance that can donate electrons), ABTSPP•+ PP reverted back to 
ABTS, with loss of its green colouration. (Figure 6.5)  




















 If the absorbance of ABTS PP•+ PP was monitored in the presence of an antioxidant, 
the fall in absorbance with time provided a measure of the antioxidant potential of the 
substance.  In the experiments, the % reduction in absorbance was monitored using 
various concentrations of the test compound after 5 minutes and represented as a plot 
(Figure 6.6).  The gradient of the straight line was a measure of the antioxidant 
(radical scavenging) activity of the compound.  The same plot was obtained for a 
positive control, Trolox (6 hydroxy-2,5,7,8-tetramethylchroma-2-carboxylic acid) 
(Figure 6.7).  Trolox is a water soluble vitamin E analogue with good antioxidant 
properties.  The gradients of the lines for the test compound and Trolox were 
compared to give the TEAC (Trolox Equivalent Antioxidant Capacity) of the 
compound.  This value showed how many times more active the compound was as a 
radical scavenger compared to Trolox.  The TEAC values of selected ferrocenyl 
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Table 6.3 TEAC values 
Series A Series B 
No. A B TEACPP a PP No. A B TEAC 
13 Ph 0.65 1 Ph 0.98 
14 4-MeOPh 1.16 2 4-MeOPh 0.49 
15 2,4-diMeOPh 1.26 3 2,4-diMeOPh 0.78 
16 2-Naphthaleny 0.35 4 2-Naphthalenyl 0.44 
18 3-Pyridinyl 1.27 6 3-Pyridinyl 1.29 
19 4-OHPh 0.83 7 4-OHPh 0.33 
27 4-CFBB3 BBPh 0.68 8 2,4-diOHPh 2.39 
28 4-NOBB2 BBPh 0.58 36 4-NOBB2 BBPh 
Fc 
1.14 
29 4-CNPh 0.35 
39 4-Pyridinyl 1.48 
 
R13 Ph 0.72 R1 Ph Fc 0.49 
Bis13 
Fc
Ph 0.48 45 Fc Fc 5.21 
C28 Ph 4-NOBB2 BBPh 0 C45 Ph Ph 0 
 C6 3-Pyridinyl Ph 0 




PP Trolox equivalent antioxidant capacity (TEAC) measures the ABTS PP•+PP radical 
  scavenging activity of test compound compared to Trolox. 
From the results, there was evidence to support an important role for ferrocene 
in the radical scavenging activity of the ferrocenyl chalcones.  This was deduced from 
the negligible scavenging activities of the phenyl analogues (C1, C6, C28) as 
compared to their ferrocenyl counterparts 1, 6 and 28 respectively.  Ferrocene 
exhibited modest scavenging activity either by itself (TEAC = 0.75) or when 
incorporated into the chalcone template (TEAC of  1 = 0.98, TEAC of 13 = 0.65).  On 
the other hand, introducing two ferrocene rings in the chalcone framework to give 
diferrocenylchalcone (45) greatly increased scavenging activity (TEAC 5.2). 
Compound 8 had the highest TEAC (2.39) of the ferrocenyl chalcones tested.  Its 
phenyl analog (C8) also had significant activity (TEAC 1.16) unlike the other phenyl 
derivatives C1, C6 and C28.  In the case of C8, the number and position of hydroxyl 
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groups on the phenyl ring A played a pivotal role.  This was evident from the lower 
TEAC values of 2’-hydroxychalcone (TEAC 0.66) and 4’-hydroxychalcone (TEAC 
0.26). Thus, the outstanding scavenging activity of compound 8 might be due to the 
presence of both ferrocene and hydroxyl substituents on the phenyl ring A.  
Reduction of the α,β-unsaturated double bond in the chalcone had mixed effects, as 
seen from the TEAC values of R1 (0.49) and R13 (0.72), compared to 1 (0.98) and 13 
(0.65).  
 QSAR had proposed that electron loss from ferrocene in series A did not 
occur as readily as in series B compounds.  If electron donation to ABTS PP•+ PP involved 
Fe PP2+ PP in ferrocene, series A compounds should be less effective donors and have lower 
TEAC values than their series B counterparts.  This was observed to some degree: of 
the 7 pairs of regioisomers investigated, lower TEAC values were found for ring A 
analogues in 4 pairs.   
 
6.4.2.2 Spin trapping measurements 
The ability of ferrocenyl chalcones to donate electrons to ABTSPP•+ PP implied that 
electron donation to other suitable acceptors might occur, with the formation of free 
radicals.  The reactions of FePP2+ PP with oxygen (Haber-Weiss reaction) and hydrogen 
peroxide (Fenton reaction) are known to generate reactive oxygen species (superoxide, 
hydroxyl radical) that can inflict considerable biological damage.  Free radical 
formation by selected ferrocenyl chalcones 1, 6, 8, 13, 27, 28 were explored by 
electron paramagnetic resonance (EPR) using two spin traps, α-phenyl-tert-
butylnitrone (PBN) and 5,5-dimethylpyrroline-N-oxide (DMPO).   
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The EPR spectra of DMPO and the test compound incubated at room 
temperature in the presence of oxygen exhibited a composite signal pattern indicative 
of the DMPO-OH and DMPO-CHBB3 BB adducts (Figure 6.8).  The formation of the 
DMPO-CHBB3 BB adduct was traced to the reaction of the solvent DMSO with the OH free 
radical.PP122PP Thus, the integral amount of both radicals were correlated to the amount of 
hydroxyl radicals initially formed by the ferrocenyl chalcone.  Figure 6.8 (a) was 
obtained using compound 1, but it was typical for all the other compounds tested.  
Incubation for periods longer than 5 min caused a decrease in the signal intensity due 
to the instability of the DMPO adducts.  A similar pattern was observed from the EPR 
spectra of compound 1 and another spin trap PBN after 45 min incubation in air.  A 














Figure 6.8 EPR spectra obtained with spin trap DMPO and PBN 
(a) EPR spectra of solutions containing DMPO (100 mM) and compound 1 (100 μM) in 1% 
v/v DMSO – water, incubated in the presence of the air for 5 min.  Simulated spectra (solid 
line) were obtained by using parameters for hydroxyl adduct (aBBNPBPB PP= 14.9, a BBHBB = 14.9 G) and 
methyl adduct, aBBNPBPB PP= 16.6, aBBHBB = 23.8 G. Relative content of the hydroxyl adduct was 58%, 57%, 
54%, 46%, 65% and 58% for compounds 1, 6, 8, 13, 27 and 28, respectively. The remaining 



















(b) EPR spectra of solutions containing PBN (100mM) and compound 1(100 μM ) in 1% v/v 
DMSO –water, incubated in the presence of the air for 45 min. Simulated spectra (solid line) 
were obtained by using: aBBNPBPB PP= 16.4, a BBHBB = 3.3 G (hydroxyl adduct  33%, 33%, 32%, 29%, 30%, 
29% and 33% for compounds C6, 1,  6, 8, 13, 27 and 28 respectively) and aBBNPBPB PP= 15.3, aBBHBB = 3.5 
G (methyl adduct 67%, 67%, 68%, 71%, 70%, 71%, and 67% for compounds C6, 1, 6, 8, 13, 























 Figure 6.9 shows the change in signal intensity of PBN adduct on incubation 
with the test compound. The increase in signal intensity signified formation of more 
radicals with time. In the case of compounds 6 and 13, the signal intensity increased 
and then reached a plateau, indicating that the adducts were unstable and participated 
in secondary reactions at high concentrations.  Table 6.4 records the total amount of 
free radicals produced during the incubation period (45 min) and the rate of free 
radical generation for each of the test compound.  
 
Figure 6.9 Free radical formation (hydroxyl and methyl adducts) obtained on 








Table 6.4 Amount of free radicals and the rate of free radical generation 
No. Ring A Ring B PBN adducts (μM) PP aPP 
Rate of PBN adduct 
formation PPb PP 
(10PP-8 PP M min PP-1 PP) 
13 Ph 2.00 11.4 
14 4-CHBB3 BBOPh   
15 2,4-(CH BB3BBO)BB2BBPh   
16 2-naphthalenyl   
18 3-pyridinyl   
19 4-OH Ph   
27 4-CF BB3BBPh 0.79 1.5 
28 4-NOBB2 BBPh 0.55 1.6 
29 4-CN Ph   
39 
Fc 
4-pyridinyl   
1 Ph 1.21 2.7 
2 4-CHBB3 BBOPh   
3 2,4(CHBB3BBO)BB2 BBPh   
4 2-naphthalenyl   
6 3-pyridinyl 2.53 11.1 
7 4-OH Ph   
8  2,4(OH)BB2BBPh 0.57 1.5 
36 4-NOBB2 BBPh 
Fc 
  
C6  3-pyridinyl Ph 0.25 0.56 
C8 2,4-(OH)BB2 BB Ph Ph   
C28  Ph 4-NOBB2 BBPh   
 Fc Fc   
 Ph Ph   
Ferrocene 0.02 0.04 
PP
a   
PPTotal concentration of PBN-OH and PBN-CHBB3 BB adducts produced during incubation (45 min, 




PP Rate of PBN adduct formation as determined from the gradient of lines in Figure 6.9. 
 
There was a good correlation between the amount of free radicals formed and 
the rate at which they were formed (Pearson correlation = 0.951, p < 0.01, n = 8).  
Ferrocene itself produced negligible levels of free radical but incorporating the 
metallocene into the chalcone template enhanced radical formation.  Compounds 6 
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and 13 produced the largest amount of radical adducts. In contrast, the non-ferrocenyl 
analogue of compound 6 (C6) produced an insignificant amount of free radicals.   
 
6.4.2.3 Correlation between TEAC and spin trapping properties of ferrocenyl 
chalcones 
Figure 6.10 ranks the ferrocenyl chalcones according to their abilities to 
produce PBN adducts, their TEAC values and in vitro antiplasmodial activities (based 
on ICBB50BB values).  The length of the bar indicated the ranking of the compound for each 
property. For example, compound 6 produced the most PBN adducts and had the best 
antiplasmodial activity among the 7 compounds tested.  Its TEAC value was 2PPnd PP 
highest, behind compound 8 which was ranked highest.  
Figure 6.10 Ranking of compounds 1, 6, 8, 13, 27, 28 and C6 based on the total 
amount of radicals formed on incubation (45 min) with PBN, TEAC and 



















PPFor each category, the most potent / active compound is ranked (7) and the least 
potent/active compound is ranked (1). 
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Compounds with high TEAC values were expected to be competent 
generators of free radical since both processes involved an initial step of electron 
donation. Thus, one would expect the bars for free radical generation and TEAC to be 
comparable in length in Figure 6.8.  This was generally true for the compounds tested, 
with the exception of compounds 8 and 13.  Compound 8 had a disproportionately 
high ranking based on TEAC, while compound 13 showed the opposite trend (highly 
ranked for free radical production, but low rank for TEAC).   In the case of 8, it may 
be that the hydroxyl groups contributed significantly to the scavenging of ABTSPP•+  PPbut 
had a lesser role in interacting with the spin trap to produce free radicals. More 
investigations on hydroxylated chalcones would be required to confirm this 
hypothesis. In the case of compound 13, no good reason could be proposed for the 
disparity.   
The correlation between free radical production and antiplasmodial activity 
was also examined.  If the oxidant properties of ferrocenyl chalcones contributed to 
activity, a direct correlation would be expected.  This was observed for compounds 6, 
8 and 13 but not for 1, 27 and 28.  Compounds 6 and 8 belonged to series B, while 
compounds 27 and 28 belonged to series A.  Not withstanding the limited compounds 
investigated, it seemed that the correlation between antiplasmodial activity and free 
radical formation was better for series B compounds (6, 8 but not 1 showed 
correlation) while a poor correlation was observed for series A compounds (only 13 
showed correlation, 27 and 28 did not).  
Compound 6 combined good antiplasmodial activity with a high level of 
radical production.  Its phenyl analog (C6) showed the opposite trend.  This 
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observation underscored an important role for ferrocene ring in free radical 
generation. Compounds 8 and 13 also showed a satisfactory correlation between free 
radical production and antiplasmodial activity. On the other hand, no correlation was 
evident for compounds 1, 27 and 28.   Mention must be made of compound 28 
because of its outstanding antiplasmodial activity among the compounds in series A. 
It had a high Eo’ value (like most series A compounds) indicating that its ferrocene 
ring was relatively resistant to electron loss. This might explain the low levels of free 
radical generation associated with 28.  Its antiplasmodial activity may be related to 
other factors that are not related to free radical formation.   
Compound 1 belonged to series B and its ferrocene ring had a lower Eo’BB BBvalue.   
Therefore its ability to produce a fairly high level of free radicals might be expected, 
but for some reason, this did not translate to good antiplasmodial activity.  
 
6.4.3 Conclusion 
 Investigations into the oxidant properties of selected ferrocenyl chalcones 
revealed that these compounds had the ability to generate free radicals.  They were 
able to donate electrons to ABTSPP•+ PP and to generate free radicals on incubation with 
two spin traps.  The role of ferrocene was important in both instances as the 
replacement of ferrocene for phenyl in some members greatly diminished the 
capacities of the resulting compounds to take part in these reactions.   
Electrochemical measurements had pointed to differences in the oxidizability 
of ferrocene, with compounds in series A being less readily oxidized than their 
counterparts in series B.  These differences should translate to series A compounds 
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having lower TEAC values and having a lower propensity to form free radicals than 
series B compounds.  With some exceptions, there was a general trend where more 
series A compounds had lower TEAC values and produced less free radicals.  
 With regard to the question as to whether there was any link between the 
oxidant properties of the ferrocenyl chalcones and antiplasmodial activity, the present 
results indicated that this may be present for the series B compound but not for the 
series A compounds.  Thus, series A and B compounds may have different 
mechanisms of antiplasmodial activity.  Oxidant properties may be more important 
for series B compounds than their series A analogues, while it is to be further justified 
by more extensive studies on additional compounds. 
 
6.5 Summary  
 The ferrocenyl chalcones were investigated for their effects on detoxification 
of heme, parasite-induced permeation pathways on Plasmodium-infected erythrocytes 
and their oxidant properties.  There was no convincing evidence to support a role for 
these compounds in the detoxification of heme that was pertinent to their 
antiplasmodial activities. Selected ferrocenyl chalcones did not inhibit the new 
permeation pathways induced in parasitized erythrocytes.  In fact, the presence of 
ferrocene might have deterred the inhibition of parasite-induced channels, as this was 
observed for several normal chalcones. 
Several ferrocenyl chalcones have a tendency to generate free radicals, a 
property not observed for non-ferrocenyl chalcones.  Unfortunately, the correlation 
between free radical generation and antiplasmodial activity was not as robust as 
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desired.  Series A compounds (like 28) that had better antiplasmodial activities 
generated free radicals at a slower rate and in smaller amounts. Oxidant properties 
may be more important for series B compounds than their series A analogues, but 
based on the present findings, no definite conclusion can be drawn.  We can propose 
that the QSAR models that have identified oxidizability of ferrocene as an important 
feature for activity is limited in not including more diverse parameters.  Another 
possibility is to consider the fact that series A compounds differed from series B in 
other properties as well.  Series A compounds were generally less lipophilic, had 
more polarized carbonyl bonds and were more planar.  These properties might in 
some way facilitate their passage or access to the putative target in the Plasmodium.  
Once this was achieved, the oxidant properties of these compounds might come into 
action.  Thus, the interaction of these properties, and not just the ease of oxidation of 
ferrocene alone, might be the final determinants of antiplasmodial activity.   








































 The objective of this thesis was to investigate the hypothesis that the 
introduction of ferrocene into the chalcone template had an important impact on 
antiplasmodial activity, namely by affecting the physicochemical characteristics of 
the target compounds.  This would in turn influence the route(s) by which these 
compounds exert their antiplasmodial activities.  In this concluding chapter, the 
degree to which this hypothesis had been proven was evaluated. 
 The introduction of ferrocene into the chalcone template was attempted in two 
ways, resulting in series A and B compounds. Among these compounds were fifteen 
pairs of regioisomers which offered opportunities to investigate the effect of location 
of ferrocene on physicochemical characteristics and antiplasmodial activities.  The 
location of ferrocene affected the physicochemical characteristics of the final 
compound.  When ferrocene was adjacent to the carbonyl linkage (series A), 
lipophilicity was reduced and the planarity of the template was enhanced.  The 
electronic environment about the carbonyl linkage was such that there was greater 
charge separation in the bond and a more deshielded carbonyl carbon in series A, 
pointing to a linkage that was more polarized and with more single bond character.  
The ferrous ion in ferrocene ring was also more resistant to oxidation when located 
adjacent to the carbonyl linkage.  On the other hand, volume and surface area 
parameters and the propensity of the carbonyl linkage to undergo reduction were not 
influenced by the location of ferrocene.  
It was established that the location of ferrocene influenced selected 
physicochemical characteristics, and it was further shown that these features 
influenced the in vitro antiplasmodial activities.  Based on multivariate analytical 
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techniques (PCA and PLS), a general trend was noted in which better antiplasmodial 
activities were associated with series A compounds.  This was in turn traced to 
properties relating to the oxidizability of ferrocene, the electronic character of the 
carbonyl bond and lipophilicity.  Thus, based on the present QSAR models, the 
location of ferrocene in the chalcone template was shown to influence selected 
physicochemical properties and to some degree, antiplasmodial activities of the 
compounds.  
 QSAR identified oxidizability of ferrocene to be an important factor in 
antiplasmodial activity.  It was shown that ferrocenyl chalcones were capable of 
generating free radicals, a property that was not observed in the few non-ferrocenyl 
chalcones concurrently investigated. However, a robust correlation could not be 
established between the capacity of compounds to generate free radicals and 
antiplasmodial activity.  Among a group of 6 compounds, half showed a correlation 
between antiplasmodial activity and free radical generation and most of these 
compounds were in series B.  Thus, free radical generation may be important for 
series B compounds, but a different mechanism may operate for series A.  It could be 
argued that the other physicochemical properties of the ferrocenyl chalcone should be 
considered together with their oxidant potential.  The better antiplasmodial activities 
of series A, despite their relatively weak oxidant properties, might be due to enhanced 
access to the target, following which the oxidant potential of these compounds could 
be manifested.     
 In conclusion, the present work has given a better understanding of the 
contributions of ferrocene when incorporated into the chalcone template. Ferrocene 
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caused location-dependent changes in the physicochemical properties of the 
compounds, which might also be observed when it is incorporated into other 
structural templates.  It also introduced a new component to the biological profile of 
the compounds that might be relevant to their antiplasmodial activity.  However, there 
are still unanswered questions.  These may be addressed by the following suggestions 
for future work.  
a) For the most active compounds 6 and 28, phenyl analogues (C6 and C28) 
had been prepared. A comparison of the activities of these compounds had been 
useful to show that ferrocene and phenyl are not bioisosteric replacements.  C6 and 
C28 had weaker in vitro antiplasmodial activities, did not quench the ABTS •PP+ PP, and 
did not bind to heme.   The availability of more non-ferrocenyl analogues of existing 
compounds would have been useful in highlighting the role of ferrocene. Thus one 
suggestion would be to synthesize additional phenyl analogues for evaluation of 
antiplasmodial and other activities to provide more support for the unique 
contribution of ferrocene. 
b) Only six compounds were tested for free radical generation in spin trapping 
experiments.  More compounds could be included to give a more comprehensive 
picture.  Alternately, the spin trapping experiments could have been redesigned to be 
more relevant to antiplasmodial activities of the compounds.  One suggestion would 
be to incubate Plasmodium with the ferrocenyl chalcone in the presence of the spin 
trap.  If the test compound killed Plasmodium by an oxidant mechanism, free radicals 
would be generated and trapped. A high level of free radical generation would point 
to the involvement of an oxidant mechanism in the activity of the test compound. 
 138
c) Ziegler and co-workers reported that licochalcone A was a potent 
membrane-active agent and caused concentration-dependent transformation of both 
infected and uninfected erythrocytes into echinocytes.PP123PP  They suggested that the in 
vitro antiplasmodial activity of licochalcone A was due to an indirect effect on the 
erythrocyte membrane because the altered membrane of the echinocytes rendered 
them resistant to plasmodial invasion. Therefore, the target of licochalcone may not 
be Plasmodium, but the host cell membrane. They also cautioned that the membrane 
activity of licochalcone should be considered whenever the compound was used in 
other in vitro assays employing whole cells.  Since this finding was based only on one 
chalcone derivative (licochalcone A), it might be worthwhile to explore its relevance 
to other chalcones in general, and to ferrocenyl chalcones in particular.   Membrane 
active properties may be investigated by microscopy of infected/normal erythrocytes 
exposed to selected chalcones to detect sites of damage on the membrane or 
morphological changes evoked by these compounds 
d) A better understanding of the in vitro antiplasmodial activity of the 
ferrocenyl chalcones could be obtained by analyzing the stage-dependency of killing, 
and by examining the synergistic or antagonistic effects of antioxidants on in vitro 
activity.  The latter might be pertinent in view of the finding that the oxidant 
properties of the compounds were relevant to the activity of selected compounds.  
e) One of the disappointing findings to emerge from this work was the 
absence of in vivo antiplasmodial activities of the two most active compounds (6 and 
28) when administered to infected mice.  While cytotoxic effects of the ferrocenyl 
chalcones were also not demonstrated on mice, it might be worthwhile to explore why 
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these compounds failed to show in vivo activity.  The present series of compounds 
may not have the correct balance of lipophilicity and solubility.  They may have been 
overly lipophilic,and lack sufficient aqueous solubility which is particularly critical 
for in vivo evaluation. Thus, solubility profiles should be considered in the future 
drug design.  More polar, but metabolically resistant substituents bearing both H-
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Table 1 Physical and analytical data of synthesized ferrocenyl chalcones 













1H-NMR (δ ppm) 
1 132.0-132.4 (i) 93.6% 316.0548     
(C19H16FeO 
=316.0551) 
C, H (Calcd: 5.10%, Found: 
5.05%), Fe (Calcd: 17.66%, 
Found: 17.25%) 
4.59   99.96 8.26 98.76 CDCl3 8.07 (m, 2H), 7.65-7.57 (m, 4H), 7.46-
7.41 (d, 1H, J=15.06), 4.86 (s, 2H), 4.56 (s, 
2H), 4.20 (s, 5H) 
2 153.6-153.7 (i) 75.4% 346.0656   
(C20H18FeO2 
=346.0656) 
C, H (Calcd: 5.24%, Found: 
5.31%), Fe (Calcd: 16.13%, 
Found: 13.82%) 
4.25    99.84 8.36 99.30 CDCl3 8.02-7.99 (d, 2H), 7.76-7.71 (d, 1H, 
J=15.45), 7.17-7.12 (d, 1H, J=16.20), 6.99-6.96 
(d, 2H), 4.59 (s, 2H), 4.47 (s, 2H), 4.18 (s, 5H), 
3.89 (s, 3H)  
3 99.2-100.0 (i) 18.5% 376.0763   
(C21H20FeO3 
=376.0762) 
C (Calcd: 67.04%, Found: 
66.20%), H, Fe (Calcd: 
14.84%, Found: 12.54%) 
4.08    99.83 8.03 98.34 CDCl3 7.71-7.68 (d, 1H), 7.58-7.53 (d, 1H, 
J=15.84), 7.09-7.03 (d, 1H, J=15.81), 6.58-6.50 
(m, 2H), 4.55 (s, 2H), 4.43 (s, 2H), 4.17 (s, 
5H), 3.90-3.88 (d, 6H) 
4 116.4-116.7 (ii) 87.8% 366.0709     
(C23H18FeO 
=366.0707) 
C, H (Calcd: 4.95%, Found: 
4.90%), Fe (Calcd: 15.25% 
Found: 14.26%) 
7.13    99.52 13.89 99.71 CDCl3 8.49 (s, 1H), 8.10-7.89 (m, 4H), 7.85-
7.80 (d, 1H, J=15.42), 7.63-7.54 (q, 2H), 7.31-
7.26 (d, 1H, J=15.84), 4.65 (s, 2H), 4.51 (s, 
2H), 4.21 (s, 5H) 
5 48.9-50.2 (ii) 17.9% 366.0709     
(C23H18FeO 
=366.0707) 
C, H (Calcd: 4.95%, Found: 
5.28%), Fe (Calcd: 15.25%, 
Found: 
12.61%) 
6.37    99.05 11.22 98.49 CDCl3 8.27-8.24 (d, 1H), 7.99-7.48 (m, 6H), 
7.49-7.43 (d, 1H, J=15.81), 6.90-6.85 (d, 1H, 
J=15.81), 4.52 (s, 2H), 4.47 (s, 2H), 4.16 (s, 
5H) 
6 149.0-150.4 (i) 82.6% 317.0503  
(C18H15FeNO 
=317.0503) 
C, H (Calcd: 4.77%, Found: 
4.50%) 
2.85    99.43 4.11 98.80 CDCl3 9.19 (s, 1H), 8.79-8.78 (d, 1H), 8.27-
8.25 (d, 1H), 7.84-7.79 (d, 1H, J=15.42), 7.47-
7.43 (q, 1H), 7.11-7.06 (d, 1H, J=15.42), 4.62 
(s, 2H), 4.54 (s, 2H), 4.20 (s, 5H) 
7 226.3-226.7 (i) 15.7% 332.0501   
(C19H16FeO2 
=332.0500) 
C, H, Fe (Calcd: 16.81%, 
Found: 14.92%) 
    DMSO 10.35 (s, 1H), 8.00-7.97 (d, 2H), 7.62-
7.57 (d, 1H, J=15.06), 7.44-7.39 (d, 1H, 
J=15.09), 6.90-6.87 (d, 2H), 4.83 (s, 2H), 4.52 
(s, 2H), 4.18 (s, 5H) 
8  218.0-220.5 b 10.4% 348.0448     
(C19H16FeO3
=348.0449) 
C (Calcd: 65.54%, Found: 
65.01%), H (Calcd: 4.63%, 
Found: 4.91%), Fe (Calcd: 
16.04% Found: 12.86%) 
4.11 98.80 8.49 97.71 DMSO 13.67 (s, 1H), 10.65 (s, 1H), 8.09 (s, 
1H), 7.77-7.73 (d, 1H, J=11.67), 7.51-7.46 (d, 
1H, J=14.67), 6.42 (s, 1H), 6.28 (s, 1H) 
9      122.3-125.4 b 21.1% 332.0500   
(C19H16FeO2 
=332.0500) 
C (Calcd: 68.70%, Found: 
67.91%), H, Fe (Calcd: 
16.81%, Found: 15.55%) 
CDCl3 13.06 (s, 1H), 7.92-7.84 (m, 2H), 7.50-
7.45 (t, 1H), 7.27-6.90 (m, 3H), 4.63 (s, 2H), 

















1H-NMR (δ ppm) 
10    82.2-83.1 b 18.8% 406.0869   
(C22H22FeO4
=406.0867) 
C, H (Calcd: 5.46%, Found: 
5.53%), Fe (Calcd: 13.75%, 
Found: 11.22%) 
 CDCl3 7.44-7.39 (d, 1H, J=15.06), 7.30-7.27 
(d, 1H), 6.97-6.91 (m, 2H), 4.73 (s, 2H), 4.52 
(s, 2H), 4.20 (s, 5H), 3.86-3.79 (t, 9H) 
11 166.9-167.3 (ii) 48.7% 360.0809   
(C21H20FeO2 
=360.0813) 
C, H (Calcd: 5.60%, Found: 
5.53%), Fe (Calcd: 15.50%, 
Found:14.26%) 
    CDCl3 8.01-7.98 (d, 2H), 7.76-7.71 (d, 1H, 
J=15.45), 7.17-7.12 (d, 1H, J=15.06), 6.98-6.95 
(d, 2H), 4.59 (s, 2H), 4.47 (s, 2H), 4.18 (s, 5H), 
4.16-4.09 (q, 2H), 1.48-1.13 (t, 3H) 
12 156.3-156.9 (ii) 74.8% 388.1128   
(C23H24FeO2 
=388.1126) 
C, H (Calcd: 6.23%, Found: 
6.11%), Fe (Calcd: 14.38%, 
Found: 13.79%) 
    CDCl3 8.00-7.97 (d, 2H), 7.76-7.71 (d, 1H, 
J=15.06), 7.17-7.12 (d, 1H, J=15.45), 6.98-6.95 
(d, 2H), 4.59 (s, 2H), 4.47 (s, 2H), 4.18 (s, 5H), 
4.07-4.02 (t, 2H), 1.83-1.50 (m, 4H), 0.99 (t, 
3H) 
13 130.4-130.6 (i) 67.5% 316.0553     
(C19H16FeO 
=316.0551) 
C (Calcd: 72.18%, Found: 
71.76%), H (Calcd: 5.10%, 
Found: 5.02%), Fe (Calcd: 
17.66%, Found: 17.09%) 
3.61    99.37 7.13 98.98 CDCl3 7.83-7.78(d, 1H, J=15.45), 7.67-7.42 
(m, 5H), 7.16-7.11 (d, 1H, J=16.20), 4.92 (s, 
2H), 4.60 (s, 2H), 4.22 (s, 5H) 
14 122.3-122.6 (i) 51.2% 346.0657   
(C20H18FeO2 
=346.0656) 
C (Calcd: 69.39%, Found: 
68.01%), H (Calcd: 5.24%, 
Found: 5.02%), Fe (Calcd: 
16.13%, Found: 14.60%) 
3.52    99.11 7.20 95.62 CDCl3 7.63-7.58 (d, 1H, J=14.67), 7.43 (m, 
4H), 7.03-6.98 (d, 1H, J=15.33), 5.07 (s, 2H), 
4.68 (s, 2H), 4.23 (s, 5H), 3.84 (s, 3H) 
15     117.6-119.0 b 77.2% 376.0760   
(C21H20FeO3 
=376.0762) 
C, H (Calcd: 5.36%, Found: 
5.45%), Fe (Calcd: 14.84%, 
Found: 12.52%) 
3.41 98.67 7.06 97.60 CDCl3 8.05-8.00 (d, 1H, J=15.84), 7.59-7.56 
(d, 1H), 7.18-7.13 (d, 1H, J=15.81), 6.66-6.49 
(m, 2H), 4.89 (s, 2H), 4.54 (s, 2H), 4.21 (s, 
5H), 3.93 (s, 3H), 3.86 (s, 3H) 
16 201.4-202.6 (ii) 57.7% 366.0707     
(C23H18FeO 
=366.0707) 
C, H (Calcd: 4.95%, Found: 
4.90%) Fe (Calcd: 15.25%, 
Found: 13.41%) 
5.20    99.31 10.75 99.55 CDCl3 8.05-7.99 (d, 1H, J=16.2), 7.94-7.79 (m, 
5H), 7.55-7.52 (m, 2H), 7.27-7.22 (d, 1H, 
J=15.45), 4.96 (s, 2H), 4.62 (s, 2H), 4.24 (s, 
5H) 
17 134.2-134.4 (ii) 51.2% 366.0705     
(C23H18FeO 
=366.0707) 
C (Calcd: 75.43%, Found, 
74.47%), H (Calcd: 4.95%, 
Found: 4.91%), Fe (Calcd: 
15.25%, Found: 13.17%) 
5.34    97.39 11.27 98.14 CDCl3 8.65-8.60 (d, 1H, J=14.79), 8.32-8.30 
(d, 1H), 7.94-7.87 (q, 3H), 7.63-7.54 (m, 3H, 
J=15.81), 7.24-7.19 (d, 1H, J=15.84), 4.95 (s, 
2H), 4.61 (s, 2H), 4.25 (s, 5H) 
18 168.7-168.9 (i) 55.0% 317.0500  
(C18H15FeNO 
=317.0503) 
C (Calcd: 68.16%, Found: 
67.18%), H (Calcd: 4.77%, 
Found: 4.61%), Fe (Calcd: 
17.61%, Found: 15.07%);  N 
(Calcd: 4.42%, Found: 4.63%) 
2.34    99.65 4.77 99.49 CDCl3 8.89 (s, 1H), 8.63 (s, 1H), 7.96-7.93 (d, 
1H), 7.80-7.75 (d, 1H, J=15.81), 7.39-7.27 (q, 
1H), 7.21-7.16 (d, 1H, J=15.84), 4.92 (s, 2H), 
4.63 (s, 2H), 4.23 (s, 5H) 
 
 III 













1H-NMR (δ ppm) 
19 173.6-174.1 (i) 76.3% 332.0499   
(C19H16FeO2 
=332.0500) 
C, H, Fe (Calcd: 16.81%, 
Found:  14.27%) 
    DMSO 9.86 (s, 1H), 7.84-7.81 (d, 2H), 7.75-
7.71 (d, 1H, J=15.09), 7.17-7.12 (d, 1H, 
J=15.42), 6.99-6.97 (d, 2H), 4.59 (s, 2H), 4.47 
(s, 2H), 4.03 (s, 5H) 
20 169.5-170.0 (i) 56.6% 330.0706     
(C20H18FeO 
=330.0707) 
C (Calcd: 72.75%, Found: 
71.79%), H (Calcd: 5.49%, 
Found: 5.38%), Fe (Calcd: 
16.91%, Found: 16.04%) 
    CDCl3 7.81-7.76 (d, 1H, J=15.45), 7.57-7.54 
(d, 2H), 7.25 (m, 2H), 7.12-7.07 (d, 1H, 
J=15.45), 4.92 (s, 2H), 4.59 (s, 2H), 4.22 (s, 
5H), 2.40 (s, 3H) 
21        155.8-156.1 (i) 51.4% 350.0155
(C19H15ClFeO
=350.0161) 
C (Calcd: 65.09%, Found: 
64.70%), H (Calcd: 4.31%, 
Found: 4.41%), Cl (Calcd: 
10.11%, Found: 10.23%), Fe 
(Calcd: 15.93%, Found: 
13.71%) 
4.55 99.54 8.75 99.54 CDCl3 7.77-7.72 (d, 1H, J=15.45), 7.60-7.57 
(d, 2H), 7.41-7.39 (d, 2H), 7.11-7.06 (d, 1H, 
J=15.84), 4.91 (s, 2H), 4.61 (s, 2H), 4.22 (s, 
5H) 
22        135.4-135.9 (i) 40.1% 350.0149
(C19H15ClFeO
=350.0161) 
C, H (Calcd: 4.31%, Found: 
4.08%), Fe (Calcd: 15.93%, 
Found: 14.74%) 
CDCl3 7.75-7.37 (m, 5H), 7.13-7.08 (d, 1H, 
J=15.06), 4.92 (s, 2H), 4.62 (s, 2H), 4.22 (s, 
5H) 





C, H (Calcd: 4.31%, Found: 
4.53), Cl (Calcd: 10.11%, 
Found: 9.90), Fe (Calcd: 
15.93%, Found: 13.53%) 
CDCl3 8.19-8.14 (d, 1H, J=15.81), 7.75-7.26 
(m, 4H), 7.13-7.08 (d, 1H, J=15.81), 4.91 (s, 
2H), 4.60 (s, 2H), 4.23 (s, 5H) 
24        108.8-109.4 (i) 75.5% 383.9774
(C19H14Cl2FeO
=383.9771) 
C (Calcd: 59.26%, Found: 
59.59%), H (Calcd: 3.66%, 
Found: 3.78), Cl (Calcd: 
18.41%, Found: 18.32%), Fe 
(Calcd: 14.50%, Found: 
12.13%) 
CDCl3 8.11-8.06 (d, 1H, J=15.45), 7.68-7.65 
(d, 1H), 7.48 (s, 1H), 7.33-7.30 (d, 1H), 7.10-
7.05 (d, 1H, J=15.81), 4.91 (s, 2H), 4.62 (s, 
2H), 4.23 (s, 5H) 
25 148.5-149.0 (i) 49.4% 334.0459  
(C19H15FFeO 
=334.0456) 
C (Calcd: 68.29%, Found: 
66.87%), H (Calcd: 4.52%, 
Found: 4.45%), F (Calcd: 
5.69%, Found: 5.36%), Fe 
(Calcd: 16.71%, Found: 
14.79%) 
    CDCl3 7.79-7.74 (d, 1H, J=15.45), 7.67-7.62 (t, 
2H), 7.15-7.02 (m, 3H), 4.91 (s, 2H), 4.60 (s, 
2H), 4.22 (s, 5H) 
26        94.6-95.4 (i) 28.0% 352.0364
(C19H14F2FeO 
=352.0362) 
C (Calcd: 64.80%, Found: 
67.79%), H (Calcd: 4.01%, 
Found: 4.60%), Fe 
CDCl3 7.83-7.77 (d, 1H, J=15.81), 7.66-7.58 
(q, 1H), 7.21-7.16 (d, 1H, J=15.81), 6.98-6.88 

















1H-NMR (δ ppm) 
27        171.0-171.4 (i) 40.4% 384.0426
(C20H15F3FeO 
=384.0424) 
C, H (Calcd: 3.49%, Found: 
3.92%), F (Calcd: 14.84%, 
Found: 14.25%), Fe (Calcd: 
14.54%, Found: 12.53%) 
4.68 99.55 8.43 99.52 CDCl3 7.83-7.67 (m, 5H), 7.20-7.14 (s, 1H, 
J=15.84), 4.92 (s, 2H), 4.63 (s, 2H), 4.23 (s, 
5H) 
28        189.8-190.9 (i) 54.3% 361.0399
(C19H15FeNO3
=361.0401) 
C,  H (Calcd: 4.19%, Found: 
4.23%), Fe (Calcd: 15.46%, 
Found: 13.18%), N (Calcd: 
3.88%, Found: 4.32%) 
4.45 99.61 8.17 97.47 CDCl3 8.30-8.28 (d, 2H), 7.83-7.78 (m, 3H), 
7.22-7.17 (d, 1H, J=15.45), 4.93 (s, 2H), 4.66 
(s, 2H), 4.24 (s, 5H) 
29 222.5-222.8 (i) 39.2% 341.0504  
(C20H15FeNO 
=341.0503) 
C, H (Calcd: 4.43%, Found: 
4.11%) 
    CDCl3 7.79-7.73 (m, 5H), 7.19-7.14 (d, 1H, 
J=15.42), 4.92 (s, 2H), 4.66 (s, 2H), 4.23 (s, 
5H) 
30 198.0-198.4 (i) 58.0% 367.0659   
(C22H17FeNO 
=367.0660) 
C (Calcd: 71.96%, Found: 
71.19%), H (Calcd: 4.67%, 
Found: 4.73%), Fe (Calcd: 
15.21%, Found: 13.21%), N 
(Calcd: 3.81%, Found: 4.21%) 
    CDCl3 9.23 (s, 1H), 8.34 (s, 1H), 8.16-7.59 (m, 
5H), 7.36-7.31 (d, 1H, J=15.45), 4.97 (s, 2H), 
4.65 (s, 2H), 4.25 (s, 5H) 
31       58.4-59.6 b 25.6% 367.0663 
(C22H17FeNO 
=367.0660) 
C (Calcd: 71.96%, Found: 
70.12%), H (Calcd: 4.67%, 
Found: 4.78%)  
CDCl3 8.87 (s, 1H), 8.35-8.15 (d, 2H), 7.67-
7.27 (m, 5H), 4.78 (s, 2H), 4.50 (s, 2H), 4.09 
(s, 5H) 
32 160.6-161.8 (i) 70.9% 317.0502  
(C18H15FeNO 
=317.0503) 
C, H (Calcd: 4.77%, Found: 
4.60%) 
    CDCl3 8.73 (s, 1H) 8.20-8.18 (d, 1H, J=7.92), 
7.89-7.45 (m, 4H), 4.69 (s, 2H), 4.51 (s, 2H), 
4.19 (s, 5H) 
33      148.6-149.6 (i) 12.7% 317.0516  
(C18H15FeNO 
=317.0503) 
C (Calcd: 68.16%, Found: 
67.70%), H (Calcd: 4.77%, 
Found: 4.62%) 
2.95 99.85 5.85 97.30 CDCl3 8.82-8.80 (d, 2H), 7.83-7.78 (d, 1H, 
J=15.42), 7.75-7.73 (d, 2H), 7.04-6.99 (d, 1H, 
J=15.45), 4.62 (s, 2H), 4.56 (s, 2H), 4.20 (s, 
5H) 
34  131.8-132.1 (i) 27.9% 361.0399 
(C19H15FeNO3
=361.0401) 
C, H (Calcd: 4.19%, Found: 
3.97%) 
    CDCl3 8.17-8.15 (d, 1H), 7.77-7.46 (m, 3H), 
7.14-7.09 (d, 1H, J=15.81), 6.62-6.57 (d, 1H, 
J=15.81), 4.48 (s, 4H), 4.16 (s, 5H) 





C (Calcd: 63.18%, Found: 
61.67%), H (Calcd: 4.19%, 
Found: 3.93%) 
CDCl3 8.79 (s, 1H), 8.43-8.33 (q, 2H), 7.89-
7.84 (d, 1H, J=15.42), 7.72-7.67 (t, 1H), 7.14-
7.09 (d, 1H, J=15.06), 4.65 (s, 2H), 4.57 (s, 
2H), 4.22 (s, 5H) 
36        217.7-218.9 (ii) 32.0% 361.0403
(C19H15FeNO3
=361.0401) 
C (Calcd: 63.18%, Found: 
62.69%), H (Calcd: 4.19%, 
Found: 4.00%) 
4.37 98.81 8.20 97.68 CDCl3 8.35-8.32 (d, 2H), 8.11-8.08 (d, 2H), 
7.85-7.80 (d, 1H, J=15.42), 7.09-7.04 (d, 1H, 

















1H-NMR (δ ppm) 
37       239.5-240.8 (i) 11.5% 359.0965
(C21H21FeNO 
=359.0973) 
C (Calcd: 70.21%, Found: 
69.80%), H (Calcd: 5.89%, 
Found: 5.70%) 
 CDCl3 7.79-7.74 (d, 1H, J=15.45), 7.57-7.54 
(d, 2H), 6.99-6.93 (d, 1H, J=15.45), 6.73-6.70 
(d, 2H), 4.91 (s, 2H), 4.55 (s, 2H), 4.20 (s, 5H), 
3.05 (s, 6H) 
38 150.7-151.9 (i) 44.7% 317.0520  
(C18H15FeNO 
=317.0503) 
C (Calcd: 68.16%, Found: 
67.82%), H (Calcd: 4.77%, 
Found: 4.51%) 
    CDCl3 8.70 (s, 1H), 7.73-7.64 (m, 3H), 7.48-
7.46 (d, 1H, J=7.17), 7.29-7.27 (d, 1H, J=7.53), 
4.98 (s, 2H), 4.61 (s, 2H), 4.23 (s, 2H) 





C (Calcd: 68.16%, Found: 
66.09), H (Calcd: 4.77%, 
Found: 4.58%) 
2.40 99.18 4.82 98.49 CDCl3 8.70-8.68 (d, 2H), 7.72-7.67 (d, 1H, 
J=15.42), 7.49-7.47 (d, 2H), 7.27-7.21 (d, 1H, 
J=15.84), 4.92 (s, 2H), 4.65 (s, 2H), 4.23 (s, 
5H) 
40        132.3-133.2 (i) 61.9% 361.0402
(C19H15FeNO3
=361.0401) 
C (Calcd: 63.18%, Found: 
62.80%), H (Calcd: 4.19%, 
Found: 3.93%) 
CDCl3 8.18-8.16 (d, 1H), 7.78-7.73 (t, 1H), 
7.67-7.61 (t, 1H), 7.49-7.47 (d, 1H), 7.15-7.09 
(d, 1H, J=15.45), 6.62-6.57 (d, 1H, J=16.2), 
4.49 (s, 4H), 4.17 (s, 5H) 
41        171.9-172.5 (i) 75.7% 361.0397
(C19H15FeNO3
=361.0401) 
C, H (Calcd: 4.19%, Found: 
3.92%) 
CDCl3 8.52 (s, 1H), 8.27-8.24 (d, 1H), 7.93-
7.90 (d, 1H), 7.84-7.79 (d, 1H, J=15.45), 7.65-
7.59 (t, 1H), 7.23-7.18 (d, 1H, J=15.81), 4.95 
(s, 2H), 4.66 (s, 2H), 4.24 (s, 5H) 
42        141.0-142.0 (i) 65.7% 359.0972
(C21H21FeNO 
=359.0973) 
C, H (Calcd: 5.89%, 
Found5.74%) 
CDCl3 7.79-7.74 (d, 1H, J=15.09), 7.57 (s, 
2H), 6.99-6.93 (d, 1H, J=15.45), 6.72 (s, 2H), 
4.91 (s, 2H), 4.54 (s, 2H), 4.20 (s, 5H) 





C, H (Calcd: 4.31%, Found: 
4.03%) 
6.49 99.94 11.75 99.78 CDCl3 7.94-7.91 (d, 2H), 7.80-7.75 (d, 1H, 
J=15.09), 7.48-7.45 (d, 2H), 7.10-7.05 (d, 1H, 
J=16.20), 4.60 (s, 2H), 4.51 (s, 2H), 4.19 (s, 
5H) 
44 158.9-161.9 (i) 36.6% 334.0462  
(C19H15FFeO 
=334.0456) 
C, H (Calcd: 4.52%, Found: 
4.36%) 
    CDCl3 8.04-7.99 (m, 2H), 7.79-7.74 (d, 1H, 
J=15.09), 7.19-7.08 (m, 3H), 4.60 (s, 2H), 4.50 
(s, 2H), 4.19 (s, 5H) 





C (Calcd: 65.14%, Found: 
64.02%), H (Calcd: 4.75%, 
Found: 4.59%) 
CDCl3 7.97-7.92 (d, 1H, J=15.45), 6.90-6.85 
(d, 1H, J=15.45), 4.53 (s, 4H), 4.48 (s, 4H), 
4.17 (s, 10H) 
R1     80.2-82.3 c 88.7% 318.0720     
(C19H18FeO 
=318.0707) 
C (Calcd: 71.72%, Found: 
71.37%) H (Calcd: 5.70%, 
Found: 5.60%) 
CDCl3 7.26 (s, 1H) 7.09-7.06 (d, 2H), 6.66-
6.63 (d, 2H), 4.76 (s, 2H), 4.48 (s, 2H), 4.10 (s, 
5H), 2.95 (s, 4H) 





C (Calcd:  68.98%, Found: 
68.63%), H (Calcd: 5.79%, 
Found: 5.69%) 
CDCl3 7.25-7.20 (t, 1H), 6.89-6.74 (m, 3H), 
4.76 (s, 2H), 4.48 (s, 2H), 4.09 (s, 5H), 3.80 (s, 
3H), 3.01 (s, 4H) 
 VI 
 













1H-NMR (δ ppm) 
R13       84.2-85.7 c 84.8% 319.0778
(C19H19FeO 
=319.0786) 
C (Calcd:  71.72%, Found: 
71.49%), H (Calcd: 5.70%, 
Found: 5.55%) 
CDCl3 7.57-7.54 (d, 2H), 7.22-7.07 (m, 3H), 
4.76 (s, 2H), 4.48 (s, 2H), 4.10 (s, 5H), 3.00 (s, 
4H) 





C, H (Calcd: 5.79%, Found: 
5.87%) 
CDCl3 7.21-7.18 (d, 2H), 6.86-6.83 (d, 2H), 
4.75 (s, 2H), 4.46 (s, 2H), 4.08 (s, 5H), 3.76 (s, 
3H), 2.98 (s, 4H) 





C, H     CDCl3 7.28-7.21 (m, 4H), 4.76 (s, 2H), 4.49 (s, 
2H), 4.09 (s, 5H), 3.01 (s, 4H) 





C, H (Calcd: 4.86%, Found: 
4.80%) 
CDCl3 7.90 (s, 2H), 7.44 (s, 2H), 4.18 (s, 9H), 
3.14 (s, 2H), 2.74 (s. 2H) 
Bis1     186.6-188.0 b  18.3% 447.1041 
(C28H23FeO2
=447.1048) 
C (Calcd: 75.35%, Found: 
74.59%), H (Calcd: 4.97%, 
Found: 4.60%) 
CDCl3 7.89-7.86 (d, 4H), 7.67-7.62 (d, 2H, 
J=15.42), 7.53-7.38 (m, 6H), 7.10-7.05 (d, 2H, 
J=15.45), 4.58 (s, 1H), 4.50 (s, 1H) 





C (Calcd: 71.16%, Found: 
69.98%), H (Calcd: 5.18%, 
Found: 4.67%) 
CDCl3 7.76-7.71 (d, 2H, J=14.31), 7.52 (s, 
4H), 6.96-6.85 (m, 6H), 4.91 (s, 4H), 4.59 (s, 
4H), 3.84 (s, 6H) 





C, H (Calcd: 4.97%, Found: 
4.71%) 
CDCl3 7.89-7.87 (d, 4H), 7.67-7.62 (d, 2H, 
J=15.06), 7.53-7.49 (t, 2H), 7.43-7.38 (t, 4H), 
7.10-7.05 (d, 2H, J=15.06), 4.58 (s, 4H), 4.50 
(s, 4H) 
Bis14        195.1-197.0 (ii) 66.7% 506.1168
(C30H27FeO4
=506.1180) 
C (Calcd: 71.16%, Found: 
69.12%), H (Calcd: 5.18%, 
Found: 4.95%) 
CDCl3 7.76-7.71 (d, 2H, J=14.31), 7.52 (s, 
4H), 6.96-6.85 (m, 6H), 4.91 (s, 4H), 4.59 (s, 
4H), 3.84 (s, 6H) 





C (Calcd: 69.73%, Found: 
68.46%), H (Calcd: 4.18%, 
Found: 4.04%) 
CDCl3 7.72-7.67 (d, 2H, J=14.70), 7.57-7.53 (t, 
4H), 7.06-7.00 (t, 4H), 6.98-6.92 (d, 2H, 
J=15.42), 4.92 (s, 4H), 4.61 (s, 4H) 
 
 
a  Recrystallization Solvents: (i) Ethanol (ii) CH2Cl2 
b  Purified by chromatography, THF/Hexane = 1/4 
c  Purified by chromatography, Ethyl Acetate/Hexane = 1/3 
 
 VII 
Table 2 Physicochemical descriptors of ferrocenyl chalcones 
No. EpFc (Red) (V) a EpFc (Ox) (V) b EpC=O (Red) (V) c 13C Shift (ppm) dEo' (V) e∆Ep (V) f Log Surface Area g Log Volume gLog kw hCharge difference of Carbonyl i
13         0.298 0.358 1.935 192.95 0.327 0.060 2.45 2.46 3.71 0.231
14         0.300 0.360 1.925 192.89 0.330 0.060 2.50 2.50 3.81 0.222
15         0.279 0.339 2.070 193.65 0.309 0.061 2.53 2.54 3.71 0.225
16         0.293 0.347 1.870 192.91 0.320 0.054 2.52 2.52 4.58 0.255
17         0.300 0.362 1.880 192.82 0.331 0.062 2.52 2.52 4.48 0.238
18         0.296 0.355 1.825 192.40 0.325 0.059 2.45 2.45 3.01 0.223
19         0.281 0.334 1.900 191.82 0.307 0.054 2.47 2.47 2.94 0.222
20         0.295 0.356 1.965 193.01 0.325 0.061 2.48 2.48 4.13 0.218
21         0.309 0.369 1.860 192.63 0.339 0.060 2.48 2.48 4.21 0.235
22         0.307 0.365 1.835 192.57 0.336 0.058 2.48 2.49 4.25 0.232
23         0.307 0.372 1.850 192.77 0.339 0.066 2.48 2.48 4.93 0.184
24         0.311 0.369 1.795 192.43 0.340 0.059 2.50 2.51 4.64 0.238
25         0.296 0.357 1.920 192.76 0.326 0.061 2.46 2.46 3.79 0.255
26         0.300 0.362 1.890 192.85 0.331 0.062 2.47 2.47 4.04 0.219
27         0.313 0.379 1.765 192.47 0.346 0.066 2.50 2.50 4.33 0.197
28         0.318 0.358 2.710 192.15 0.338 0.040 2.49 2.49 3.76 0.228
29         0.313 0.371 1.680 192.23 0.342 0.058 2.49 2.49 3.59 0.318
30         0.310 0.371 1.730 192.39 0.340 0.061 2.51 2.52 3.81 0.175
31         0.314 0.382 1.640 192.20 0.348 0.068 2.51 2.52 3.73 0.231
38         0.248 0.316 1.866 193.28 0.282 0.063 2.45 2.45 2.82 0.218
39         0.308 0.386 1.697 192.26 0.347 0.073 2.45 2.45 2.72 0.217
40         0.173 0.245 2.212 192.44 0.209 0.067 2.48 2.50 3.42 0.226
 VIII 
 No. EpFc (Red) (V) a EpFc (Ox) (V) b EpC=O (Red) (V) c 13C Shift (ppm) dEo' (V) e∆Ep (V) f Log Surface Area g Log Volume gLog kw hCharge difference of Carbonyl i
40  0.173 0.245 2.212 192.44 0.209 0.067 2.48 2.50 3.42 0.226 
41         0.304 0.381 2.020 192.25 0.343 0.072 2.49 2.49 3.53 0.247
42         0.200 0.273 2.121 193.13 0.237 0.068 2.53 2.53 3.91 0.228
1         0.172 0.237 1.920 189.86 0.205 0.064 2.46 2.46 3.80 0.148
2         0.165 0.224 2.005 188.12 0.194 0.059 2.50 2.50 3.94 0.163
3         0.161 0.220 2.080 190.42 0.190 0.059 2.52 2.54 3.92 0.150
4         0.178 0.238 1.840 189.60 0.208 0.060 2.52 2.52 4.87 0.155
5         0.186 0.238 1.950 195.70 0.212 0.052 2.50 2.53 4.33 0.136
6         0.191 0.257 1.810 188.23 0.224 0.066 2.45 2.45 3.40 0.163
7         0.165 0.223 1.890 186.26 0.194 0.058 2.47 2.47 3.89 0.175
8         0.176 0.233 1.800 190.54 0.204 0.057 2.48 2.48 3.22 0.161
9         0.154 0.244 1.700 192.75 0.199 0.090 2.47 2.47 4.18 0.178
10         0.167 0.226 2.040 190.50 0.197 0.059 2.56 2.57 3.72 0.163
11         0.163 0.220 2.000 188.04 0.191 0.057 2.53 2.52 4.42 0.163
12         0.170 0.230 2.025 188.09 0.315 0.060 2.58 2.57 5.16 0.122
32         0.148 0.215 1.830 188.42 0.182 0.062 2.45 2.45 3.24 0.132
33         0.151 0.223 1.739 188.87 0.187 0.067 2.45 2.45 3.07 0.138
34         0.150 0.223 2.223 192.35 0.187 0.068 2.47 2.50 3.50 0.151
35         0.141 0.207 2.068 187.10 0.174 0.061 2.49 2.49 3.97 0.167
36         0.160 0.229 2.641 188.04 0.195 0.064 2.49 2.49 3.89 0.167
37         0.138 0.208 2.074 187.43 0.173 0.065 2.53 2.53 4.15 0.148
43        0.088 0.157 1.461 188.44 0.123 0.069 2.48 2.48 4.31 0.148 




i Difference in Gasteiger-Huckel charges of oxygen and carbon atoms. 
h HPLC derived capacity factor determined at pH 7.0 
e Half wave potential Eo' = {Ep Fc-Ox + Ep Fc-Red } / 2 
c Reduction potential of carbonyl function  
d 13 C Chemical shift of carbonyl carbon  
g Connolly surface area and volume 
 
a Reduction potential of ferrocene  
b Oxidation potential of ferrocene  
















Table 3 X- ray crystallography data of compound 1, 12 and 28 
1 12 28 
Atom        Xa           Yb           Zc Atom        X            Y            Z Atom        X            Y            Z 
Fe       -2.7170    1.0933    0.1481 Fe       -5.4452   -1.4089   -0.1031 Fe        0.6370   -2.0345    2.3842 
O1        1.4098   -2.1292   -1.7570 O1       -1.1415    1.7170   -1.9749 O1        2.7738    0.4840    0.4715 
C1        1.7444   -1.6029   -0.7128 O2        4.5297    0.4857    0.5511 O2       -3.8389    4.0732   -4.7201
C2        0.7360   -0.9964    0.1934 C1       -0.8622    1.0641   -0.9747 O3       -2.2344    4.1048   -6.1397
H2        1.0119   -0.5350    0.9645 C2       -1.9160    0.4830   -0.1207 N1       -2.6941    3.8314   -5.0422
C3       -0.5529   -1.1078   -0.0886 H2       -1.6713   -0.0464    0.6164 C1        1.6002    0.4072    0.7902 
H3       -0.7785   -1.5839   -0.8671 C3       -3.1997    0.6923   -0.3717 C2        0.5198    0.8629   -0.1126 
C4        3.1931   -1.5301   -0.3462 H3       -3.4067    1.2037   -1.1328 H2       -0.3754    0.7784    0.1613
C5        3.6877   -0.7315    0.6818 C4        0.5635    0.8791   -0.5805 C3        0.7872    1.3847   -1.2926 
H5        3.0953   -0.2434    1.2245 C5        0.9874   -0.0548    0.3366 H3        1.6902    1.3794   -1.5536
C6        5.0481   -0.6566    0.9039 H5        0.3571   -0.6175    0.7485 C4       -0.1556    1.9706   -2.2433
H6        5.3797   -0.0952    1.5810 C6        2.3171   -0.1787    0.6604 C5        0.3242    2.3723   -3.4855 
C7        5.9269   -1.4004    0.1389 H6        2.5897   -0.8494    1.2600 H5        1.2260    2.2212   -3.7035
H7        6.8524   -1.3440    0.2935 C7        3.2524    0.6687    0.1160 C6       -0.5016    2.9890   -4.4032
C8        5.4366   -2.2289   -0.8565 C8        2.8615    1.5990   -0.8023 H6       -0.1707    3.2666   -5.2381
H8        6.0267   -2.7587   -1.3612 H8        3.4924    2.1722   -1.1985 C7       -1.8122    3.1868   -4.0692
C9        4.0800   -2.2755   -1.1060 C9        1.5250    1.6865   -1.1415 C8       -2.3314    2.8098   -2.8392
H9        3.7538   -2.8194   -1.7999 H9        1.2626    2.3233   -1.7812 H8       -3.2327    2.9732   -2.6282
C10      -1.6538   -0.5629    0.6927 C10       5.5680    1.3301    0.0629 C9       -1.5006    2.1930   -1.9362
C11      -1.5831    0.4413    1.7194 H10A    5.3505    2.2713    0.2283 H9       -1.8398    1.9179   -1.1038
H11      -0.8002    0.8472    2.0448 H10B    5.6899    1.2012   -0.9009 C10       1.1997   -0.1080    2.1008
C12      -2.9070    0.7094    2.1533 C11       6.8221    0.9379    0.8116 C11       2.0850   -0.7412    3.0269
H12      -3.1505    1.3221    2.8233 H11A    6.6844    1.1132    1.7659 H11       3.0133   -0.8455    2.9222
C13      -3.8053   -0.1030    1.4063 H11B    6.9613   -0.0263    0.7050 C12       1.3196   -1.1814    4.1243
H13      -4.7411   -0.1203    1.4934 C12       8.0659    1.6541    0.3669 H12       1.6519   -1.6372    4.8762
C14      -3.0366   -0.8787    0.5101 H12A    7.9593    2.6178    0.5095 C13      -0.0297   -0.8248    3.9083
H14      -3.3784   -1.5010   -0.1059 H12B     8.2089    1.5014   -0.5905 H13      -0.7445   -0.9937    4.4949
C15      -2.1884    1.6192   -1.7618 C13       9.2669    1.1538    1.1472 C14      -0.1207   -0.1719    2.6618
H15      -1.6862    1.0989   -2.3625 H13A    10.0628    1.6229    0.8516 H14      -0.9062    0.1622    2.2680
C16      -1.6723    2.5411   -0.8442 H13B     9.3773    0.2021    0.9956 C15       0.6988   -3.0017    0.5926
H16      -0.7632    2.7482   -0.7247 H13C     9.1283    1.3166    2.0934 H15       0.9622   -2.6227   -0.2262
C17      -2.7449    3.1047   -0.1315 C14      -4.3144    0.2073    0.4158 C16       1.5513   -3.6406    1.5262
H17      -2.6791    3.7513    0.5476 C15      -5.6847    0.5795    0.2134 H16       2.4795   -3.7617    1.4402
C18      -3.9431    2.5255   -0.6182 H15      -5.9955    1.2042   -0.4165 C17       0.7529   -4.0606    2.6057
H18      -4.8135    2.7194   -0.3209 C16      -6.4884   -0.1472    1.1159 H17       1.0521   -4.5156    3.3720
C19      -3.5948    1.6057   -1.6292 H16      -7.4234   -0.0892    1.1937 C18      -0.5667   -3.6799    2.3348
H19      -4.1924    1.0774   -2.1265 C17      -5.6384   -0.9801    1.8849 H18      -1.3076   -3.8346    2.8923
  C19      -0.5988   -3.0332    1.1003
  H19      -1.3631   -2.6797    0.6827
 
a The position of atom on “X” axis. 
b The position of atom on “Y” axis. 
c The position of atom on “Z” axis. 
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Table 4 Cytotoxicity of ferrocenyl chalcones against KB3-1 and MDCK cells 
Ring A Ring B
O
 






1 phenyl Fc 76.5 40.9 
2 4-methoxyphenyl Fc 102 63.5 
3 2,4-dimethoxyphenyl Fc 67.9 37.8 
4 2-naphthalenyl Fc 52.8 59.2 
5 1-naphthalenyl Fc 127 125 
6 3-pyridinyl Fc 39.7 24.2 
7 4-hydroxyphenyl Fc 69.4 62.2 
8 2,4-dihydroxyphenyl Fc 100 92.6 
9 2-hydroxyphenyl Fc 111 54.3 
10 2,3,4-trimethoxyphenyl Fc 76.5 51.7 
11 4-ethoxyphenyl Fc 101 45.1 
12 4-butoxyphenyl Fc 94.4 101 
13 Fc phenyl 58.9 55.3 
14 Fc 4-methoxyphenyl  19.5 30.8 
15 Fc 2,4-dimethoxyphenyl 33.1 68.2 
16 Fc 2-naphthalenyl 38.7 50.4 
17 Fc 1-naphthalenyl 86.0 38.6 
18 Fc 3-pyridinyl 20.8 48.4 
19 Fc 4- hydroxyphenyl 28.9 102 
20 Fc 4-methylphenyl 88.6 71.8 
21 Fc 4-chlorophenyl 29.8 52.0 
22 Fc 3-chlorophenyl 47.7 54.3 
23 Fc 2-chlorophenyl 63.6 69.4 
24 Fc 2,4-dichlorophenyl 48.8 66.5 
25 Fc 4-fluorophenyl 213 62.1 
26 Fc 2,4-difluorophenyl 155 67.4 
27 Fc 4-trifluoromethylphenyl 69.1 27.7 
28 Fc 4-nitrophenyl 187 76.6 
29 Fc 4-cyanophenyl 297 87.5 
30 Fc 3-quinolinyl 15.9 68.3 
31 Fc 4-quinolinyl 105 208 
32 2-pyridinyl Fc 654  
33 4-pyridinyl Fc 127  
34 2-nitrophenyl Fc 134  
35 3-nitrophenyl Fc 21.4  
36 4-nitrophenyl Fc >500  
37 2,4-dimethylaminophenyl Fc 75.1  
38 Fc 2-pyridinyl 33.5  
39 Fc 4-pyridinyl 57.1  
40 Fc 2- nitrophenyl 136  
41 Fc 3- nitrophenyl 40.0  
42 Fc 2,4-dimethylaminophenyl 168  
R1 phenyl Fc >500  
R13 Fc phenyl 121  
R14 Fc 4-methoxyphenyl 160  
R21 Fc 4-chlorophenyl 385  
Bis1 phenyl Fc 303  
Bis13 Fc phenyl >500  
Bis14 Fc 4-methoxyphenyl >500  
Bis25 Fc 4-fluorophenyl 121  
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